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Aplastic Anaemia (AA) is a bone marrow failure syndrome (BMFS) characterized by bone 
marrow aplasia and peripheral blood pancytopenia. The presenting symptoms in patients with 
AA are often those of anaemia, haemorrhage or purpura and, less frequently, infection. These 
symptoms usually lead to medical evaluation (1, 2).  Presentation can range from non-severe or 
moderate, to sometimes life-threatening cytopenias. In the Western World, the annual 
incidence of Acquired Aplastic Anaemia (AAA) is 2 cases per million persons (3). A biphasic 
age distribution has been reported. AA primarily affects children, young adults, and those 
over 60 years of age. Males and females display no significant difference in incidence. The 
majority (70-80%) of AA cases are classified as idiopathic, as their primary aetiology is 
unknown (4). Drugs or infections that precipitate bone marrow failure, can be identified in a 
subset of AA cases. AA is constitutional in approximately 15-20% of patients, with the 
commonest inherited bone marrow failure syndrome (IBMFS) being Fanconi Anaemia (FA). 
Five percent of idiopathic AA have undiagnosed IBMFS because the full disease phenotype 
has not manifest itself (5, 6). 
An autoimmune pathogenesis is favored to cause stem cell depletion. Severe AA is invariably 
fatal without treatment. The currently available treatment options including allogeneic bone 
marrow transplantation (BMT), are improving patient survival in developed countries (2, 7, 8). 
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare clonal haemopoietic stem cell (HSC) 
disorder which may arise de novo or evolve from AA. This bone marrow failure disorder 
manifests with haemolytic anaemia, marrow failure (peripheral blood cytopenias) and 
thrombophilia. AA and PNH are closely related, and small PNH clones are detectable in more 
than half of AA patients. PNH is also the most common clonal disorder that occurs in AA 
patients after treatment with immunosuppressive therapy (IST) (7, 9-18). 
This project was conducted in order to delineate the demographic and clinico-haematological 
profile of the adult patient cohort diagnosed with AA within the Kwa-Zulu Natal (KZN) 
public health care sector. Inkosi Albert Luthuli Central Hospital (IALCH) in Cato Manor, 
Durban is the only public sector hospital in Kwa-Zulu Natal (KZN) equipped with the 
facilities and resources to diagnose this rare condition, as well as to treat AA. Due to the rare 
occurrence of this haematological disorder, there is a paucity of information regarding AA in 
South Africa (SA), as well as in African countries in general. To date, there have been no 
published studies on Adult AA from our centre or other centres within SA.  
Aims and objectives: The aim of this retrospective observational study was to collect data 
regarding the demographics, clinical presentation, aetiology/associations, laboratory 
parameters and outcome of adult patients with a bone marrow diagnosis of Aplastic Anaemia 
at the National Health Laboratory Service (NHLS), IALCH, Durban, KZN, over a 10-year 
period. 
The specific objectives of the study were to illustrate patient demographics, to correlate the 
full blood count (FBC), bone marrow aspirate and trephine (BMAT) findings and to 
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document disease severity. Other aims included documenting aetiological associations, in 
particular viruses such as Human Immunodeficiency Virus (HIV), and connective tissue 
disorders such as systemic lupus erythematosus (SLE). Another objective in HIV infected 
patients, was to establish if a relationship with the CD4 count/viral load and disease 
presentation, exists. The presence, or subsequent emergence, of a PNH clone and cytogenetic 
abnormalities, if any, were also documented. Patient outcomes, including response to 
treatment and overall survival, was also assessed. 
Methods: BMAT biopsies with a confirmed diagnosis of Aplastic/Hypoplastic anaemia at the 
NHLS Haematology Laboratory at IALCH, were reviewed over a 10-year period (2005-
2015). Demographic data, clinical information and laboratory parameters were recorded on a 
standardized data collection sheet, and then transcribed onto a Microsoft Excel spreadsheet 
for analysis. The demographic and clinical data was obtained from the referral forms and 
clinical notes. Laboratory results were extracted from the TrakCare Lab Information System 
(LIS).  
Results: A total of 92 BMATs were reviewed. There were 42 males (M) and 50 females (F), 
with a M:F ratio of 0.8:1. The median age at presentation was 24 years, with an absence of a 
second peak of presentation in older patients. Twenty nine patients had very severe AA 
(VSAA), 36 had severe AA (SAA) and 27 had non severe AA (NSAA). Symptoms of 
thrombocytopenia (TCP) prevailed in the majority (61%) of patients at presentation, followed 
by symptoms of anaemia (53%). Symptoms of neutropenia, occurring in 6 patients (7.5%), 
were the least frequent. Ninety three percent of patients presented with pancytopenia. Thirty 
percent of patients had a severe anaemia (Hb <6g/dl). Sixty percent of patients had a severe 
thrombocytopenia (platelets < 20x109/l). A severe neutropenia (ANC < 0.5 x 109/l) was 
observed in 62% of patients. Reversal of the lymphocyte: neutrophil ratio was observed in 
92% of patients. All bone marrow trephines were markedly hypocellular for age. Twenty two 
patients had an initial failed BMAT biopsy. Cytogenetic abnormalities were noted in 2 
patients at presentation. The majority of patients had idiopathic AA, with no identifiable 
aetiology. Two patients had FA, and a PNH clone was demonstrable in 4 patients at 
presentation. Thirteen patients (16.3%) were HIV positive. Four patients were pregnant at the 
time of presentation and their outcomes varied. Different modalities of treatment were used, 
including observation, androgens, immunosuppressive therapy [ciclosporin (CSA) 
with/without anti-thymocyte globulin (ATG)] and allogeneic bone marrow transplantation 
(BMT). Thirteen patients did not reach the clinical haematology unit, 35 patients are alive, 22 
patients demised and 22 have been lost to follow up (LTFU). Two patients had clonal 
evolution to PNH and one to MDS.  
Conclusion: The clinico-epidemiological profile of patients in this study is similar to that 
reported in the literature. A significant number of patients did not reach the clinical 
haematology unit at IALCH. An unusually high number of failed initial BMATs were 




It is my intention to provide the haematology department with this vital information and to 
allow comparison of similarities/differences in the findings from this study with that reported 
within the literature. I hope that this study will inform and educate readers on the existence of 
this rare condition, as well as provide much needed insight into the disease presentation and 
diagnosis so that patients may be referred timeously/promptly for specialist management.  
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CHAPTER ONE: LITERATURE REVIEW 
 
1.1 Introduction 
Aplastic anaemia (AA) is defined as a pancytopenia with a hypocellular bone marrow in the 
absence of abnormal infiltration or increased reticulin. The very first case of AA was described 
by Ehrlich in 1888. It was documented in a young woman who died of an abrupt illness with 
severe anaemia, haemorhage, hyperpyrexia, and a hypocellular bone marrow (19). 
Acquired aplastic anaemia (AAA) is a largely immune mediated condition. It may present 
concurrently with clonal haemopoietic stem cell disorders, most commonly paroxysmal 
nocturnal haemoglobinuria (PNH). It may later evolve to myelodysplastic syndrome (MDS) in 
up to 15-20% of patients or acute leukaemia (AL) (2, 20). Furthermore, there is overlap between 
AA and MDS in the form of the entity hypocellular MDS, which is often difficult to distinguish 
from AA on morphologic criteria, especially when AA is of the non-severe subtype (21). 
Several inherited (genetic/constitutional) disorders may be characterized by bone marrow failure 
(BMF). Usually, one or more somatic abnormalities (which may often be diagnostic of the 
disorder) is associated with these conditions (22). These inherited BMF syndromes (IBMFS) are 
heterogeneous disorders characterized by clinically significant haematological cytopaenias. The 
haematological features may manifest at variable periods. Some may occur in the neonatal 
period, however in other disorders such as Fanconi Anaemia (FA) or Dyskeratosis Congenita 
(DKC), cytopenias may develop later in childhood or can even present at any time in life (23). 
As the exemplar of human bone marrow failure syndromes, AA has undergone paradigmatic 
shifts in our understanding of disease pathophysiology. This has profound implications for 
treating this fatal blood disease (24). 
The first successful allogeneic bone-marrow transplantation for AA was performed in 1972 (25). 
Prognosis of this invariably fatal illness was improved by the development of bone-marrow 
transplantation and potent immunosuppressive therapy in the 1970s. Although still a potentially 






1.2. Incidence and Epidemiology 
Acquired AA has an annual incidence of approximately 2-3 million per year (all age groups) in 
the West (Europe). A 2-3-fold higher incidence rate was demonstrated in East Asia (27-30). Little 
evidence is available for the ethnic variability in AA rates. A suggested explanation for the 
higher incidence in the Far East has been the easy accessibility and the increased use of medical 
drugs, such as antibiotics, which are available without prescription. Pesticide exposure has also 
been implicated (31-33, 34) . 
Epidemiological studies demonstrate a bimodal age distribution. An early peak at 10-25 years, 
as well as a later peak > 60 years has been documented (25, 31-34). 
There is no significant reported gender difference in incidence between males and females (35). 
The sex ratio has been close to 1:1 in most reported cases. This is unusual for immune mediated 
diseases, which usually demonstrate a female predominance (36).  
Incidence rates in studies refer to moderate and severe AA. The severity is determined by 
assessing the patients initial blood counts. Although some moderate AA patients may show a 
worsening pancytopenia, other patients remain stable, never needing treatment. Individuals with 
constitutional marrow failure, either not tested for Fanconi Anaemia (FA) (based on the absence 
of physical anomalies) or with telomere complex mutations (for which diagnostic assays were 












1.3. Pathophysiology of Acquired Aplastic Anaemia 
The majority of AAA cases can be pathophysiologically characterized by T-cell-mediated, organ 
specific destruction of bone marrow hematopoietic stem cells (HSC). In individual patients, the 
aberrancy of the immune response may occasionally be linked to a prior drug or chemical 
exposure or a preceding viral infection. Evidence for other mechanisms is rare. This may include 
factors such as direct stem cell toxicity or a deficiency of stromal-cell or hematopoietic growth 
factor function. The quantitative degree of HSC destruction, as well as the variations in immune 
response may sometimes explain the variability in clinical course and response to treatment (37). 
1.3.1 Hematopoietic failure 
Failure of blood cell production is responsible for the empty bone marrow of AA. The earliest 
observers noted the “yellow fat” and the absence of the morphologically diverse precursors of 
mature blood components within bone marrow spaces. This is a striking feature on bone marrow 
aspirate and trephine biopsy (BMAT) examination (3). Vertebrae display uniform marrow 
replacement with fat on magnetic resonance imaging (MRI). Fluorescent-activated flow 
cytometry can also be used for quantification of immature haemopoietic cells. This method 
detects the CD34 cell antigen (an adhesion protein present on less than 1% of normal bone 
marrow). In AA, there is an almost complete absence of CD34 cells. There is a marked reduction 
of progenitor cells, which are capable of forming erythroid, myeloid, and megakaryocytic 
colonies. A similar consistent and severe deficit is also demonstrated in assays of very primitive, 
quiescent, hematopoietic cells. These are cells that are closely related, if not identical, to HSC 
(38). 
Functional studies of aplastic BM have indicated, that patients with AA present with 
pancytopenia when stem-cell and progenitor-cell populations have been reduced to 
approximately 1% or less of normal. This profound deficiency has qualitative consequences, as 
evidenced in the shortened telomere length of granulocytes of AA patients (39). 
1.3.2 Immune Destruction 
Runt disease, in animals and transfusion-associated graft-versus-host disease (GVHD), in 
humans are primary examples of the efficiency of immune system at destroying blood-forming 
cells (40). In such conditions, fatal AA is induced by a small number of alloreactive T cells. In 
mouse studies the stem cell destruction has been rapid and almost complete. There is abundant 
laboratory data which supports the hypothesis that lymphocytes are responsible for 
hematopoietic cell compartment destruction in AAA (37). 
Early experiments demonstrated that lymphocytes suppressed hematopoiesis, by producing a 
soluble, inhibitory factor eventually identified as interferon-y (IFN-ᵧ). There is activation of a T-
helper cell type 1 (TH-1) T-cell response resulting in excessive production of interferon (IFN), 
tumor necrosis factor (TNF), and interleukin-2 (IL-2). Flow cytometric detection of intracellular 
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IFN-ᵧ in patient samples can be performed. This may be correlated with patient response to 
immunosuppressive therapy (IST). It may also predict disease relapse (41).   
The altered immune system results in fas-mediated destruction, specifically of CD34 cells. 
Intracellular pathways are activated and cell-cycle arrest ensues. The antigenic nature of the 
pathologic immune response is obscure. Molecularly, lymphocytes in AA show similarity to T 
cells in other conditions such diabetes and multiple sclerosis and other similar illnesses. The 
immune response is oligoclonal as demonstrated by characterization of the T-cell-receptor b 
chain (TCR-B) of activated lymphocytes. There are a relatively limited number of active clones 
infiltrating the marrow. Some immune responses may be public, meaning that it is distributed 
among patients with the same histocompatibility background (42).   
1.3.3 Immunopathogenesis of Hepatitis Associated Aplastic Anaemia (HAAA) 
Various immunological aberrations result in the development of HAAA.  CD8+ kupffer cells 
appear as a mediator of this syndrome (43, 44). CD8 cells residing in the BM during HAAA 
produce high levels of interferon gamma (IFN-ᵧ). Tumor necrosis factor alpha (TNF-α) and IFN-ᵧ 
cause onlooker damage to hepatocytes (in genetically modified mouse models). However, 
several studies have indicated that an increased level of soluble IL-2 receptor is a large 
contributor to the non-specific inflammation of HAAA (45, 46). In children, HAAA pathogenesis 
has been linked to an imbalance of lymphocyte sub-populations and T lymphocyte activation (47). 
There is no known genetic tendency with HAAA (48).  
1.3.4 Pathogenesis of the IBMFS 
Although rare, FA is the most common congenital marrow failure syndrome. It is a genetically 
heterogeneous multisystem disorder, in which twenty genes have been causally associated. FA is 
a DNA repair disorder characterized by chromosomal instability, which results from germline 
mutations in the DNA repair genes of the FA/BRCA pathway (23). 
Germline mutations in important telomere biology genes which result in dysfunctional telomere 
maintenance have been implicated in DKC (23). Mutation in TERC (gene for the RNA component 
of telomerase) and TERT (the gene for the telomerase reverse transcriptase catalytic enzyme), 
which are genes of the telomere repair complex, reduce the regenerative capacity of bone 








Inherited bone marrow failure syndromes (IBMFS), of which Fanconi anaemia is the 
commonest, account for 15-20% of cases of AA. Approximately 5% of patients with idiopathic 
AA have an undiagnosed IBMFS, in which the full disease phenotype has not yet manifest (5,6). 
The remainder and majority of cases of AA (70-80%) are classified as idiopathic, due to the 
aetiology being unknown (5,6). An immunologic pathophysiology has been implicated in acquired 
AA. Similar to other autoimmune conditions, environmental triggers and individual host factors 
are hypothesized to determine risk. Although many drugs and chemicals have been implicated as 
causal agents of AA, reasonable evidence is only available for very few (25, 50-53) (See Table 1.1 
below). 
There has been a link to exposure to benzene and pesticides to AA (54). Marrow failure occurring 
as a severe idiosyncratic complication, has been reported following the use of certain medical 
agents such as chloramphenicol (54).  AA can follow infections with certain viruses, as in 
postseronegative hepatitis (55). AA has also been documented as a rare complication of pregnancy 
(56). There are reports of clusters of AA in the literature (57-60). However, there is a poor 
description of the mechanisms linking environmental triggers to bone marrow failure. Hence, 
most cases are labeled as idiopathic (29). 
Table 1.1: Aetiology of acquired idiosyncratic AA (61) 
 
AA- aplastic anaemia. PNH- paroxysmal nocturnal haemoglobinuria 
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1.4.1 Drug associated AA  
Aplastic anaemia has been attributed to an idiosyncratic reaction to drug or chemical exposure. 
This association with AA is of great importance. Not only is it devastating to physicians and 
patients but it also presents serious legal implications and contributes problems in 
pharmaceutical drug development, government regulation and the manner in which warning 
labels are worded (53,54). 
Of utmost importance is a careful drug history, which should document all drug exposures from 
6 months before and ending one month prior to presentation (51,52).  
Anticonvulsants, anti-rheumatic drugs, anti-thyroid medications, anti-tuberculosis drugs and 
non-steroidal anti-inflammatory drugs (NSAIDS) have commonly been implicated in the 
aetiology of AA. Few of the specific drugs cited include: amidopyrine, butazone, 
chloramphenicol, felbamate, gold salts, methimazole, penicillamine, sulfonamide, and 
trimethoprim/sulfamethoxazole (50, 62-64). 
Many drugs reported to cause AA, can also more commonly cause mild bone marrow 
suppression. Idiosyncratic drug reactions are extremely rare. This may be a consequence of 
genetic variations in drug metabolism, alterations in major histocompatibility antigens as well as 
their peptide-binding abilities (37).  
If the patient is taking a drug that is implicated in AA at presentation, then the drug should 
immediately be discontinued. Patients should not be re-challenged with such drugs after recovery 
of the blood counts, at a later stage (7).  
Irradiation and chemotherapy-induced bone marrow aplasia are different entities. These should 
not be called AA (65). 
Three cases of AA occurring in association with anti-tuberculosis chemotherapy have been 
reported (66). The patients had been on anti-tuberculosis chemotherapy for 13, 11 and 14 months 
respectively, prior to the diagnosis of AA. Agents used included streptomycin, thiacetazone, 
isoniazid, p-aminosalicylic acid and dimethylcarbazine. Recovery from aplasia did not occur 6, 
1.5 and 0.8 months, respectively, after the discontinuation of the suspect myelotoxic agents and 
despite the use of myelostimulatory agents. All three patients died of haemorhage secondary to 
thrombocytopenia. The observations reported were consistent with a protracted and probably 
irreversible damage of the bone marrow by anti-tuberculosis agent(s) in susceptible individuals. 
However, there are no other case reports/series available. 
There are 5 reported cases of AA from Zambia, as a consequence of traditional herbal remedies. 
Three of the patients died. A feature of the haemorhagic tendency from severe thrombocytopenia 




A study conducted by Handoko et al, 2006, revealed that exposure to antiepileptic drugs (AED) 
increased the risk of AA nine fold. Felbamate was the most frequently reported drug, however 
Carbamazepine and Valproic acid (which are the most widely prescribed AEDs) were also 
commonly implicated (68). 
Two cases of fatal AA associated with Clopidogrel use, have been reported in 2001 (69). 
Eight cases of sulfonamide related AA, as well as six cases of nifedipine-related fatal AA have 
been reported (70). 
A case of AA following the use of Sulphaphenazole (“Orisulf”) has also been published (71). 
Tabulated below are some of the currently licenced drugs which have been reported as a rare 
association with aplastic anaemia (Table 1.2). 
 
Table 1.2. Currently licenced drugs which have been reported as a rare association with 
aplastic anaemia. 
Antibiotics                                                                 Chloramphenicol*, Sulphonamides, 
                                                                                   Cotrimoxazole, Linezolid 
Anti-inflammatory                                                     Gold, Penicillamine, Phenylbutazone, 
                                                                                   Indomethacin, Diclofenac, Naproxen, 
                                                                                   Piroxicam, Sulphasalazine 
Anti-convulsants                                                        Phenytoin, Carbamazepine 
Anti-thyroids                                                              Carbimazole_, Thiouracil 
Anti-depressants                                                        Dothiepin, Phenothiazines 
Anti-diabetics                                                            Chlorpropamide, Tolbutamide 
Anti-malarials                                                            Chloroquine 
Others_                                                               Mebendazole, Thiazides, Allopurinol 
*No association with chloramphenicol tablets was observed in recent study from Thailand (Issaragrisil et   al, 2006). There is no evidence for an 
association between chloramphenicol eye drops and aplastic anaemia 
(Gordon-Smith et al, 1995; Lancaster et al, 1998; Wilholm et al, 1998). 
_More likely to cause neutropenia from epidemiological study in Thailand (Issaragrisil et al, 2006). 
 
Evidence based on case reports or uncontrolled series (Young & Alter, 1994) or case control 







1.4.2 Toxins: Occupational and Environmental exposures 
The association between the development of AA and prior exposure to drugs or industrial 
chemicals is a well-recognized one. Often, it is based on epidemiological evidence of the 
temporal relationship between an exposure and aplasia developing in the bone marrow. In about 
70% of cases, there is no obvious aetiological agent. A careful occupational history of the patient 
may reveal exposure to chemicals or pesticides that have been associated with AA, as 
summarized in Table 1.3 below (7). 
 
Table 1.3. Occupational and environmental exposures as potential aetiological agents in 
aplastic anaemia (7) 
 
Benzene and other solvents (evidence based on large industrial studies (Yin et al, 1987; Smith, 1996; 
Yin et al, 1996; Issaragrisil et al, 2006) 
 
Agricultural pesticides:        Organochlorines e.g. Lindane, Organophosphates, Pentachlorophenol [Muir 
et al, 2003 (case control study), Fleming & Timmeny, 1993; Roberts, 1997 (literature reviews of case 
reports)], DDT and Carbamates (Issaragrisil et al, 2006) 
 
Cutting oils and lubricating agents (Muir et al, 2003) 
 
Non-bottled water, non-medical needle injury, farmers exposed to ducks and geese, animal fertiliser 
(Issaragrisil et al, 2006) 
 
Recreational drugs: methylenedioxy-methamphetamine, MDMA, Ecstasy, [evidence based on case 
reports, (Marsh et al, 1994b; Clark & Butt, 1997)] 
DDT- dichlorodiphenyltrichloroethane. MDMA- 3,4 methylenedioxy-methamphetamine 
 
Solvents have been investigated as potential aetiological agents in AA (72,73).  
Benzene is one of the oldest and most widely accepted aetiologic associations between 
environmental exposures and marrow failure. Exposure to benzene through occupational and 
other routes is the most convincingly causally related exposure to the disease. Benzene is used as 
a solvent in a number of industries including rubber, gum and resin production. It is also used in 
the dry cleaning industry and in the manufacture of dyes, leathers and shoes. Occupational 
exposure to benzene is anticipated to be much higher than non-occupational sources, although 
benzene is also a common agent found in a number of household cleaning products and exposure 
also occurs during the handling of petrol. High dose direct administration of benzene to animals 
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has shown it to be a marrow toxin producing marrow hypoplasia, hyperplasia and even 
malignancies (74).  
There is less clear evidence for other common solvents having a role in the aetiology of AA. 
Solvents such as pure toluene or xylene are not thought to be marrow toxins (75). The fact that 
benzene is concentrated in the fat of the bone marrow may partly account for such a difference in 
toxicity (76).  
Pesticides have been investigated as aetiological agents for AA, particularly the insecticides 
chlordane, lindane and dichlorodiphenyltrichloroethane (DDT) (53, 77-79). Lindane (γ-
hexachlorocyclohexane) is an organochlorine. It was first was used as an insecticide in 1942. It 
becomes concentrated in the fatty tissue of the bone marrow (80). “The WHO report on Lindane 
concluded that there was sufficient laboratory evidence that the chemical was carcinogenic in 
animal experiments and that it is reasonable to regard such a chemical as posing a carcinogenic 
risk in man” (81). There are multiple documented reports of bone marrow injury associated with 
Lindane (82).  
The potential dangers of hair dye (which are in widespread use) have been re-emphasized as 
reports on the carcinogenity and mutagenicity of hair colourants have emerged (83,84). A case 
report from Nottingham reported a case of fatal aplastic anaemia in a 52-year-old housewife 
using a new hair dye (85). The hair dye used contained paratolylenediamine (2-methyl 1.4 
phenylenediamine) in a concentration of 0.03%. Phenylenediamine has been used for many years 
in the dyeing industry and its effects on the bone marrow are well known (85). Two groups 
previously reported studies on the mutagenic and carcinogenic properties of the various 
paraphenylenediamine dyes (83,84). The mutagenic properties are retained even after mixing with 
hydrogen peroxide, the oxidant used in the lotion developer, and appreciable quantities may be 
absorbed through the skin during one episode of hair dyeing. Although individual sensitivity is 
extremely rare, these substances used in hair dyeing must continue to be the subject of close 
scrutiny.  
Radiation is a recognized hazard that results in bone marrow ablation (86). The predictable 
pancytopenia that follows radiation exposure in therapeutic applications is not permanent. 
Marrow recovery ensues after completion of the exposure. Occupational radiation exposure 








1.4.3 Viruses and Aplastic Anaemia 
An association between viral infections and BM failure implies a direct effect on the HSC.  
Viruses other than hepatitis implicated as aetiological agents in AA include: Parvovirus B19, 
Cytomegalovirus (CMV), Epstein Barr virus (EBV), Echovirus 3, GB virus-C, Transfusion 
Transmitted virus, SEN virus and non-A-E hepatitis virus (unknown viruses) (37, 92-100). 
Association of the Torque teno virus (TTV) was reported in a 12-year-old Japanese boy. He 
presented with cytopenias following acute hepatitis. Other studies have also been conducted to 
assess the role of TTV as an aetiological agent of HAAA (98, 101). 
A documented report of AA in a 6-year-old boy, two months after the onset of the acute hepatitis 
demonstrated an associated with Echovirus-3 (98). 
In HIV infected patients, SAA has developed after subsequent co-infection with Herpes Simplex 
Virus-6 (HSV- 6) (102, 103). 
 
1.4.3.1 Hepatitis Associated Aplastic Anaemia (HAAA)  
Hepatitis Associated Aplastic Anaemia is a well-recognized variant of AAA. It is rare, having 
been reported in 2-5% of cases in the West (96). In the Far East, a viral aetiology has previously 
been documented in up to 4-10% of cases of AA. This could be in keeping with the increased 
prevalence of certain viral infections in the Far East such as Hepatitis and HIV (104, 105). HAAA 
can occur in any age group, and has been found in children as well as adolescent and young men 
predominantly. There is no gender preference and also no correlation with the severity of 
hepatitis at the onset of AA (41, 98-99, 106).  
Aetiology of the syndrome has been attributed to various agents and factors which may include 
pathogenic viruses, autoimmune responses, liver transplantation, bone marrow transplantation, 
radiation and drugs administered to control the viral replication (107). 
Marrow failure and pancytopenia usually follow an acute attack of hepatitis (100, 108-109). The 
pancytopenia, usually occurs two to three months “[62days: ranging from 14 to 225]” after the 
acute hepatitis attack (55, 63). AA will rarely complicate a case of hepatitis that has already been 
diagnosed (110). It may be acute or chronic, mild and transient, self-limiting or fulminant. The 
development of AA is uniformly fatal if treatment is not instituted on time (43, 100, 111). Severe 
posthepatitic AA usually responds well to immunosuppressive therapy (IST). However, most of 
the reported cases of HAAA had fulminant hepatitis with a mortality rate of 85% (102).  
Aplastic anaemia associated with viral hepatitis has a late appearance (weeks or months after the 
episode of hepatitis) and is markedly severe and usually irreversible (111, 112). Of the hepatitis 
viruses, hepatitis A, B, C, E and G have been implicated (44, 113, 114, 115). There has been no 
documented association with blood transfusion, toxins and drugs (102).   
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1.4.3.2 AA associated with Parvovirus B19 infection 
Human parvovirus B19 has been associated with a broad spectrum of haematological diseases. It 
is an under-recognized hepatotrophic virus and has been documented as an offending agent in 
HAAA. Manifestations range from abnormal liver function to fulminant hepatic failure and AA 
(92). A case of SAA was reported following asymptomatic infection with Parvovirus B19, in a 
previously healthy boy without any underlying diseases (116). 
Further studies were conducted (1995/1996), to explore the frequency of parvovirus B19 
infection in children with SAA (117). Parvovirus B19 DNA and antibodies were investigated in 
thirty cases of SAA. Six cases were associated with active or recent parvovirus B19 infection and 
the study concluded that parvovirus B19 infection might be associated with childhood SAA and 
should therefore be considered as a possible aetiologic agent in some children with SAA (118). 
1.4.3.3 AA and Epstein Barr Virus (EBV) 
Aplastic anaemia is a rare complication of infectious mononucleosis. The pathogenic 
mechanisms involved in EBV infection include direct cytotoxicity or modulation of the host 
immune response (100, 102, 107, 119). 
In a case report published in Toronto in 1987, a previously healthy 17-year-old female was 
diagnosed with AA on bone marrow biopsy. Her presenting symptoms were petechiae and 
epistaxis a week after an episode of pharyngitis. She also had cervical lymphadenopathy and 
fatigue. Positive results were demonstrated with the monospot test. Elevated titres of antibody to 
EBV capsid antigen were detected.  
1.4.3.4 AA and Human Immunodeficiency Virus (HIV) infection 
Various haematological alterations have been documented in acquired immunodeficiency 
syndrome (AIDS) patients.  The prevalence of these have been reported to be increased 
according to progressive immunologic deficiencies and the severity of retroviral infection (120). 
Cytopenias occur frequently. Amongst this, common haematological manifestation are 
thrombocytopenia, leucopenia, anaemia and granulocytopenia. Anaemia, of which the causes are 
multifactorial, is prevalent in approximately 63-95% of patients with acquired immunodeficiency 
syndrome (AIDS) (121, 122). Pancytopenia is commonly evident in patients with HIV-1 infection 
and virtually all patients with advanced AIDS (group IV) are pancytopenic (123). It has also been 
observed that antibody directed against the glycoprotein (Gp) 120 of HIV contributes to 
haemopoietic suppression (120). 
Bone marrrow failure is multifactorial in patients with HIV/AIDS, and multiple different 
aetiologies may account for the varied histological findings on BM examination of these patients. 
Bone marrow findings may vary, and hypocellularity has been reported. One study found that 12 
out of the 60 HIV positive bone marrows examined was hypocellular (124, 125).  
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Frank hypocellularity is exceptional and bone marrow aplasia in the form of severe aplastic 
anemia (SAA) extremely rare (123). 
There are very few reported patients with AA in the setting of HIV, and SAA is a rare disease, 
that has been exceptionally reported (126). Aplastic anaemia secondary to HIV infection has been 
reported in a 13-year-old female in India. This patient acquired HIV through a blood transfusion 
at age 5. Her AA responded very well to the ART combination composed of stavudine (D4T), 
lamivudine (3TC) and nevirapine (NVP) (127). Another documented case report was that of a 34-
year-old HIV positive male patient, who had received an allogeneic HSCT for AA (128). 
In the setting of HIV, management of SAA remains challenging (136). No documented evidence 
for the use of ATG and ciclosporin for treatment of AA in the setting of HIV, exists. AA in some 
patients may have an excellent haematological and clinical response to ARV therapy (129).  
The observation that HIV positive patients do not receive the standard first-line drug therapy for 
SAA (combination of horse ATG and CSA) reflects the concern of an anticipated higher risk of 
severe infection with full immunosuppressive therapy in the setting of HIV infection.   
It has been documented that BMT in AA associated with HIV, is not very useful (130). However, a 
recent study has identified 8 patients who were diagnosed with SAA associated with HIV 
infection (129-130).  
Four patients were offered HSCT, whereas the other 4 were managed with non-transplant 
therapeutic modalities. A worse outcome was observed in the non-transplanted group, were 3 of 
the patients demised from infections that were not HIV related. Of the 3 patients: two patients 
demonstrated no response (one to ciclosporin and steroids and the other to androgens) and the 
third patient had a partial response to anti-thymocyte globulin (ATG) associated with CSA. Only 
one of the non-transplanted patients demonstrated an early and durable remission on 
eltrombopag treatment (for a 23-month follow-up period) (131). 
Conversely, long term survival with a median follow-up of 59 months (54-101 months) was 
documented in 3 of the 4 patients in the transplanted group. All 3 patients had received a reduced 
intensity conditioning (RIC) regimen. The fourth patient was the only patient who received a 
myeloablative conditioning (MC) regimen. He experienced veno-occlusive disease and died of 
multiorgan failure at 39 months’ post-transplant. Hence, BMT is an approach that should 
possibly be considered for SAA in HIV infected patients (126). 
New alternate therapies, such as eltrombopag, warrant further evaluation for the management of 




1.4.4 Autoimmune Disorders 
Aplastic anaemia has been reported with many systemic autoimmune disorders. Amongst them 
are Eosinophilic fasciitis (EF), Systemic lupus erythematosis (SLE), Sjorgen syndrome (SS), 
coeliac disease, as well as association with Thymoma, which have all been reported. 
Transfusion-associated graft-versus-host disease (GVHD) is another autoimmune disorder which 
almost invariably results in fatal AA. 
1.4.4.1 Systemic Lupus Erythematosus (SLE) and AA 
Aplastic anaemia and myelofibrosis have been reported in association with fulminant cases of 
SLE. These are exceedingly rare events and occur much less commonly than peripheral 
autoantibody induced cytopenias (132, 133). 
Worldwide there are at least 19 reported cases of pancytopenia, myelofibrosis and AA. A female 
preponderance was evident, with more than 80% of the patients being female. The age group 
varied vastly between five months to 74 years, with a mean age of 27.4 years. In the majority of 
cases, AA either preceded the diagnosis of SLE, or developed later during the course of the 
illness. In the minority of cases, AA is a simultaneous diagnosis with AA (134).  
A case of AA presenting simultaneously with the classical features of SLE at onset, has been 
described in a 17-year-old Indian female (134). There are also 2 reported cases of SLE, in which 
AA and pancytopenia were the sole manifestations of the disease, months prior to the appearance 
of other clinical features. The interval from the onset of pancytopenia to the diagnosis of SLE 
ranged from 3 to 12 months (135). 
1.4.4.2 Primary Sjogren’s syndrome (SS) and AA 
There have been rare reports of SS with AA, and these were only in lymphoma patients. An 
exceptional case of primary SS and SAA without lymphoma was reported in a 28-year-old white 
male in February 1990. Cytogenetic and immunological abnormalities were documented in this 
case. This may also give clues to the pathogenesis of “idiopathic’ AA (136, 137). 
1.4.4.3 AA associated with Thymoma 
AA is a rare complication of thymoma and is extremely infrequent after thymectomy. The 
reported incidence of AA with thymoma is 0-1.4% (136, 137). AA is exceedingly uncommon 
following the surgical removal of a thymoma (138-140).  
An immunologic origin is proposed in thymoma-associated haematologic dyscrasias. A case of 
VSAA following thymectomy, was reported in a 60-year-old female patient who was 
successfully treated with immunosuppressive therapy (cyclosporine A) and G-CSF (141). 
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1.4.4.4 Ulcerative Colitis (UC) associated with AA 
Ulcerative Colitis is an inflammatory bowel disease of unknown aetiology, which predominantly 
affects the mucosa of the colon and rectum. Several cases of salazosulfapyridine or mesalazine-
associated AA have been reported in UC patients (142). A case of UC associated with AA was 
reported in a 45-year-old man who presented with thrombocytopenia before any diagnosis of UC 
or treatment with mesalazine (143). The clinical course implied that the subsequent pancytopenia 
was not drug-induced. The AA responded well to treatment with danazol and ciclosporin (CSA), 
strongly suggesting an immunopathogenetic aetiology. The observation made in several case 
reports, indicating that the same HLA-DR2 haplotype is associated with both UC and AA also 
suggests a common immunologic impairment underlying the development of these diseases (140). 
1.4.4.5 AA associated with Eosinophilic Fasciitis (EF)  
Eosinophilic Fasciitis may sometimes be associated with haematologic disorders, particularly 
AA. It is not known whether AA associated with this condition is an autoimmune disease and/or 
if it could be the initial manifestation of an evolving clonal myeloid disorder. In a cohort of 19 
patients with EF and AA, 8 patients demised from complications of AA (144-158). Patients with EF 
and AA were more likely to be men (70%) and older (mean age, 56years; range 18-71 years), 
compared to patients with isolated EF. 4 patients with EF and associated SAA were reviewed by 
Masson et al in 2013 (159). 
 
1.4.5 Pregnancy and AA 
The first time that AA was described as a clinical entity was in the year 1888, in a pregnant 
woman. Since then, 61 documented cases of AA in pregnancy have been reported (160-164). 
Although, the precise relationship between these two conditions remains a matter of speculation, 
pregnancy is still mentioned as a possible causative factor of AAA (161,165). 
It has been reported that the pregnant state results in an increased production of factors such as 
oestrogen, placental lactogen and erythropoietin. Although placental lactogen and erythropoietin 
may stimulate increased haematopoiesis, high doses of oestrogen are suggested to inhibit bone 
marrow production. Hence, it is hypothesized that BM hypoplasia during pregnancy results from 
an imbalance of hormonal factors. This is supported by the descriptions of spontaneous 
haematological recovery that have been observed following termination of pregnancy, as well as 
the relapse of AA in subsequent pregnancies (56, 166, 167). 
An epidemiological survey, to evaluate pregnancy as a possible aetiological factor in AA, was 
conducted in France in 1997. The 3 year prospective multicentric study documented the 
incidence, suspected aetiology and patient follow-up findings in 32 pregnant women. The 
patients’ ages ranged from 15-44 years. In this cohort, 2 pregnancy-associated cases of AA (6%) 
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were demonstrated. This percentage (6%) is within the range of percentages found in both the 
patient cohort as well as in the general population (168). 
Preexisting AA is sometimes worsened in pregnancy (169). This observation may be explained by 
the fact that patients with AA cannot respond to the stress of pregnancy with a normal marrow 
response. This results in worsening of the pre-existing but undiagnosed pancytopenia. 
Furthermore, the bone marrow (BM) in patients with AA is still damaged and cannot respond 
normally to the stress of pregnancy. This results in a reduction in circulating blood cells (170). 
There is no predilection for a specific gestational period in pregnancy associated AA. AA may 
develop in the first or subsequent pregnancies, and it may occur early or late in the pregnancy 
(161, 163, 164, 170). 
Spontaneous haematological improvements following induced abortion or delivery, has been 
reported, although only in one third of cases (169). Relapses during subsequent pregnancies has 
also been described, particularly in patients who have had a prior response to 
immunosuppressive therapy (IST). On the contrary, pregnancy does not trigger relapse in 
patients who have undergone successful allogeneic HSCT (170). 
Increased antenatal complications have been demonstrated with AA.  Maternal haemorhage and 
sepsis rates are escalated. Impaired oxygenation of the fetus results in growth retardation and 
even intrauterine death (IUD). Postpartum haemorhage (PPH), due to thrombocytopenia as well 
as impaired platelet function, has also been reported in patients with AA. “On review of the 
literature (among pregnant women with the diagnosis of AA), the rate of preterm birth was 
12.1%, intrauterine death 16.7%, stillbirth 15.1%, and spontaneous miscarriage 16.7%” (167, 171-
174). 
There have been few reports of pregnancy following diagnosed AA. Although these are rare 
occurrences, successful pregnancy is possible with advances in supportive management 
(transfusion and treatment of infection) (162, 164, 172). 
Although vaginal delivery is preferred, caesarian section (CS) should only be performed for 







1.5. Clinical presentation 
Patients with AA most commonly present with symptoms of anaemia (pallor), skin or mucosal 
haemorrhages or visual disturbances due to retinal haemorrhages. Infection may be a presenting 
feature but is less common. There is no lymphadenopathy or hepatosplenomegaly (in the absence 
of infection), and these findings would strongly suggest another diagnosis (176). A preceding 
history of jaundice, usually 2-3 months before the diagnosis is made, may indicate a post-
hepatitic AA (25, 176).  
A careful history and physical examination is crucial and may help to exclude inherited forms of 
AA, especially in children and young adults. It has recently been realized that the typical features 
of inherited BMFS may be absent and/or other features may be present in older patients. The 
findings of short stature, café-au-lait spots, abnormal thumbs and forearms, and skeletal 
anomalies would raise the possibility of an inherited form of AA, specifically Fanconi Anaemia 
(FA). However, FA may present in adults without physical anomalies. The most common 
presentation for patients with FA is between the ages of 3 and 14 years, although they can 
occasionally present later in their thirties (up to 32 years in males and 48 years in females) (19). 
The findings of leucoplakia, nail dystrophy and pigmentation of the skin are characteristic of 
Dyskeratosis Congenita (DKC), another inherited form of AA. The median age at presentation of 
DKC is 7 years (range 6 months to 26 years) (177, 178).  
None of these clinical features may be evident in some affected patients. The diagnosis is usually 
made at a later stage, when patients have failed to respond to IST (177, 179). The family history is 
very important in patients with AA and an inherited TERC/TERT mutation. The pedigree may 
reveal avascular necrosis of bone, cirrhosis, pulmonary fibrosis, osteoporosis, low blood counts 
or cancer. In children or young adults, a diagnosis of Shwachman Diamond Syndrome (SDS) 
should be considered if there is a previous history of malabsorption or neutropenia, especially as 
the malabsorption often resolves in later life (25, 176). 
In the context of other primary BM disorders, PNH usually refers to AAA. BM failure is the 
primary cause of anaemia in these patients. Hypocellular BMs, more severe thrombocytopenia 
(TCP), small PNH clones, lower reticulocyte counts, and modest or no elevation in LDH levels 
are more frequent in these patients. Less commonly, thrombosis may occur (180).  
Subclinical PNH is asymptomatic or patients have normal/almost normal blood counts. Few 
(usually <10%) PNH granulocytes may be observed. These patients often have a diagnosed mild 
AA or have recovered hematopoiesis after treatment of AAA. Relapse of AA may be 




1.6. Classification, Diagnostic work-up and differential diagnosis of Aplastic    
Anaemia 
1.6.1 Diagnostic criteria: 
To diagnose AA, at least two of the following criteria must be present: 
(1) Haemoglobin below 10g/dl 
(2) Platelet count below 100 x 109/l and 
(3) Neutrophil count below 1.5 x 109/1 
Bilineage or trilineage cytopenias less severe than indicated above are not classified as AA. 
These patients should have their blood counts closely monitored to determine whether they will 
develop AA later (182). 
AA severity is graded into very severe, severe and non-severe AA, according to the blood count 
parameters and bone marrow findings, (see Figure 1.1 on page 18). 
The classification of AA is related to the severity of depression of peripheral blood (PB) counts.  
The modified Camitta criteria are used to assess severity (183). 
a) Severe Aplastic anaemia (SAA) is defined by: 
-Bone marrow cellularity <25%, or if cellularity 25-50% with <30% residual hematopoietic cells         
 -AND any 2 out of 3 of the following: 
 Peripheral blood neutrophil count < 0.5 x 109/l 
 Peripheral blood platelet count < 20 x 109/l 
 Peripheral blood reticulocyte count <20 x 109/l  
b) Very severe aplastic anaemia (VSAA): As above, but absolute peripheral blood neutrophil 
count of <0.2 x 109/l  
c) Non-severe aplastic anaemia (NSAA):  
-Patients fulfilling the criteria for AA, but are neither severe or very severe. 
Treatment decisions are based on disease severity assessment, which is also of prognostic 
significance. 
In Severe AAA, infections are a major cause of death (184). The main risk factor is the profound 






       Figure 1.1 : Classification of AA a) BM trephine- severe AA   b) Non-severe AA (186) 
           AA- aplastic anaemia. BM- bone marrow 
1.6.2 Diagnosis of Hepatitis Associated Aplastic Anaemia (HAAA) 
 The following parameters can be used to diagnose hepatitis: 
-An increase in serum Alanine Transaminase (ALT), Aspartate Transaminase (AST), by at least    
 three times above the normal values.  (which are 6 to 41U/l, 9-34U/1, 5-58U/L for ALT and   
 AST respectively) (48, 92, 93, 104, 106, 187, 188, 189). 
 
-An increase in serum Alkaline phosphatase (ALP), gamma glutamyl transferase (GGT) and 
 bilirubin (39-117U/1, 5-58 U/1, and 2-7 micromol/L respectively). 
 
-Peripheral blood count can be determined by flow cytometry analysis with directly conjugated 
  monoclonal antibodies for CD2, CD3, CD4, CD8, CD19 and HLA-DR 
 
-Haematopoietic failure with bone marrow hypocellularity can be elucidated in terms of absolute 
 neutrophil count (less than 500 per mm3), Platelet count (less than 20,000 per mm3), 
 Reticulocyte count (less than 60,000 per mm³) (189) and Prothrombin 
 Index (%): normal value 70-100% (190). 
 
-Various virological and serological markers are available for the detection of hepatitis A, B, C, 
 D, E, G, TTV and parvovirus. 
 Among these tests, anti-HAV Ig total antibodies, HBsAg, HB core antigen, HBsIgG antibodies, 
 various HCV recombinant antigens and hepatitis E virus IgM and IgG are being in use. 
 However, to determine the causative nature of all hepatitis viruses such as HCV, HDV, HEV    
 and HGV, they can be qualitatively detected by RT-PCR reaction and DNA of parvovirus B19.    
-TTV can be detected by Nested PCR (107, 189).
 
-IgG antibody for Cytomegalovirus, EBV and parvovirus has been found a useful tool for the 
 diagnosis (48). 
-However, serological and virological parameters for hepatitis A, B and C were found negative 
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 in majority of the HAAA cases reported in several studies (102, 191). 
 
Idiopathic AA is a diagnosis of exclusion. No single test reliably diagnosis idiopathic AAA. The 
diagnostic evaluation must include an assessment of alternative aetiologies of bone marrow 
failure. The “empty” marrow on histology of AA is characteristic, and is a prerequisite for 
diagnosis. To diagnose AA with certainty, it is important to consider and exclude other possible 
causes of pancytopenia with a hypocellular bone marrow such as aleukaemic leukaemia and 
hypocellular MDS. There is increasing recognition that IBMFS are commoner than previously 
thought and may present in adulthood. Hence, the correct diagnosis of IBMFS is vital for 
appropriate management in terms of therapeutic options, with implications for the choice of 
conditioning regimen and donors for HSCT. Patient education, genetic screening and counselling 
of family members is paramount (192). 
1.6.3 Haematological investigations 
1.6.3.1 Full Blood Count (FBC) 
A pancytopenia is present. The haemoglobin (Hb) concentration, platelet counts and neutrophil 
counts are uniformly depressed. Isolated cytopenia(s) particularly thrombocytopenia, may occur 
in the early stages. There is preservation of the lymphocyte counts with a reversal of the 
neutrophil:lymphocyte ratio (7). 
Blood smear examination: Anisopoikilocytosis is demonstrated. Macrocytosis is frequent. 
Neutrophils may show toxic granulation. Platelets are small in size. Abnormal platelets, blasts, 
dysplastic neutrophils as well as other abnormal cells, such as “hairy cells” are indicative of 
other causes of pancytopenia that are part of the differential diagnosis of pancytopenia with a 
hypocellular bone marrow (7). 
1.6.3.2 Reticulocyte count 
 A reticulocytopenia is invariably present (7). 
1.6.3.3 Bone marrow aspirate and trephine biopsy (BMAT) 
Bone marrow aspirate fragments and trails are hypocellular for age. Prominent fat spaces are 
evident with a variable number of residual haemopoietic cells. Megakaryocytes and granulocytic 
(myeloid) cell series are absent or severely reduced. Dysplasia of these cell lineages is not a 
feature of AA. Erythropoiesis is markedly reduced or absent. Dyserythropoiesis, often marked, is 
a common finding that does not distinguish MDS from AA. Lymphocytes and plasma cells often 
appear prominent. Mast cells may also be easily seen. Early stages of AA may reveal increased 
macrophage activity with occasional haemophagocytosis. Background eosinophilic staining, 
representing interstitial oedema, may be apparent (193). 
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The BM trephine biopsy is uniformly hypocellular in most cases. Occasionally, hypocellularity 
can sometimes be patchy with residual cellular areas being present. Focal hyperplasia of 
erythroid or granulocytic cells at a similar stage of maturation may be evident. Small lymphoid 
aggregates can sometimes be seen, usually in the acute phase of AA or if the disease is 
associated with systemic autoimmune diseases, such as rheumatoid arthritis (RA) or SLE. 
Fibrosis (demonstrated by increased reticulin staining), dysplastic megakaryocytes and blasts are 
not seen in AA. The presence of these indicate a hypoplastic MDS or evolution to acute 
leukaemia (7). 
1.6.3.4 Cytogenetics and FISH analysis  
Prior assumptions stating that the presence of an abnormal cytogenetic clone was indicative of 
MDS and not AA, have been rectified. It has been demonstrated that abnormal cytogenetic 
clones are present in up to 12% of otherwise typical AA patients at diagnosis. These may be 
transient. They include (amongst others), del (13q) and trisomy 8. Monosomy 7, which is more 
often found in childhood MDS, can often be seen with adult AA. Due to insufficient metaphases, 
karyotyping may fail in severely hypocellular marrows. In these situations, FISH analysis for 
chromosomes 5, 7, 8, and 13 should be performed. Abnormal cytogenetic clones may be present 
at diagnosis or arise during the course of AA. The appearance of new karyotypic aberrations may 
provide evidence of clonal evolution (194). 
1.6.3.5 Flow cytometry (FCM)  
Flow cytometry for PNH should be performed on peripheral blood specimens of all patients with 
AA. This is a sensitive and quantitative test performed to detect deficient GPI anchored proteins. 
These proteins include CD14, CD16, CD24, as well as fluorescent aerolysin (FLAER) on white 
blood cells; and CD55 and CD59 on red cells. These markers are reduced/absent in PNH (see 
Chapter 4). Small PNH clones occurring in up to 50% of patients with AA, can be detected by 
FCM (195-197). 
1.6.4 Investigations required to screen for IBMFS: 
a) Peripheral blood chromosomal breakage analysis: diepoxybutane test (DEB test) 
A clastogen stress test should be performed on all children with AA. A false negative test can 
result from somatic reversion of the FA gene mutation. This is found in at least 10% of cases 
(198). If there is a negative stress test but the clinical suspicion remains high, the diagnosis of FA 
can be confirmed by testing skin fibroblasts for increased chromosomal breakage. 
Complementation group determination and mutational analysis can then facilitate genetic 
counseling. It has been recommended that this test be performed in patients younger than 50 
years. However, older patients should also be screened if FA is clinically suspected. Defining an 
upper age limit for FA screening is difficult as cases have been reported in the fourth, and rarely 
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fifth decade of life (199). All siblings of patients with FA, as well as potential transplant 
candidates should be screened using this test (7). 
Testing for other IBMFS will depend on the degree of clinical suspicion. 
b) Peripheral blood leucocyte telomere length (Flow-FISH) 
The detection of very short telomeres in blood leucocytes is characteristic of DKC. This is 
typically less than the 1st centile for age. However, not all patients with DKC have short 
telomeres and short telomeres may also occur in AAA with reduced stem cell reserve. Flow 
cytometry with fluorescent in situ hybridization (Flow-FISH) is a laboratory technique used to 
screen for abnormal telomere length. It is however, unavailable for routine clinical testing (199).   
Mutation screening for TERC and TERT aberrations, is an alternative method. There are 
probably many, as yet, unidentified mutations (200). A negative genetic screen is hence 
insufficient to exclude DKC. However, these tests are useful for disease screening for telomere 
gene mutations in classic DKC, although less specific in adult onset AA with TERC/TERT 
mutations (7).  
c) Molecular analysis of the Shwachman Bodian Diamond Syndrome (SBDS) gene  
This test can confirm a diagnosis of Shwachman-Diamond Syndrome (SDS), however 10% of 
children with SDS do not have a mutation in the SBDS gene (201). The exocrine pancreatic 
insufficiency that can be screened for as a child, usually improves with age and may not present 
in adults. 
d) Emerging diagnostic tests which are not currently routine diagnostic tests, but are likely to 
be so within the next few years include: 
Next generation sequencing, gene panels for:  
 Telomere gene complex mutations 
 Other IBMFS 
 Acquired somatic mutations, typical of myeloid malignancies, to help distinguish AA    
            from hypocellular MDS and for early detection of clonal evolution to MDS/AML 
Single nucleotide polymorphism array karyotyping 






e) Ancillary tests to support a diagnosis: 
Radiological investigations are useful if an IBMFS is suspected. X-rays of the hands, forearms 
and feet will reveal skeletal abnormalities as in FA. If DKC or constitutional RUNX1 bone 
marrow failure syndrome is suspected, a high resolution CT scan of the chest is indicated. 
Abnormal or anatomically displaced kidneys are a feature of FA, and are evident on abdominal 
ultrasound scan (7). 
HbF% (Foetal Haemoglobin) 
HbF is often elevated in constitutional syndromes. As it is an important prognostic factor in 
children, the levels must be measured pre transfusion (7). 
1.6.5. Investigations to exclude other aetiologies: 
Vitamin B12 and Folate 
A documented vitamin B12 or folate deficiency must be treated before a diagnosis of AA is 
made, although bone marrow aplasia as a result of vitamin deficiency is exceedingly rare (7). 
Anti-nuclear antibody and anti-double stranded DNA 
Pancytopenia in SLE may rarely be associated with a hypocellular marrow.  It is usually 
autoimmune with a cellular bone marrow, or may occasionally be associated with myelofibrosis. 
In a patient with signs and symptoms of SLE, the above tests aid in the diagnosis (7). 
Virological tests: Viral studies for hepatitis A/B/C, EBV, CMV, HIV and Parvovirus B19 are 
routinely performed in the work-up of patients with AA. In post-hepatitic AA the serology for 
the known hepatitis viruses is usually negative. If SCT is being considered, CMV should be 
assessed. HIV and parvovirus B19 are very rare causes of AA (7).  
Abdominal ultrasound scan  
Splenomegaly and/or lymphadenopathy warrant investigation for malignant haematological 
disorders that are secondary causes of pancytopenia (7).  
Biochemistry investigations 
Liver function tests (LFTs): should routinely be performed to detect antecedent/on-going 
hepatitis and exclude any other pathology that may be present (7). 




1.7 Management of AA 
Although AA is rare, it is a serious disease and the treating physician responsible for the patient 
must contact a haematology centre/haematologist with experience and skill in the management of 
AA. This must occur as soon as possible after the patient presents and has been assessed, in order 
to formulate a patient management plan. All patients should be offered the opportunity to be 
assessed at a specialist Centre. Where possible, patients with AA should be enrolled into 
prospective clinical trials (193). 
Initial management constitutes stabilizing the patient clinically. Blood loss should be controlled 
and infections treated, prior to administration of disease specific therapy. Infection is an adverse 
factor affecting the outcome post HSCT. It may, however, sometimes be required to proceed 
with HSCT whilst active infections (particularly fungal), are present. In this situation, BMT may 
provide the best chance of early neutrophil recovery. A delay in BMT could result in progression 
of the fungal infection (193). 
1.7.1 Supportive Care 
1.7.1.1 Blood product support 
a) Red blood cell (RBC) Transfusion  
 
In patients with AA, RBC transfusion is mandatory to preserve a safe Hb level, thereby 
improving the symptoms of anemia and maintaining a good quality of life (QOL). It is the 
clinical symptoms (signs of anemia) that determine when RBC transfusion is necessary. 
The patient’s age as well as any cardiac, pulmonary or vascular co-morbidities must be 
considered. No specific pre-transfusion Hb concentration trigger has been suggested, however it 
is important to be symptom free and maintain QOL. Elderly patients as well as those with co-
morbidities may require a higher transfusion trigger. In doing so, the optimal method of RBC 
transfusion involves maximizing patient outcome whilst simultaneously avoiding wastage of 
blood products (202). 
The commonest risks associated with regular transfusion therapy include alloimmunization 
against red cell antigens and iron overload. The alloimmunization risk can be limited with the 
provision of phenotype-matched blood (for Rh and Kell blood groups) (203). 
b) Platelet (plt) Transfusion  
 
Platelet transfusion support may frequently be required for patients with AA. With the exception 
of one publication, literature pertaining to plt transfusion support in AA is deficient (204). 
Information has been taken from studies looking at patients with reversible thrombocytopenia, 
and their requirement for plts (205, 206).  
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The following recommendations have been made by the British Committee for Standards in 
Haematology (BCSH):  
 
1) Prophylactic platelet transfusions are necessary for stable AA patients on active therapy 
with a platelet count <10 X 109/1.  
 
2) In septic patients, the platelet count should be kept >20 x 109/1.  
 
3) In patients with TCP, who require invasive procedures, plt transfusions are required. The 
aim should be to achieve a platelet count in line with BCSH guidelines for the relevant 
procedures. (British Committee for Standards in Haematology, 2003) A platelet count 
should be checked pre-procedure.  
 
4) Whilst on ATG treatment, worsening TCP may result as a consequence of increased 
platelet consumption in the presence of cross-reacting antibodies to ATG, binding to 
platelets. The exact threshold for platelet transfusion prior to ATG treatment is not 
known. However, a threshold of 20 x 109/1 has been suggested (207, 208). 
 
5) HLA and non-HLA (minor histocompatibility) alloimmunization resulting from regular 
RBC and plt transfusion results in poor platelet increments as well as post HSCT graft 
rejection risk. This risk may be reduced, but not completely eliminated by leucodepletion 
of cellular blood components (209, 210).  
 
6) For patients’ refractory to plt transfusion due to HLA alloimmunization, the use of HLA-
matched platelets is a consideration. Other causes of platelet refractoriness (such as 
infection) must be excluded prior to this. If HLA antibodies are absent and patients do not 
demonstrate an increment with the administered HLA-matched platelets, investigation 
and matching for human platelet antigen antibodies is warranted (203).  
 
c) Granulocyte transfusions 
 
In patients with severe neutropenia-related life-threatening infections, the use of irradiated 
granulocytes may be considered as it may be a life saving measure. There is limited data 
regarding the efficacy of granulocyte concentrates. There have also been reports of adverse 
events, such as transfusion-related acute lung injury (TRALI), alloimmunization and febrile 
reactions, linked to its use (211). 
d) Use of irradiated cellular blood components for AA patients 
 
Irradiation of cellular blood components prevents transfusion-associated graft-versus-host 
disease (TA-GVHD). Although it is a rare complication of blood transfusion, TA-GVHD has a 






Irradiation of cellular blood components is indicated for: 
 
1) AA patients undergoing HSCT (213). 
2) All granulocyte concentrates and HLA- matched platelets. 
3) Patients receiving ATG. It is uncertain as to how long after ATG therapy, irradiated 
blood products should be continued for. It has been suggested that it should be continued 
while patients continue to take CSA following ATG therapy (214, 215). 
4) Patients treated with alemtuzumab (213). 
 
e) Iron chelation therapy 
 
Tissue iron overload is a serious complication in AA patients receiving regular RBC transfusion. 
Although it is an unreliable parameter, the serum ferritin is still the most widely used indicator 
for assessment of iron overload. In HSCT patients, a raised serum ferritin reflects an adverse 
outcome. Cardiac and liver iron can be quantified by magnetic resonance imaging (MRI) (T2* or 
R2). Although this method is an extremely useful adjunct, there have been no publications 
regarding its utility in AA. Data regarding iron chelation therapy (ICT) in AA is lacking (216). 
A study conducted by Lee et al, 2010, confirmed that ICT with deferasirox can be safely 
administered to aplastic anaemia patients. There was a reduction in serum ferritin levels, and 
drug-induced cytopenias did not occur (211). Dose adjustments are necessary to chelate heavily 
transfusion dependent patients. Renal dysfunction may occur with deferasirox, which should be 
used cautiously in AA patients consuming CSA. Deferiprone, although extremely efficacious, 
cannot be used in AA patients as it is contraindicated in neutropenic patients (217). Venesection 
can also be performed for iron overload. It is recommended in those patients responding to 
immunosuppression, and can even be used after successful HSCT (203). 
1.7.1.2 Infection: prevention and treatment 
The major cause of death in patients with AA is infection (218). Neutropenia in SAA is protracted 
and persistent. Invasive fungal infections (IFI) and severe bacterial sepsis occur frequently. This 
is contrary to neutropenia experienced in cancer patients post chemotherapy (215). 
a) Prevention of infections  
 
Ideally, isolation facilities should be available in hospital for nursing severely neutropenic AA 
patients. Antibiotics, antifungals, mouth care products (antiseptic mouthwash such as 
chlorhexidine or saline), and meals with low bacterial content are common prophylactic 
measures. Hospitals should have local policies guiding the use of prophylactic antibiotics. Many 
clinicians advocate the use of two non-absorbables (e.g. colistin and neomycin) or quinolones 
(e.g. ciprofloxacin). An antifungal, preferably itraconazole or posaconazole, is advised 
depending on availability. Prophylaxis against Pneumocystis jirovecii is not routine practice. 
Anti-viral prophylaxis in untreated patients with AA is also not recommended (214).  
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Acyclovir or valaciclovir is used prophylactically during and post ATG therapy. However, sub-
clinical reactivation of CMV and EBV, which is usually self-limiting, is a common occurrence 
during ATG therapy (203).  
b) Treatment of infections 
 
Clinicians should be guided by local hospital policy and protocols for the management of febrile 
neutropenia. Patients should be assessed and treated for bacterial, viral and fungal infections (219). 
If an IFI is clinically suspected, empirical anti-fungal therapy should be initiated early. 
Granulocyte transfusions are a potentially lifesaving measure especially in conditions such as 
severe sepsis due to invasive fungal disease. They are also particularly important for patients due 
to proceed to HSCT (220). 
1.7.1.3 Haemopoietic growth factors (HGF) 
Erythropoiesis-stimulating agents (ESA) and granulocyte colony-stimulating factor (G-CSF) are 
HGF.  They are often ineffective in maintaining blood counts in patients with AA (221). However, 
the thrombopoietin-mimetic (eltrombopag) has demonstrated encouraging preliminary results 
(222). 
1.7.2 Specific Therapy 
1.7.2.1 Immunosuppressive therapy 
a) Current standard first line IST  
 
Standard first line IST constitutes the combination of horse ATG (ATGAM; Pfizer, New York, 
NY, USA) and CSA. Lymphoglobuline horse ATG, which was previously used, is no longer 
available (1, 7, 223). Studies have reported significantly improved therapeutic responses, as well as 
survival rates with horse ATG compared to rabbit ATG (207, 224). G-CSF is not routinely indicated 




ATG + CSA is indicated as first line therapy for: 
 NSAA patients who are bleeding, experiencing infections, transfusion dependent or for 
the preservation of lifestyle activities.  
 SAA/VSAA patients with no HLA-matched sibling/donor 
 SAA/VSAA patients approaching >35-50 years of age 
 
Although there is no set upper age limit for ATG, the mortality rate is reported to be higher in 
patients aged >60 years treated with ATG (225, 226). Careful co-morbidity assessment is necessary 
to evaluate medical fitness prior to consideration for ATG in patients aged >60 years.  
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Post ATG therapy, these patients complicate with bleeding and infection. This culminates in 
increased mortality in this age group (203). 
If there is a failure to respond to therapy the first time, or if patients relapse after a first course, 
and even if the patient does not warrant an unrelated donor (UD) HSCT, a second course of ATG 
may be indicated (1, 7, 223). Rabbit ATG may be used for a second course. As an alternative, horse 
ATG may also be utilized for the second course. The disadvantage is the association with more 
immediate and late (serum sickness) side effects (224). Rabbit ATG, in contrast to horse ATG, is 
known to produce a severe prolonged lymphodepletion. In some studies, a higher infection rate 
has been reported with rabbit ATG making adequate prophylactic antimicrobial support 
fundamental with its use (203). 
c) Administration of ATG:  
 
Antithymocyte globulin is a potent immunosuppressive agent which is administered on an in-
patient basis. Familiarity with the drug, its use and potential side effects is essential. Patients 
should be afebrile (ideally), as well as clinically and hemodynamically stable prior to starting 
ATG therapy.  
Platelet refractoriness must be excluded with platelet count increment studies. Administration of 
all prophylactic antiviral, antibiotic and antifungal medications should be commenced before 
ATG (203). 
Antithymocyte globulin has both early and delayed adverse effects. Early reactions include: 
fever, rash, rigors, hypo/hypertension, fluid retention, and rarely acute pulmonary oedema/adult 
respiratory distress syndrome and anaphylaxis. Delayed side effects include serum sickness 
occurring 7-14 days from ATG commencement. This commonly occurs with arthralgia, myalgia, 
rash and fever. 
Treatment of serum sickness includes: adequate analgesia and intravenous hydrocortisone 100mg 
four times a day (QDS). This is usually required for a few days. Serum sickness results in 
platelet consumption, and additional platelet transfusions are often needed during this period. 
There is no reported proven benefit of using G-CSF with ATG + CSA.  Neither patient response 
nor overall survival (OS) is improved (225). 
The equine/horse ATG (ATGAM) dose is 40 mg/kg/d for 4 d, administered as an intravenous 
infusion over 12-18h. A prior ‘test’ dose must be administered, due to the anaphylactic risk. Each 
dose of ATG should be preceded with intravenous (IV) methyl prednisolone 1 mg/kg and 
chlorphenaramine. Platelet transfusions are necessary to maintain the platelet count >20-30 x 
109/1 (1, 7).  
Febrile episodes, should be treated with broad-spectrum IV antibiotics, irrespective of the 
neutrophil count. Fluid balance is critical, especially in elderly patients, as fluid retention is a 
common occurrence whilst on ATG treatment. Prednisolone at a dose of 1 mg/kg/d for 2 weeks, 
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is started on the day after ATG is completed. Rapid tapering of prednisolone over the next 2 
weeks must follow (203). 
 
Treatment with CSA is commenced as the prednisolone dose is tapered. CSA is initiated at a 
dose of 5 mg/kg/d to achieve trough blood levels of 100-200 µg/l. It must be continued whilst the 
blood count continues to steadily improve. To reduce the risk of later relapse, slow CSA tapering 




Patient and disease response to ATG therapy is often delayed. It usually starts after an average of 
3-4 months. Horse ATG has a 6-month response rate of approximately 70%. The five-year 
overall survival is age-dependent. ATG + CSA have significantly higher response rates in 
NSAA, compared to CSA alone (277). Up to 35% of patients relapse after treatment with ATG. 
There is a risk of clonal evolution to MDS/acute myeloid leukaemia (AML) in 15% of cases. 
10% of patients may develop hemolytic PNH (1, 229).  
 
Studies report that approximately 35% of refractory AA patients and 55-60% of relapsed AA 
patients respond to a second course of ATG (1, 26, 31, 35, 228, 230). 
 
e) Other immune suppressive drugs: 
 
Other immune suppressive drugs have been used in AA, however it is recommended that expert 
advice be sought when considering these. Amongst those not recommended in the treatment of 




The potential risk of relapse of AA following vaccinations in responders to IST, exists.  
Evidence is limited, however the hypothesis that a viral insult is likely to be the trigger in the 
pathogenesis of AA is a crucial one (231, 232). Vaccinations in non-transplanted patients should be 
avoided. This includes the influenza vaccine. Vaccinations are however, routinely recommended 
following HSCT for AA (203). 
 
1.7.2.2 Haemopoietic stem cell transplant (HSCT) in AA 
a) Current indications for HSCT in adults 
The current indications for HSCT are guided by the European Blood and Marrow 
Transplantation (EBMT) SAA working party (SAAWP) (233). 
HLA identical sibling donor: Up-front HSCT from a matched sibling donor (MSD) is indicated 
in young and adult patients, with SAA who have a MSD. Similar outcomes have been reported 
for patients aged 40-50 as those aged 30-40 years (230). Co-morbidities should, however be 
carefully assessed, to evaluate medical fitness for up-front transplantation instead of IST for 
patients aged 35-50 years (203). 
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Unrelated donor: UD HSCT is indicated for SAA if there was a failure in response to one 
course of IST. No strict upper age limit has been delineated. However, this should be 
individualized according to co-morbidities at the transplant institute. Donors should be a 10/10- 
or 9/10- match, based on HLA high resolution typing for class 1 (HLA-A, -B, -C) and class II 
(HLA-DRBI, -DQBI) antigens (203). 
Alternative donor: HSCT using either cord blood, a haploidentical family donor or a 9/10-
matched UD are possible considerations, among other treatment options. They may be performed 
after failure to respond to IST or in the absence of a matched sibling donor (MSD) and a suitably 
matched UD (233, 234). Donor screening for donor-directed HLA antibodies must be performed, as 
these are associated with a very high risk of graft rejection, if detected.  Clear guidance on the 
exact indication for alternative donor HSCT is lacking, as it has been reported to be less 
successful than MSD or UD HSCT (203). 
Syngeneic donor: In the rare circumstance that a syngeneic donor is available, HSCT should be 
considered in all patients irrespective of the patients age. It has been reported that the long term 
OS exceeds 90% (218). 
b) Timing of donor search/availability 
HLA tissue typing must be performed at the time of diagnosis in all newly diagnosed AA 
patients, who are potential transplant candidates. This facilitates a MSD HSCT to proceed as 
early as possible, thereby avoiding the complication of sensitization to HLA and minor 
histocompatibility antigens. Also, as potential availability of UDs has been realized, patients may 
proceed to UD HSCT should there be no response to a course of ATG and CSA. This can even 
be considered earlier if the patient has severe and/or recurrent infections. A response to IST is 
usually assessed at 3-6 months. 
c) Pre-transplant work up 
A multi-disciplinary team (MDT) approach is a necessity in the pre-transplant patient work up, 
which aims to: (i) confirm the diagnosis and exclude/document clonal evolution, (ii) evaluate co-
morbidities, (iii) select the donor, conditioning regimen, stem cell dose and source, (iv) address 
fertility issues and (v) inform the transfusion laboratory of the potential transplant and review of 
transfusion requirements (203). 
d) Conditioning regimens 
The (i) patient’s age, (ii) donor type and (iii) choice of antibody (ATG or alemtuzumab) 
determine the choice of conditioning regimen to be used (235-238). 
The survival for adult MSD HSCT is age dependent. The OS between the ages of 30 and 50, is 
reported to be 70-85%. Recent analysis has indicated that outcomes after UD HSCT are no 
longer inferior to MSD HSCT (239-240). 
1.7.2.3 Thrombopoietin mimetics: Eltrombopag 
Eltrombopag, a small molecule, oral thrombopoietin receptor agonist was observed to have 
haematological responses, including a trilineage response, in 40% of patients in a study 
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performed to assess its use in AA. Most patients tolerated the therapy well. Deranged LFT’s 
particularly, an elevated transaminase level has been observed. There have been reported 
concerns about clonal evolution, including monosomy 7, which requires further evaluation (226). 
Eltrombopag has been Food and Drug Administration (FDA) approved in the United States of 
America (USA), for treatment of SAA refractory to IST. It has also been licensed for SAA 
refractory to IST or patients who are heavily pre-treated and unsuitable for HSCT. It should be 
cautiously used with meticulous long term monitoring for clonal evolution. A BMAT should be 
performed to exclude an abnormal cytogenetic clone typical of MDS/AA, particularly 
monosomy 7, prior to starting treatment (203). 
 
1.8. Management of AA in specific populations 
1.8.1 Management of AA in pregnancy  
The relationship between AA may be either causal or coincidental, however it remains a serious 
condition which poses management challenges, and variability in clinical outcome. The 
diagnosis of AA may be made for the first time during pregnancy, at an early or late gestation 
(203). 
Cytopenia(s) will often progress during the pregnancy. However, there have been reports of 
spontaneous disease remission after abortion (spontaneous or therapeutic) or post-delivery (170). 
Relapse of AA is a common occurrence during pregnancy in patients who have previously 
responded to ATG. This occurs particularly in patients who demonstrate a partial response (241).  
On the contrary, pregnancy does not trigger disease relapse in patients who had undergone 
successful HSCT (203). 
A study conducted by Tichelli et al, 2002, evaluated the outcomes of 36 pregnancies in women 
previously treated with IST. Approximately 50% involved maternal complications, of which 3 
abortions, and 2 cases each of eclampsia and maternal deaths, were reported. Fetal 
complications, including 5 premature deaths were also documented. Relapse of AA was evident 
in 19% and a further 14% needed transfusion support during delivery. The presence of normal 
blood counts prior to conception did not safeguard against relapse of AA during pregnancy (241). 
Improvements in maternal and fetal outcome have been reported in recent years due to improved 
supportive care, particularly the supply of blood products (171). Counselling regarding the 
potentially serious risks to both the mother and baby must be discussed with patients and their 
family (242). Patients must be monitored frequently throughout the pregnancy. They can be seen 
monthly initially, however the frequency should be increased later according to disease severity. 
Close liaison with the obstetric team and haematologist is essential in the management of these 
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patients. The presence of a PNH clone warrants discussion with a specialist haematology centre.  
The mode of delivery is to be determined on obstetric grounds (203). 
The mainstay of treatment of AA in pregnancy is supportive care. The platelet count should 
ideally be maintained above 20 x 109/l. Although platelet transfusions are usually necessary to 
achieve this, the risk of alloimmunization and platelet refractoriness need to be considered. CSA, 
which is safe during pregnancy, is recommended for patients who are transfusion dependent.  
ATG, androgens and allogeneic HSCT are not recommended for AA during pregnancy (243). 
 
1.8.2 Management of AA in elderly patients  
Compared to younger patients, the management of elderly patients with AA (aged >60 years) is 
considerably more complex. To compound this, patient outcomes are worse due to poor 
treatment tolerability (203).  
Patient management should be individualized. They should be thoroughly assessed for co-
morbidities and other conditions which are more common in this age group, such as hypoplastic 
MDS, which should be excluded. A good quality of life is an important outcome in this age 
cohort and patients should have their specific requests respected. Even in the very elderly, older 
age per se, is not a reason to withhold treatment. The treatment of choice in SAA remains 
immunosuppression.  
In NSAA patients, the combination of ATG and CSA has demonstrated more rapid and complete 
responses compared to CSA alone (228). The disadvantage is that patients must be hospitalized. 
The risk of acute and delayed toxicity is also higher compared to younger patients. Hence the 
risk-benefit ratio of treatment should be weighed up individually. The risks of infection, 
bleeding, cardiac failure and arrhythmias with ATG is significantly elevated in the elderly. 
Therefore, all patients must have a thorough assessment prior to treatment initiation. An inferior 
survival rate has been documented in older patients after ATG therapy compared to younger 
patients (226).  
Allogeneic HSCT has no place as first line therapy in patients aged >60 years. HSCT, may 
however be considered in specific individuals with a syngeneic donor. Whilst some have 
reported that the treatment which is most convenient and least toxic should be administered, 
others considered how quickly a response is desired. Examples of these include patients with life 
threatening cytopenias (neutrophil count <0.2 x 109/1) or patients hospitalized for severe 
infection, who should be treated more intensely compared to those with less severe AA (203). 
Alternative treatments such as CSA alone, oxymetholone (or danazol) or alemtuzumab, have 
been used in elderly patients (228). CSA alone has the advantage of being convenient as it is 
outpatient-based treatment. Patients require close monitoring to detect nephrotoxicity and 
hypertension. Alemtuzumab as a single agent, is a consideration in refractory/relapsed AA. 
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However, very careful assessment of medical fitness in older patients prior to considering this 
agent is necessary (1). 
In men who are intolerant or unresponsive to CSA, oxymetholone or danazol can be considered 
(236, 244). Danazol, which is known to have fewer masculinizing adverse effects than 
oxymetholone, is a better alternative for female patients. Nephrotoxity, hepatic tumours, mood 
changes, cardiac failure, prostatic enlargement and raised blood lipids have necessitated careful 
monitoring of oxymetholone therapy. Best supportive care should be offered to patients who are 
intolerant of, or who decline IST (203). 
1.8.3 Management of HAAA 
As a result of the poor prognosis in HAAA, the standard treatment remains allogeneic BMT from 
HLA matched siblings (105, 235). HLA matched donors are easier to locate because HAAA mostly 
occurs in children (237). IST post BMT is effective. ATG and CSA have been safely administered 
without eliciting any acute side effects. Glucocorticoids have also been employed in combination 
with immunosuppressive medications for the treatment of HAAA patients (237).  
High doses of Cyclophosphamide (CY), (a potent immunosuppressive drug which elicits its 
effects by readily destroying the lymphocytes and committed myeloid cells) induces a durable 
remission in HAAA. HSC release an enzyme called aldehyde dehydrogenase which inactivates 
the drug. Hence, HSC are not susceptible to CY toxicity (105).  
It has been reported that the administration of antiretroviral therapy improves Parvovirus induced 
AA (113, 238). Antiviral therapy for treating hepatitis B associated HAAA is not known. However, 
there have been studies in which the nucleoside analog, lamivudine (3TC), has been 
administered for AA secondary to HBV infection. Remission of AA was the result in patients 
with SAA accompanied by HBV infection.  
 
Although Interferon is a known and effective treatment for both HBV and HCV infections, it has 
myelosuppressive effects, which limit its use as a potential therapy for HAAA (113).  
 
1.8.4 Management of PNH 
The only widely effective therapies for classical PNH patients is terminal complement inhibition 
using eculizumab and allogeneic bone marrow transplantation (BMT). Corticosteroids may 
reduce hemolysis and improve hemoglobin levels in some PNH patients. However, the long-term 
toxicity and limited efficacy restricts their use.  
a) Eculizumab 
Eculizumab is a humanized monoclonal antibody that is highly effective in treating PNH. The 
natural history of the disease has been altered with this drug (245-248). By binding to C5, it blocks 
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terminal complement. It is the only approved treatment for PNH (249, 246, 247, 250).  It requires 
intravenous administration every 7 days for the first 5 weeks, and then biweekly thereafter. 
Eculizumab inhibits MAC formation. This compensates for the CD59 deficiency in PNH 
patients. There is, however, no compensation for the CD55 deficiency.  Hence, this drug is 
highly effective in abrogating the IVH in PNH, but the mild to moderate extravascular hemolysis 
due to C3d deposition on the PNH red cells, continues (251). 
Treatment decisions should not be based solely on the size of the PNH clone. BM failure is not 
alleviated by therapy with Eculizumab, hence patients with AA are unlikely to derive benefit 
from its use and therapy should address the BM failure. Nearly all classical PNH patients will 
respond to eculizumab. 
b) Bone Marrow Transplant (BMT) 
Given the risks of transplant-related morbidity and mortality, BMT should not be offered as 
initial therapy for patients with classical PNH (252, 253). In countries where eculizumab is not 
available or in patents with the heterozygous c.2654G→A mutations in C5, this may be an 
exception (254). 
Patients with the prerequisites for SAA with PNH clones, are good candidates for BMT if they 
are young and have a suitable donor. Myeloablative conditioning regimens are not necessary to 
eliminate PNH clones as cure can result from allogeneic BMT following non-myeloablative 
conditioning regimens (255, 256).  
Non-myeloablative regimens preserve fertility and are preferred in patients with moderate organ 
dysfunction who may not tolerate a myeloablative regimen. Continued use and investigation of 










CHAPTER TWO:  PATIENTS AND METHODS 
 
2.1. Study design and population 
This is a retrospective study of all adult patients (according to hospital admission criteria-males 
and females over 12 years of age) with a confirmed bone marrow diagnosis of 
Aplastic/Hypoplastic Anaemia made at the NHLS Haematology Laboratory at Inkosi Albert 
Luthuli Central Hospital, Durban, Kwa Zulu Natal, during the period January 2005 to October 
2015. 
The inclusion criteria were: 
All patients with a bone marrow diagnosis of aplastic/hypoplastic anaemia made at the 
haematology laboratory at the NHLS, IALCH were included in this study.  
The exclusion criteria were: 
Patients whose bone marrows were sent to laboratories other than the NHLS at IALCH, and 
whose diagnosis of aplastic/hypoplastic anaemia was made at other laboratories were not 
included in this study. 
Patients not fulfilling the definition of aplastic/hypoplastic anaemia (ie. a peripheral 
pancytopenia together with a hypocellular/acellular bone marrow in the absence of an abnormal 
infiltrate or marrow fibrosis).  
2.2. Methods 
Data was collected retrospectively. The bone marrow aspirate and trephine (BMAT) biopsy of 
each patient was reviewed in great detail. Available demographic, clinical and laboratory 
parameters for each patient were documented on a standardized data collection sheet (Appendix 
1). Data was obtained from documented bone marrow referral forms/letters, bone marrow 
recording journals, laboratory information computer systems and available results on TrakCare 
laboratory information system. Demographic and clinical data for patients who were referred to 
IALCH was obtained from patient hospital records on the Soarian and Meditech databases. 
2.3. Data analysis 
Data was recorded in an EXCEL spreadsheet and analyzed by a statistician. STATA v13.1 
statistical software was used in the analysis. Missing data was excluded from the analysis. The 
data was summarized using frequency and percents for categorical data. Numeric data was 
examined using Shapiro Wilk test for normality. Means (SD) were used for data meeting the 
assumption of normality and medians (IQR) for others. Sub group comparisons were made using 
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the Chi square test for categorical data and t test or ANOVA for comparing means. A p value of 











CHAPTER THREE: RESULTS 
3.1 Hospital referral system 
The pie chart on the following chart displays the hospitals from which the bone marrow aspirate 
and trephine biopsies were referred to Inkosi Albert Luthuli Central Hospital (IALCH) for 
assessment (Figure 3.1). 
The largest number of referrals were from hospitals with a wide drainage area in terms of the 
number of other hospitals referring to them. These include King Edward Hospital (15 cases), 
Ngwelezane Hospital (NGH) (15 cases), Greys hospital (10 cases), R K Khan Hospital (RKK) 
(11 cases), Prince Mshiyeni Memorial Hospital (PMMH) (9 cases) and Mahatma Gandhi 
Memorial Hospital (PMMH) (9 cases).  
Despite being diagnosed at the NHLS Haematology Laboratory at IALCH, 13 of the 92 patients 
did not reach the clinical team at IALCH, which is the only haematology centre in the KZN 
public sector that offers treatment for this condition. Of the 13 cases, 5 were from King Edward 
Hospital, 2 from Edendale Hospital, 2 from King George Hospital (now known as King Dinizulu 
hospital) and 1 each from Greys hospital, Stanger hospital, RKK and NGH. All of these patients 
that had not been referred to IALCH Clinical Haematology for assessment and management 
were categorized as Severe AA (SAA) according to their peripheral blood counts and BMATs. 
One patient demised at KEH. As the other 12 patients did not reach IALCH, clinical information 














Figure 3.1: Distribution of referral hospitals 
 
 
ADH- Addington Hospital. EDH- Edendale Hospital. KEH- King Edward Hospital. KGV- King George V Hospital. 
LPH- Ladysmith Provincial Hospital. MGMH- Mahatma Ghandi Memorial Hospital. NDH- Northdale Hospital. 
NEW- Newcastle Hospital. NGH- Ngwelezane Hospital. PSH- Port Shepstone Hospital. PMMH- Prince Mshiyeni 
Memorial Hospital. RKK- R K Khan Hospital 
 
3.2 Patient characteristics 
A total of 92 patients with Aplastic/Hypoplastic anaemia were diagnosed between January 2005 
and October 2015. There were 42 males (M) and 50 females (F), with a male: female (M:F) ratio 
of 0.8:1.    
The median age at presentation was 24 years (range 13-75 years). The inter-quartile range (IQR) 
was 19-35 years. The median age amongst the males was 23 years (range 15-75 years). The 
inter-quartile range (IQR) was 20-29 years. The median range amongst the females was 25 years 
(13-68 years). The inter-quartile range (IQR) was 18-43 years. 
Of the 92 patients, 80% (73 of 92) were Black, 15% (14 of 92) Indian and 5% (5 of 92) 
Caucasian. In the cohort of Black patients, the median age at presentation was 23 years (range13-
59years). The Indian patients had a median age of 33 years (range16-68years). The median age 
in the Caucasian population was 48 years, with a range of 17-75years. 
Approximately 53% of patients (49 of 92) were between the ages of 13-25 years. Of these, 25 































Only 5.4% of patients (5 of 92) were older than 60 years. Within the cohort aged older than 60 
years, 4 patients were Indian and 1 was Caucasian. 3 patients were female and 2 were male.  
The number of patients between the ages of 26 and 59 years, constituted 38%. Blacks comprised 
26 patients; Indians 6 and Caucasians 3 in this cohort. 19 patients were female and 16 were male. 
No Black patients were older than 60 years of age at presentation (see Figures 3.2a and 3.2b 
below). 
 


























































3.3 Failed Bone Marrow Aspirate and Trephine Biopsies (BMATs) 
Of the 92 BMATs received, 15 patients had a single failed BMAT at the base hospital.7 patients 
had 2 previous failed BMATs at the following base hospitals: Greys, KEH, PMMH (2 patients), 
RKK and ADH. In addition to the above mentioned hospitals, the following hospitals had 1 
failed BMAT sample: NGH, and Stanger hospital (See Table 3.1 on the following page). Repeat 
successful BMAT biopsies were performed on all these patients at the IALCH Clinical 
Haematology department. 
 






































Table 3.1: Distribution of failed BMATs from referral hospitals 
 
Hospital Number of patients Failed x 1 Number of patients Failed x 2 
NGH 5 1 
RKK 4 1 
GREYS 2 1 
PMMH 1 2 
STANGER 2 0 
ADH 1 1 
KEH 0 1 
IALCH 0 0 
    
NGH- Ngwelezane Hospital. RKK- R K Khan Hospital. PMMH- Prince Mshiyeni Memorial Hospital. ADH- 
Addington Hospital. KEH- King Edward Hospital. IALCH- Inkosi Albert Luthuli Central Hospital 
 
3.4 Clinical features 
Clinical data was available for 80 patients. 12 patients had no available clinical data. 
Symptoms (sx) of thrombocytopaenia (bleeding and bruising) were present in 61% of patients 
(49 of 80), at presentation. 34 patients presented with bleeding in the form of epistaxis, gum 
bleeds and menorrhagia. 1 patient had bleeding during pregnancy.  Symptoms of anaemia 
(weakness/fatigue/dizziness) were present in 53% of patients (42 of 80) at presentation. 27 
patients complained only of fatigue or weakness. 13 patients experienced bleeding as well as 
fatigue/weakness.  
At presentation, only 7,5% (6 of 80) of the cohort had infections, presenting in the form of skin 
abscesses, tonsillitis and gastroenteritis. Other less common presenting features were jaundice, 
due to Viral Hepatitis in two patients and acute loss of vision in one patient due to CMV retinitis. 
One patient presented with clinical features pathognomonic of Dyskeratosis Congenita (DKC). 
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Figure 3.3 correlates the symptoms at presentation with the gender. No significant difference was 
noted between males and females. 
No patients had lymphadenopathy, hepatomegaly or splenomegaly at presentation. 
 
Figure 3.3: Histogram for clinical symptoms at presentation and gender 
 
 
Sx- symptoms. Tcp- thrombocytopaenia 
 
3.5 Patient comorbidities 
Of the 92 patients, 34 had co-existing medical conditions (Table 3.2). No co-existing medical 
conditions were documented in the remaining patients. 
Only 13 patients were HIV positive. 3 patients had a diagnosis of Hepatitis. 3 patients were 
known Epileptics. 6 patients had hypertension. 1 patient had pregnancy induced hypertension. 1 
patient had a Cerebrovascular accident (CVA). 1 male patient had Dyskeratosis Congenita 
(DKC). 2 patients had Fanconi Anaemia. 1 patient had Cytomegalovirus (CMV) associated 
retinitis. 1 patient had Uveitis. 1 patient had Angina. 1 patient had Diabetes Mellitus. 1 patient 







































Table 3.2: Summary of patient comorbidities 
 
Comorbidity Number of patients 
HIV 13 
Drug induced Hepatitis 2 






Cerebrovascular Accident 1 
Dyskeratosis Congenita 1 
CMV Retinitis 1 
Fanconi Anaemia 2 
Uveitis  1 
Psychiatric Disorder  1 
Pulmonary Tuberculosis  1 
Angina 1 
Diabetes Mellitus 1 
      
HIV- human immunodeficiency virus. CMV- cytomegalovirus 
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3.6 Patient medications 
At the time of diagnosis, 56 of the 92 patients had not been consuming any regular medications 
in the period preceding diagnosis. 14 cases had no available information regarding use of 
medication. Table 3.3 illustrates the name and the number of medications consumed by the 21 
patients who were on medication. 
 
Table 3.3: Summary of patient medications 
 
Name of medication Number of patients 
Anti-hypertensives: Ziak, Norvasc, Ridaq, 
Aldomet 
7 
Antiretrovirals: AZT/D4T/3TC, FDC 5 
Anti-epileptics: Sodium Valproate, 
Carbamazepine, Phenytoin 
3 
Anti-tuberculosis treatment: Rifinah 1 
Angina medication 1 
Antipsychotics: Clozapine 1 
Azathioprine 1 
Anti-diabetic medications: Metformin 1 
Digoxin 1 
 








3.7 Patient occupations 
No data was available for 19 patients. 24 of the 73 patients were scholars, 1 was a university 
student and 2 were pensioners with no preceding work history. 30 patients were unemployed and 
had never worked. Within the cohort of employed patients (16 of 73), no specific job description 
was provided for 3 patients. The following occupations prevailed: Administration workers, 
Receptionists, Cashiers, Chef, Security guards, Merchandisers, Painter, Miners and Factory 
workers (see Table 3.4 below). 
 
Table 3.4: Summary of employment at the time of BMAT 
 




Miner (coal mine) 2 
Painter 1 
Factory worker 1 
Domestic worker 1 
Cashier 1 
Nurse 1 
Security guard 1 
 
3.8 Patient exposures 
No identifiable exposure was noted in 69 patients. Data was not available for 16 patients. 2 
patients had regular exposure to alcohol and cigarette smoke. 1 patient had exposure to herbal 
medications after he consulted a traditional healer for his bleeding symptoms. 1 patient had daily 
exposure to pesticides for 5 years. She was a nurse whose hobby was gardening and who sold 
rose plants.1 patient was employed as a painter. Two patients worked in coal mines with 
exposure to benzene. 
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3.9 Pregnant patients  
Of the patients with AA, 5 patients were pregnant at the time of diagnosis. This included one 
patient who had a miscarriage at presentation of AA. This was at 6 weeks gestation. The 
pancytopenia was diagnosed on the presentation FBC and the diagnosis of AA was subsequently 
confirmed on BMAT. 4 patients had viable pregnancies at the time of presentation of AA. They 
were diagnosed at the following gestations: 6 weeks, 18 weeks, 20 weeks and 31 weeks 
respectively. Table 3.5a displays the range and the medians for the pertinent laboratory 
parameters in the pregnant cohort. 
 
Table 3.5: Summary of laboratory parameters in pregnant patients 
 
Parameter Range Median 
Haemoglobin (Hb) 5.9-9.5 g/dl 7.8 g/dl 
MCV 82-94.2 fl 93.7 fl 
Platelets  6-35 x 109/l 15 x 109/l 
WCC 1.26-6.06 x 109/l 2.14 x 109/l 
Lymphocyte count  0.76-5.39 x 109/l 0.99 x 109/l 
Neutrophils 0.14-0.91 x 109/l 0.28 x 109/l 
 
Hb- haemoglobin. g/dl- grams per deciliter. MCV- mean cell volume. fl- femtolitres. WCC- white cell count 
 








3.10 Laboratory Results 
For normal laboratory reference ranges, see Appendix 6  
The laboratory parameters reviewed in each case were as follows: 
Haematology 
• Full Blood Count including Mean Cell Volume, Differential Count and smear 
• Reticulocyte Production Index (RPI) 
• Bone marrow aspirate and trephine biopsy (BMAT) findings 
• Cytogenetics (Chromosomal analysis) 
• Fanconi DNA PCR testing 
• Fanconi anaemia: Chromosomal breakage test (CBT) 
• PNH screen 
• ANF Screen 
Biochemistry  
 Urea and electrolytes (U&E) 
 Liver function test (LFT) 
Virology 
• HIV 
• Hepatitis B 
• Hepatitis A 
• Hepatitis C 
• CMV 
• EBV 









3.10.1 Haematology Results 
a) Cytopenias 
As illustrated in Figure 3.4 below, 93% of patients (86 of 92) presented with a pancytopenia. 
Five patients presented with a bicytopenia (anaemia and thrombocytopenia). One patient had a 
bicytopenia with a leucopenia (WCC of 2.51 x 109/l) and anaemia (Hb of 2.8 g/dl). The platelet 
count was 124 x 109/l in this patient. The BMATs were markedly hypocellular for age in the 
patients who did not present with a pancytopenia. All these patients had a prior transfusion 
record. 





b) Full Blood Count (FBC) findings 
Table 3.6 below depicts the relevant FBC findings. The lowest, highest and median values are 
tabulated as well as the interquartile range, which is expressed as a range from the 25th percentile 







Number of patients with
Pancytopenia
Number of patients with
bicytopenia(anaemia and tcp)





Table 3.6: Summary of FBC findings 
 
Parameters Minimum Maximum p50 p25 p75 iqr 












WCC 0.34 x 
109/l 





















P50- 50th percentile. p25- 25th percentile. p75- 75th percentile. iqr-interquartile range. MCV-mean cell volume. 
WCC- white cell count.  
 
The median Haemoglobin (Hb) was 7.30g/dl with a range of 2.20-11.90g/dl. The median platelet 
count was 12 with a range of 1-136 x 109/L. The WCC range was 0.34-6.6 x 109/l with a median 
WCC of 2.08 x 109/l.  
Figure 3.5a (on the next page) demonstrates the total number of patients who presented with 
anaemia at the time of the BMAT biopsy. A Hb level of <6 g/dl was evident in 30% of the cohort 
(27 of 92 patients). 71% had a Hb level of <8 g/dl (65 of 92 patients) and 95% (87 of 92) had Hb 
levels < 10 g/dl. It was also noted on the BMAT request forms of 28 patients, that Red Cell 
Concentrate (RCC) transfusions had been administered prior to BMAT. Hence the erroneously 






Figure 3.5a: Summary of various Hb levels in total patient cohort 
 
 
     Hb- haemoglobin. g/dl- gram per decilitre. 
 
 
Figure 3.5b on the following page demonstrates the percentage of patients who presented with 
symptomatic anaemia at the time of the BMAT biopsy being performed. All (100%) of patients 
with an Hb level <6g/dl were symptomatic at the time of presentation for BMAT, whereas 95% 
of patients with an Hb between 6-8g/dl were symptomatic. This does not include the cohort of 
patients with an Hb of less than 6g/dl. The 90% of symptomatic patients with an Hb level of 8-







































Figure 3.5b: Summary of symptomatic anaemia at various Hb levels  
 
 
Hb- haemoglobin. g/dl- gram per decilitre. 
 
 
Figure 3.5c (on the following page) illustrates the platelet counts for the total patient cohort. 
Forty three percent of patients (40 of 92) had a platelet count of <10 x 109/l. A platelet count of 
<20 x 109/l was noted in 60% of patients. This includes the cohort of patients with a platelet 
count of <10 x 109/l. Eighteen patients had been transfused with platelets (as indicated on their 
BMAT request forms), yielding erroneously high platelet count values.  








































































































b) WBC and differential count 
The WCC ranged from 0.34-6.65 x 109/l with a median WCC of 2.08 x 109/l.       
With regard to the differential count, the neutrophil count ranged from 0.00-2.59 x 109/l with a 
median neutrophil count of 0.33 x 109/l. The lymphocyte count ranged from 0.00-5.39 x 109/l 
with a median lymphocyte count of 1.49 x 109/l. 
Figure 3.4e illustrates the number and percentage of the cohort categorized according to the 




Figure 3.5e: Summary of ANC as severity 
 
 


















c) Neutrophil:Lymphocyte ratio 
Data was not available for 6 patients. 7 patients had a normal ratio. 92% (79 patients) had a 
reversal of the ratio, with lymphocyte percentages being relatively higher than neutrophil 
percentages. 
Lymphopenia was present in 40 patients at diagnosis. Of these 40 patients, seven were HIV 
positive. The lowest lymphocyte count and neutrophil count values, as determined by the 
automated FBC and differential count analyser, was 0. This is possibly due to the low WCC at 
diagnosis. 
Nine patients had a neutrophil count of 0.0 x 109/l. Seventeen patients had a neutrophil count of 
<0.1 x 109/l. The lymphocyte count was 0.0 x 109/l in seven patients. 
d) Mean cell volume and peripheral smear 
The Mean Cell Volume (MCV) ranged from 74.60-116.20 fl with a median MCV of 85.70 fl. 
52% of cases (48 of 92) had normocytic indices ranging from 83.6-99.7 fl. 7% of cases (6 of 92) 
had macrocytic indices ranging from 102.1-116.2 fl. 40% of cases (37 of 92) had microcytic 



















Smear findings were unremarkable for the patients with normocytic normochromic anaemia. 
Mild anisopoikylocytosis was occasionally noted. Round macrocytes were observed on the PB 
smear of patients with macrocytic indices. Microcytosis was not a prominent feature of the 
patients with microcytic indices. The microcytosis was also noted to be mild.  
Figure 3.5h (on the following page) depicts the relationship between MCV and the differences in 
gender. Amongst the males, 17 patients were microcytic, 22 were normocytic and 3 patients 
were macrocytic. Females demonstrated microcytosis in 20, macrocytosis in 3 and normocytic 
indices in 26 patients. Iron studies, Vitamin B12 and folate levels were performed in these 











Figure 3.5h: Histogram for MCV and Gender 
 
 
MCV- mean cell volume 
 
Figure 3.5i (on the next page) illustrates the differences in MCV and Ethnicity. Amongst the 
Black population, 32 patients were found to demonstrate microcytic indices, 37 had normocytic 
indices and 3 had macrocytic indices. Within the Indian population, 4 patients’ demonstrated 
microcytic indices, 8 patients had normocytic red cell indices and 2 patients had macrocytic 
indices. 1 microcytic, 8 normocytic and 2 macrocytic indices were evident in the Caucasian 
population. It has been reported in the literature that black females have a higher rate of 








































Figure 3.5i: Histogram for MCV and Ethnicity 
 
 
MCV- mean cell volume 
 
e) Reticulocyte Production Index (RPI) 
The RPI was <1 in all cases.  
 
f) BMAT findings 
The bone marrow aspirate sample was aparticulate in 30 patients. The aspirate was mild-
moderately hypocellular in 37 patients and markedly hypocellular in 25 patients.  
All patients had hypocellular BM trephine biopsies. The bone marrow trephine was hypocellular 
(25-30% cellularity) in 23% (21 of the 92 cases) and markedly hypocellular (<25% cellularity) in 
77% (71 of the 92 cases).  
In patients with a PNH clone the BMATs, despite being markedly hypocellular, displayed 































erythroid islands. There were no bone marrow granulomas detected in the patients already on TB 
treatment, and in any of the other patients 
g) Severity of Disease 
Of the 92 patients, 29 were classified as very severe Aplastic Anaemia (VSAA), 36 were 
classified as severe (SAA) and 27 as non-severe AA (NSAA) according to the Camitta criteria 
(51). (Figure 3.6a below depicts the histogram for disease severity. There were no significant 
differences in gender in terms of severity.  
A statistically significant finding (p value=0.005) was found with disease severity and younger 
age patients. The patients with VSAA were significantly younger, with a mean age of 25.0 years 
and a SD of 11.4 compared to patients with SAA, who had a mean age of 27.0 years and patients 
with NSAA, who had a mean age of 37.0 years (Figure 3.6b on the next page).  
 
Figure 3.6a: Histogram for Disease Severity 
 


































Figure 3.6b: Histogram for Mean Age by Severity 
 
 
NSAA- non severe aplastic anaemia. SAA-severe aplastic anaemia. VSAA-very severe aplastic anaemia 
 
h) Cytogenetics (Chromosomal analysis) 
Cytogenetic samples were sent for 33 patients only. 16 patients had failed karyotyping due to 
insufficient metaphases. Results were available for 17 patients only. A normal male and female 
karyotype was demonstrated in 6 and 9 patients, respectively. 1 patient had a monosomy 8.  1 

















Figure 3.7b (on the next page) depicts the referral hospitals from which clinicians did not send 























Figure 3.7b: Distribution of hospitals from which cytogenetic testing was not requested by 
referring doctor 
 
ADH- Addington Hospital. EDH- Edendale Hospital. KEH- King Edward Hospital. MGMH- Mahatma Ghandi 
Memorial Hospital. NGH- Ngwelezane Hospital. PMMH- Prince Mshiyeni Memorial Hospital. RKK- R K Khan 
Hospital 
Figure 3.7c (on the following page) depicts the referral hospitals from which unsuitable (failed) 

































Figure 3.7c: Distribution of hospitals with unsuitable cytogenetic samples  
 
 
EDH- Edendale Hospital. KEH- King Edward Hospital. NGH- Ngwelezane Hospital. PMMH- Prince Mshiyeni 
Memorial Hospital. PSH- Port Shepstone Hospital. RKK- R K Khan Hospital 
i) Fanconi Anaemia: DNA PCR testing 
Data was not available for 72 patients. The test was negative in 18 patients. 2 patients tested 
positive and were homozygous for the FANCG c. 637_643 deletion mutation. Somatic 
abnormalities in keeping with Fanconi anaemia, were evident in both these patients. One patient 
had 3 siblings, all of whom were diagnosed with FA. Both FA patients received steroids and 
androgen therapy. One patient eventually succumbed to the complications of bone marrow 
failure and demised from gram negative septicaemia. The other FA patient was lost to follow up 
(LTFU). 
j) Fanconi Anaemia: Chromosomal breakage tests (CBT) 
Data was not available for 78 patients. The test was unsuccessful (failed) in 7 patients, and a 
further 7 tested negative. The CBT was not performed in the 2 patients who tested positive for 
the Fanconi Anaemia DNA PCR test.  
k) PNH screen 
Testing for PNH was performed on peripheral blood samples. Screening for PNH was not 


















cells for analysis, and the samples were thus unsuitable for assessment by flow cytometry 
(FCM). A PNH clone was detected in 4 patients. Two patients had a small clone (6-8% and 7% 
respectively), one patient had an intermediate sized clone (20-25%) and one patient had a large 
PNH clone of 75%.  
The patients with PNH clones were discovered between June 2014 and June 2015. All the 
patients presented with a pancytopenia and reduced reticulocyte count/reticulocyte production 
index.  Iron studies were normal in these patients. Aside from a 23-year-old pregnant patient (6 
weeks gestation) who was on TB treatment for Pulmonary Tuberculosis, there were no other 
significant comorbidities, medications consumed or exposures demonstrable in the patients with 
PNH. The renal and liver function tests were normal, and hemolytic or thrombotic episodes had 
not been reported within these patients. 
Subsequent flow cytometry testing, to assess the status of the PNH clone, was not performed on 
these patients. Three of the patients with PNH are well and transfusion independent post 
ciclosporin therapy. However, the patient with a small PNH clone at baseline, has disease 
evolution to MDS. Follow-up peripheral blood samples for PNH flow cytometry were not 
requested/performed. 
Of note, 2 patients with negative baseline PNH FCM results at presentation in 2011, 
subsequently developed large PNH clones (75-80%) in 2015. These patients were well, 
transfusion independent and maintaining their counts post completion of ATG and CSA therapy. 
The clinical presentation of both these patients, in 2015 was that of a severe symptomatic 
anaemia and hemolysis, requiring transfusion. PNH FCM testing subsequently confirmed the 
diagnosis. 
l) ANF Screen 
Data was not available for 23 of the 92 patients. The Anti-Nuclear Factor (ANF) screen was 
negative in the majority of cases (68 of 92). At diagnosis of AA, 1 patient had a positive ANF 
(titer of 1:50). Subsequent testing 2 months later, revealed a negative ANF test in this patient, 
who did not have any features of autoimmune disease. 
3.10.2 Biochemistry: 
a) Urea and Electrolytes (U&E) 
A baseline U & E performed at presentation, demonstrated no abnormality in 88% of cases. Data 
was not available for six patients. Other tests such as urine protein creatinine ratio and ultrasound 
scans of the kidneys were not routinely performed at baseline. Renal function tests were also 
performed at follow up visits. The four patients that had deranged U&E results also 
demonstrated deranged LFTs. Two patients were clinically septic. The first patient was a 22-
year-old HIV positive female with an unknown CD4 count/ viral load, not on antiretroviral 
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therapy (ART). Klebsiella Pneumonia was diagnosed on blood cultures and the patient had been 
receiving nephrotoxic antibiotic therapy (amikacin). 
The second septic patient was a 14-year-old female who had been referred to the clinical 
haematology unit with a diagnosis of pancytopenia and sepsis. No further information was 
available. 
The remaining 2 patients with renal dysfunction were taking chronic medications. A 40-year-old 
female was on psychiatric medication and had a previous nephrectomy. The other was a 26-year-
old HIV positive male on cART and anti-epileptic medications.  
Table 3.7 below summarizes the renal function test values as well as patient characteristics. 
 
Table 3.7: Summary of U&E derangements 
 
Patient Urea  Creatinine GFR Patient characteristics 
1. 14.1 95 Not performed Severe klebsiella sepsis, colostomy, 
parvovirus IgM + 
2. 16.8 638 Not performed HIV +, Sepsis, Antibiotics, Iron overload, 
Deranged LFTs 
3. 4.8 138 54ml/min HIV +, cART, Antiepileptics, previous PTB, 
iron overload, infection (ESR >120), 
deranged LFTs 
4. 17.2 159 31ml/min Deranged LFT, previous nephrectomy, 
infection (CRP>30), multiple drugs, iron 
overload, previous PTB 
                     
GFR- glomerular filtration rate. IgM- immunoglobulin M. HIV- human immunodeficiency virus. LFTs- liver 
function test. cART- combination antiretroviral therapy. PTB- pulmonary tuberculosis. ESR- erythrocyte 










b) Liver Function Tests (LFT) 
A baseline liver function test was performed for majority of the patient cohort at diagnosis. Data 
was unavailable for 11 patients. LFT’s were normal in 84% of patients (68 of 81). 13 patients 
(16%) had a deranged LFT. Of the derangements, 23% were of a hepatitic nature (3 of 13), 46% 
(6 of 13) were cholestatic and 31% (4 of 13) had a mixed picture. LFT’s were also performed at 
follow up visits in the majority of pts. 
As illustrated below, many of the patients had concomitant bacterial and/or viral infections. 8 of 
the 13 patients (62%) were overtly septic (Table 3.8). Some were on antibiotic and/or antiviral 
treatment. 8 patients were iron overloaded from recurrent blood transfusion, and one patient had 
a history of ingestion of herbal remedies. These are some of the possible contributory factors to 
the LFT derangements. 

























ALT AST GGT ALP  Patient characteristics 
1. 19.5  44 93 120 113 HIV +, Sepsis, Antibiotics, Iron 
overload, Renal failure 
2. 35 14 52 53 127 273 Iron overload on exjade + ciclosporin 
3. 16  121 69 26 43 Sepsis, Iron overload 
4. 9.1  64 44 112 201 Herbal medication, sepsis 
5. 456 378 381  209 229 Hepatitis, Enterobacter sepsis and 
Herpes simplex infection 
6. 23 19 202 174 119 138 Severe klebsiella sepsis, colostomy, 
renal dysfunction, parvovirus IgM + 
7. 16  40 77 129 164 DKC, CMV IgM+, Iron overload 
8. 18  128 64 64 85 Parvovirus IgM +, Iron overload 
9. 393  2016 2685 79 133 HAAA, CMV PCR +, CMV Viral 
Load 1315 
10. 70  8 11 175  HIV +, cART, Antiepileptics, 
previous PTB, iron overload, 
infection (ESR >120) 
11. 17.9  176 86 345 188 Steroids, Iron overload, Occupational 
exposure 
12. 38  16 17 165 190 Renal dysfunction, previous 
nephrectomy, infection (CRP>30), 
multiple drugs, iron overload, 
previous PTB 
13. 8  88  131 108 Sepsis, antibiotics 
 
ALT- alanine aminotransferase. AST- aspartate aminotransferase. GGT- gamma glutamyl transferase. ALP- alkaline 
phosphatase. HIV- human immunodeficiency virus. IgM- immunoglobulin M. DKC- dyskeratosis congenita. CMV- 
cytomegalovirus. HAAA- Hepatitis Associated Aplastic Anaemia. PCR- polymerase chain reaction. cART- 





3.10.3 Viral Screen 
a) Human Immunodeficiency Virus (HIV) 
The diagnosis of HIV was made on ELISA-based assays. 66 patients were HIV negative. 12 
patients had no HIV records.13 of the 80 patients (16.3%) were HIV positive at diagnosis of AA.  
An Equivocal HIV result was obtained in 1 patient. This could not be confirmed to be 
positive/negative due to the patient’s subsequent demise. Findings are depicted in Figure 3.8a 
below. 
Figure 3.8a: Histogram for patient HIV status 
 
 
HIV- human immunodeficiency virus. Pos- positive. Neg- negative 
 
The HIV positive population ranged from 22-46 years of age, with a median age of 33. The M:F 
ratio was 0.6:1 with 8 HIV positive females and 5 HIV positive males (see Figure 3.8b below). 
Within the female cohort, the range was 22-46 years with a median of 33 years. The male 











































The BMAT of the first HIV positive patient with AA was reviewed in 2007. The 13 HIV positive 
patients were consecutively distributed over the years. There was no real increase in the number 
of HIV positive cases over the years, or no preponderance of cases in a certain time period. 
A simultaneous diagnosis of HIV and AA was made in 5 patients, when testing for HIV was 
performed as part of the viral screen work-up upon diagnosis of AA (see Table 3.9 below). The 
diagnosis of HIV was made prior to the diagnosis of AA in the remaining 8 HIV positive 
patients. In these patients, the duration between the diagnosis of HIV and AA ranged from just 
over a month to 7 years. Two patients experienced a 6 and 7-year interval between the diagnosis 
of HIV and the diagnosis of AA, respectively (see Table 3.10 below). 5 patients were diagnosed 
with AA within a year of their HIV diagnosis. 
Only seven HIV positive patients had a lymphopenia. The remainder had normal lymphocyte 
counts. 
The low viral loads in patients 1, 3 and 5 (in Table 3.9 on the next page) is interesting. It may 
reflect patients who have been rather recently infected or patients with a low viral multiplication 
rate. It may also be due to patients having already been started on cART but who had not 
































Table 3.9: Characteristics of patients with a simultaneous diagnosis of HIV and AA 
 
Patient Month and Year of 
Diagnosis of HIV 
and AA 





Viral Load at 
presentation 
(copies/ml) 
1. May 2008 238 cells/mm3 <20 copies/ml 
2. Nov 2008 Not done Not done 
3. Oct 2010 50 cells/mm3 240 copies/ml 
4. Nov 2013 839 cells/mm3 11730 copies/ml 
5 Feb 2014 323 cells/mm3 <40 copies/ml 
 
HIV- human immunodeficiency virus. AA- aplastic anaemia. CD4- cluster differentiation 4. Nov- November. Oct- 

















































1. 2007 2014 7 years Unknown Unknown N 151 
2. 2008 May 2013 6 years Unknown Unknown Y 36 
3. March 2011 June 2013 27 months 228 348 Y 448 
4. April 2011 Nov 2011 8 months 500 44 Y 535 
5. Oct 2011 Feb 2012 4 months 117 Unknown N Unknown 
6. Sep 2012 June 2013 10 months 147 <150 N Unknown 
7. April 2014 May 2015 11 months 388 Unknown N 235 
8. June 2015 July 2015 1 month 381 Unknown N     - 
 
HIV- human immunodeficiency virus. AA- aplastic anaemia. CD4- cluster differentiation 4. cART- combined       












CD4 count and Viral Load 
 
CD4 counts and viral loads (VL) were available in almost all the patients with a simultaneous 
diagnosis of HIV and AA. Only one of the patients with a simultaneous diagnosis of HIV and 
AA did not have a baseline CD4 count/viral load performed. She was diagnosed with HIV on 
admission, and demised shortly thereafter. The CD4 count ranged from 50-839 cells/mm3 in the 5 
patients from the simultaneous diagnosis cohort. The viral load ranged from <20-11730 
copies/ml (Table 3.9 above).  
Of the 8 patients with an interval between the diagnosis of HIV and AA, only 6 had available 
CD4 counts. The CD4 count ranged from 117-500 cells/mm3. The 2 patients with outstanding 
baseline CD4 counts had been diagnosed with HIV approximately 6 and 7 years prior to the 
diagnosis of AA. In these patients, the CD4 count at diagnosis of AA was 36 and 151 cells/mm3, 
respectively. The majority of patients did not have viral loads performed. Viral loads were only 
available for 3 patients, and ranged from 44-348 copies/ml. Only 3 of the 8 patients were on 
ARV therapy at the time of AA being diagnosed (Table 3.10 above). One of the 3 patients had 
defaulted therapy for 5 years, and re-initiated therapy with second line agents when AA had been 
diagnosed. Another had her regimen changed due to toxicity.  
Follow up CD4 counts/viral loads were also performed for two of the patients at ARV clinics at 
their base hospitals. These patients that were lost to follow up (LTFU) at IALCH continued their 
base hospital visits. The follow-up CD4 counts were accessible on the TrakCare laboratory 















b) Hepatitis B Virus (HBV) 
The Hepatitis B Surface antigen was negative in the majority of patients (74 of the 92). No data 
was available for 14 patients. A positive HepBSAg result was documented in 3 patients. 1 patient 
had an equivocal result, which was not subsequently repeated. The Hepatitis B Core IgM and 
Hepatitis E Antigen tests were negative in these patients. The HepBSAg was persistently positive 
in these patients who had normal LFTs, possibly indicating a chronic carrier state. Hepatitis B 
viral loads were not available. 
c) Hepatitis A virus (HAV)  
Hepatitis A IgM:  
Testing for active infection was not performed in 52 patients. 40 patients tested negative.  
Hepatitis A IgG: 
Testing for previous exposure to Hepatitis A virus, was not performed in 81 patients. 11 patients 
tested positive for Hepatitis A IgG indicating previous exposure to Hepatitis A infection. 
d) Hepatitis C virus  
Hepatitis C IgM 
Results were available for 10 patients only. These were all negative.  
Hepatitis C IgG 
Results were available for 10 patients only. These were all negative.  
e) Cytomegalovirus (CMV) 
CMV IgM 
Of the 92 patients: 26 patients had no records, 61 patients tested negative, 4 patients tested 
positive for acute exposure and 1 patient had an equivocal result. 
CMV IgG 
No records could be found for 33 patients. 4 patients tested negative, and 55 patients tested 
positive for previous infection/exposure. 
CMV PCR 
CMV PCR was not performed in 82 patients. 9 patients had a negative PCR. Only 1 patient had a 
positive CMV PCR. CMV serology and viral load was not available for this patient. 
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f) Epstein-Barr virus (EBV)  
EBV IgM 
Of the 92 patients, 36 patients had no records. 55 patients tested negative and 1 patient 
demonstrated acute exposure to EBV.  
EBV IgG 
No results were found for 45 patients. 6 patients tested negative and 41 patients tested positive 
for past exposure to EBV. 
g) Parvovirus  
Parvovirus IgM 
Of the 92 patients, 41 had no records and 46 patients tested negative. 5 patients had a positive 
parvovirus IgM indicating acute exposure to parvovirus B19. 
Parvovirus IgG 
No records were found in 41 patients. 16 patients tested negative. 2 patients had an equivocal 
parvovirus IgG and 33 patients demonstrated positive results, indicating previous exposure to 
parvovirus B19. 
Parvovirus PCR 













These findings are summarized in Table 3.11 below. 
Table 3.11: Summary of viral investigations performed 
 




EBV CMV Parvovirus 
Serology: IgM: 
positive 
  1 4 5 
Serology: IgM: 
negative 
40 10 55 61 46 
Serology: IgM: 
not available 
52 82 36 26 41 
Serology: IgM 
equivocal 








 10 6 4 16 
Serology: 
IgG: 
not available  




    2 
PCR 
positive 
   1  
PCR 
negative 
   9 14 
PCR not 
available 
   82 78 
 





3.11. Patient management and outcomes 
The following definitions have been used as criteria for responses to therapy in aplastic 
anaemia(7) 
Complete response:   Haemoglobin normal for age 
                                  Neutrophil count >1.5 x 109/l 
           Platelet count >150 x 109/l 
Partial response:   Transfusion independent 
                              No longer meeting the criteria for severe AA 
Failed/None:    Not meeting the above criteria 
 
Relapse:    Loss of a complete or partial response 
                                 
Thirteen patients with a bone marrow diagnosis of AA, made at the NHLS haematology 
laboratory at IALCH did not reach the clinical haematology unit at IALCH. All 13 patients were 
classified as SAA according to PB counts and BMAT findings. One of these patients demised at 
KEH. The outcome of the others is uncertain, though it is likely that they may have demised. 
Six patients presented at the initial visit only. They were referred back to their base hospital for 
supportive management (blood, platelets and antibiotic therapy) after the work-up had been 
completed by the clinical haematology team at IALCH. Of the 6 patients, 4 had VSAA with 
platelets ranging from 2-5 x 109/l and the ANC from 0.01-0.03 x 109/l. The other 2 patients had 
SAA. It is likely that these patients who were symptomatic at presentation could have demised at 
home or at the base/referral institution. 
A 68-year-old Indian female was diagnosed with NSAA. She was being observed, with blood 
product support as required.  
Four patients had spontaneous recovery of the blood counts. Three had NSAA and 1 had SAA. 
Amongst the NSAA patients, was a 49-year-old female, whose counts recovered spontaneously 
after almost one year. Spontaneous recovery of blood counts also occurred in a 19-year-old 
female 11 months’ post diagnosis of AA. The third patient who was pregnant at diagnosis, and 
her blood counts recovered spontaneously 3 months’ post-delivery. These patients had received 
occasional transfusion but no CSA or ATG. The patient with SAA was HIV positive. Her blood 
counts improved in just over three months from the initiation of HAART. 
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Table 3.12 below provides a general summary of the patient outcome and management for 
patients in the study.  
Table 3.12: Summary of patient management 
Patient characteristic Number of patients 
  
Never reached IALCH 13 
One visit only 6 
Observation only 1 
Spontaneous recovery 4 
LTFU` 7 
Demised 22 
Disease Transformation 3 
  
Treatment  
Ciclosporin alone: 26 
Good response (Complete/Partial) 11 
No response 4 
LTFU (on ciclosporin) 11 
  
Triple Therapy 10 
Good response (Complete/Partial) 5 
No response 5 
LTFU after triple therapy 4 
  




Bone Marrow Transplant 4 
 
IALCH- Inkosi Albert Luthuli Central Hospital. LTFU- lost to follow up. ATG- anti thymocyte globulin.  
 
Table 3.13a: Summary of patients with a response to CSA 
Ciclosporin:  
a)  Complete response        7 
b)  Partial response        4 
Total        11 
 
Table 3.13b: Summary of patients with a response to ATG and CSA 
Triple therapy:  
a)  Complete response        2 
b)  Partial response        3 
Total        5 
Triple therapy- ciclosporin/atg/methyprednisone 
Forty patients were treated with immune suppressive therapy. CSA alone, at a dose of 5mg/kg 
daily with weekly monitoring of trough levels was used for 18-24 months in patients responding 
to this treatment modality or until the development of CSA toxicity. In patients not responding to 
ciclosporin, treatment was discontinued after 6 months. Triple therapy 
(ATG/Methylprednisolone/CSA) was used in other patients.  
The term triple therapy denotes the use of equine ATG (ATGAM) at a dose of 40mg/kg for 4 
days (administered through a central venous catheter), with the concurrent intravenous 
administration of 500mg methylprednisolone daily for 5 days. Patients received premedication 
with paracetamol and phenergan prior to ATG administration, and the platelet count was kept at 
>40 x 109/l (on the days of ATG administration), by daily administration of single donor 
apheresis (SDA) platelets. 
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Ciclosporin was initiated on day 6 of the protocol at a dose of 5mg/kg daily. Weekly trough 
levels were monitored (and CSA doses adjusted as necessary). Renal and liver function tests 
were also evaluated to detect toxicity. Patients were monitored for infections and bleeding. 
The 2 patients with Fanconi Anaemia (1 with SAA and 1 with VSAA) had been on androgens 
for several years, however response to this therapy was poor. One patient demised of sepsis and 
the other was LTFU. It is likely that this patient also demised. 
Ciclosporin alone: Twenty-six patients received CSA alone. Of the patients on CSA alone, 11 
patients achieved a favourable response and remain well. Seven patients recovered their blood 
counts (complete response) and four remain transfusion independent (partial response) (Table 
3.13a above). One patient had no response to CSA therapy (failed response) initially, in 
2005/2006. She subsequently became iron-overloaded and required iron chelation therapy (ICT). 
Treatment was re-initiated at higher CSA doses in 2010, to which the patient responded 
favorably.  
No response (failed response) to CSA therapy was noted in 4 patients, 3 of whom had VSAA. 1 
of these patients was subsequently LTFU. 2 patients subsequently demised. The fourth patient 
had a failed response to CSA therapy on two occasions. ATG had not been considered for him, 
the reason for which is unknown. He is currently transfusion dependent (Table 3.13 above). 
Of the 26 patients, 11 patients commenced on CSA therapy were subsequently LTFU. 
Of the 26 patients, 3 experienced treatment interruptions/discontinuation due to adverse effects 
of CSA. One patient experienced severe gum hypertrophy and was changed to tacrolimus. He is 
still transfusion dependent. Another experienced liver dysfunction and was LTFU whilst 
awaiting ATG. The third patient experienced mild renal impairment which subsequently 
improved. She achieved a complete response and is transfusion independent. 
Triple therapy: Five patients achieved a favorable response with the combination of 
ATG/Methyprednisolone/CSA. Two of these five patients recovered their blood counts 
(complete response), and three patients had a partial response and are transfusion independent 
(Table 3.13b on the preceding page). One patient was subsequently lost to follow up after being 
in remission for one year. Two of the patients, both who had been in remission for almost 2 
years, had disease evolution to PNH (Table 3.15).  
Five patients had a failed response to triple therapy (Table 3.14).  
One of them was a 51-year-old male with SAA who had no response to a previous course of 
equine ATG and CSA administered in 2016. He completed a course of rabbit ATG and CSA in 
July 2017. Rabbit ATG (Fresenius) was administered at a dose of 3.75mg/kg daily for 5 days.  
Presently, he is on CSA and prednisone. He is currently maintaining his counts without 
transfusion support.  
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Another patient, also with SAA and a poor response to ATG/CSA therapy in 2014, was 
subsequently treated with tacrolimus. This patient remained transfusion dependent and 
transfusion requirements increased in April 2017. A BMAT was performed which demonstrated 
disease transformation to MDS with excess blasts-1 (MDS-EB1). This patient had a PNH clone 
of 6-8% and normal cytogenetics at presentation in 2014. The PNH clone in April 2017 was <1% 
and a monosomy 7 was now evident on karyotyping. 
Three patients demised after therapy with ATG/CSA. The interval ranged from <1 week to 2 
months’ post therapy. The cause of death in all 3 patients was septic shock. 
Of the 4 patients on triple therapy who were LTFU, 1 patient had a complete response (as 
indicated above). The other 2 patients failed to demonstrate any response to therapy, and were 
still transfusion dependent at their last recorded visits. The last patient defaulted treatment and 
the outcome in terms of disease response to therapy, is uncertain. 
Allogeneic BMT: Four patients received an Allogeneic Bone Marrow Transplant from matched 
sibling donors (Table 3.14). The conditioning regimen used was that of Fludarabine, 
cyclophosphamide and equine ATG. One patient was transplanted twice. Her initial presentation 
was that of a spontaneous miscarriage during which an incidental pancytopenia had been 
discovered. The diagnosis of AA was confirmed on BMAT. The first transplant in October 2011, 
was complicated by ABO blood group incompatibility. The patient was re-transplanted in 
February (Feb) 2013. She had a complete response to therapy and is currently well and in 
remission.  
The other successfully transplanted patient was a 53-year-old nurse with regular exposure to 
pesticides. She presented in Feb 2013 and her transplant was performed in June 2013. She also 
had a complete response to therapy, is well and in remission at present. Both patients had their 
younger sisters as bone marrow donors.   
The BMTs were unsuccessful in the remaining 2 patients. A 20-year-old male, diagnosed with 
AA in December 2012 was transplanted in March 2013. He died of treatment-related 
complications, namely acute-GVHD, within the first 100 days’ post-transplant. A 27-year-old 
female diagnosed with AA in May 2011, was transplanted in July 2011. Her BMAT biopsy was 
still aplastic 5 months’ post BMT and the patient demised in Dec 2011, from an IFI whilst on 
CSA therapy.  
 
Table 3.14 (on the following page) categorizes the severity of AA and the response to different 





Table 3.14: Disease severity with treatment response 
 
Treatment option VSAA SAA NSAA Total 
Triple therapy -
Remission 
3 0 2 5 
Triple therapy-No 
Response 
1 1 3 5 
Triple therapy- LTFU             1    
Triple therapy-Demised           3  
     
CSA-Remission 2 6 3 11 
CSA-No Response 3 0 1 4 
CSA- LTFU            1    
CSA- Demised            2    
     
BMT-Remission 2 0 0 2 
BMT-Demised 1 1 0 2 
 
ATG- anti thymocyte globulin. CSA- ciclosporin. BMT- bone marrow transplant 
Tabulated below are the detailed outcomes for the 79 patients that were managed by the clinical 
haematology unit at IALCH (Table 3.15). The 13 patients that had a BM diagnosis of AA made 








Table 3.15: Outcome of the patients referred to IALCH 
 
Patient Outcome Number of patients 
Alive 32 
  
Alive with Clonal evolution 3 
  
Lost to follow up (LFTU) 22 
  
Demised: 22 
Before treatment 14 
On ciclosporin, awaiting ATG 2 
Post ATG therapy 3 
Transplant related 2 
Fanconi Anaemia 1 
  
Total 79 
*This table does not include patients with a diagnosis of AA that did not reach IALCH  
LTFU- lost to follow up. ATG- anti thymocyte globulin. 
 







Figure 3.9a illustrates the outcome of the 92 patients in the study cohort. 
Figure 3.9a: Patient Outcomes 
 
LTFU- lost to follow up. IALCH- Inkosi Albert Luthuli Central Hospital. 
Figure 3.9b illustrates the treatment status of the 35 patients who are currently alive.  
 



















Clonal evolution- not on treatment
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Figure 3.9c illustrates the remission status of the 5 patients who are alive and currently being 
managed supportively with red cell concentrate and/or plt transfusions, or with ciclosporin. 
Treatment of infections, with antibacterial or antifungal drugs was also part of the supportive 
treatment offered to patients, when required. The individual patient treatment details are 
tabulated in Table 3.16  
Figure 3.9c: Characteristics of patients who are alive and on treatment 
 
Figure 3.9d illustrates the remission status of the 28 patients who are alive and currently not on 
treatment. The 6 patients in the supportive care category are transfusion dependent, and receive 
2-weekly red cell and/or platelet transfusions. 












Alive and not on treatment








     ATG- anti thymocyte globulin. CSA- ciclosporin. HSCT- haemopoietic stem cell transplant 
Twenty-two of the ninety-two patients demised. Figure 3.9e demonstrates when, in relation to 
treatment, these patients demised.  
Figure 3.9e: Characteristics of patients who demised 
 
ATG- anti thymocyte globulin. CSA- ciclosporin. HSCT- haemopoietic stem cell transplant 
 
Figure 3.9f (on the following page) illustrates the characteristics of the 22 patients who were 
LTFU. Six patients had only a single visit to the haematology clinic at IALCH. They were 
subsequently referred to the base hospital for supportive management and/or initiation of 
HAART, and never returned to the IALCH clinical haematology department for their follow-up 
visits. One patient with FA and a poor response to androgen therapy was LTFU. Eleven patients 










Total number of Deaths
Before initiation of treatment
On CSA, awaiting ATG
Post ATG therapy
HSCT related
Fanconi anaemia with a poor
response to androgen therapy
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Figure 3.9f: Characteristics of patients LTFU 
 
ATG- anti thymocyte globulin. CSA- ciclosporin.  
Figure 3.9g demonstrates the outcomes of patients on CSA therapy. 
Figure 3.9g: Outcome of patients on CSA therapy 
 






Total number of patients LTFU
One visit only













The details of when in relation to treatment, the 11 patients that were treated with CSA were 
LTFU are depicted in Figure 3.9h below. 
Figure 3.9h: Characteristics of LTFU patients on CSA therapy  
 
ATG- anti thymocyte globulin. CSA- ciclosporin.  
Figure 3.9i demonstrates the outcome of patients on ATG/CSA therapy. 
Figure 3.9i: Outcome of patients on ATG/CSA therapy 
 





Patients LTFU on CSA therapy
After initiating CSA
In remission-not on CSA
No response to CSA










Figure 3.9j demonstrates the outcome of patients post allogeneic HSCT. 
Figure 3.9j: Outcome of patients post-HSCT 
 






Figure 3.9k (on the following page) depicts the outcome of the 13 HIV positive patients. One 














Figure 3.9k: Outcome of HIV positive patients 
 
 





Table 3.16 (on the following page) illustrates the outcome of the HIV positive patient cohort. 
Included in the 7 patients who had been LTFU, was one patient who recovered her counts after 
initiation of ARV therapy. She was discharged from the haematology clinic and was being seen 


















Table 3.16: Detailed outcome of HIV positive patients 
 
a)Alive                                                                  5 
 Well/Transfusion independent not 
on CSA (Partial response) 
                                           
3           
 
 Well/Transfusion independent on 
CSA (Partial response) 
                                
1 
 
 Poor response to CSA x 2 (Failed 
response) 
                                  
1 
 
    
b)LTFU                                7            
 After recovering counts with CSA 1  
 After initiating CSA therapy 1  
 Awaiting ATG 1  
 After initiating ARVs 1  
 After recovering counts with 
ARVs 
1  
 After initial visit 1  
 Never reached IALCH 1  
    
 










                                 Table 3.17: Summary of outcome of pregnant patients 
 
Patient  Gestation at 
diagnosis of AA 
Pregnancy Outcome Patient outcome 
1. 6 weeks Spontaneous 
Miscarriage 
BMT x2, currently well 
2. 6 weeks Elective Termination of 
pregnancy (TOP) at 8 
weeks 
Good response to ATG/CSA. 
Currently not on any meds and 
transfusion independent 
3. 18 weeks NVD at term, 
Macerated still birth 
(MSB) of 1.0kg 
CSA initiated post-delivery, 
however patient LTFU 
4.  20 weeks Intrauterine death 
(IUD) 
Patient demised of neutropenic 
sepsis in the Intensive Care Unit 
(ICU) at 22 weeks gestation 
5.  31 weeks Normal vaginal 
delivery (NVD) with 
healthy baby 
Patient was still aplastic 8 
months’ post-delivery. Had a 
good response to CSA. Currently 
well, only on HAART 
 
BMT- bone marrow transplant. TOP- termination of pregnancy. ATG- anti thymocyte globulin. CSA- ciclosporin. 
NVD- normal vaginal delivery. MSB- macerated stillbirth. LTFU- lost to follow up. IUD- intrauterine death. ICU- 
intensive care unit. 
 
 








Table 3.18: Characteristics of survivors 
Alive: Outcome Number of patients Details of patient 
A) On treatment Remission 1 On CSA therapy 
 Not in remission 1 Transfusion 
dependent 
  1 Transfusion 
dependent  
  1 4 months post rabbit 
ATG/CSA, on CSA 
and prednisone 
 Not in remission with 
clonal evolution 
               1 Poor response to 
CSA, now with 
evolution to MDS-
EB1 
Total on treatment  5  
    
B) Not on treatment Remission 11 Post CSA therapy 
  5 Post ATG/CSA 
therapy 
  2 Post HSCT therapy 
  4 Spontaneous 
recovery 
 Remission with clonal 
evolution 




 Supportive care 6 Transfusion 
dependent 
Total not on 
treatment 
 30  
ATG- antithymocyte globulin. CSA- cyclosporin. HSCT- haemopoietic stem cell transplant. MDS-EB1- 
myelodysplastic syndrome with excess blasts 1. PNH-paroxysmal nocturnal haemoglobinuria 
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CHAPTER FOUR: DISCUSSION 
4.1 Hospital referral system 
The NHLS laboratory at IALCH is the only government referral centre for BMATs in KZN. 
Though the drainage area for the bone marrows were wide, the majority of the BMATs received 
were from tertiary hospitals, and there were occasional referrals from district level institutions.  
The process of obtaining/performing a BMAT requires several steps: 
1) The patient must be referred to an institution that can perform BMATs. 
2) Referring doctors from peripheral hospitals must telephonically consult one of the 
haematology registrars at the IALCH laboratory, regarding the indication for BMAT. 
3) If approved by the registrar, the BMAT must be “booked” with the laboratory at the base 
hospital. 
4) The booking date is often for a later date, depending on the ability of the laboratory staff to 
accommodate the marrow, as well as the patient’s ability to return on that specified date. 
5) Once the BMAT is performed, it must be transported to the laboratory at IALCH were the 
sample must be received and processed. Staining of the aspirate slides is required and the 
trephine biopsy is sent to anatomical pathology for decalcification and slide preparation. 
6) The turn-around-time (TAT) for a complete BMAT is 14 days. BM aspirates are reported 
within 48 hours, and trephines within 2 weeks of the sample arriving in the laboratory. 
Urgent bone marrow cases (AA or Leukaemia) warrant the registrar/pathologist informing 
the referring doctors of the diagnosis. 
7) Often, the patients are out-patients and cannot be contacted to return sooner. They are usually 
advised to return on a certain date. 
The diagnosis may have been delayed if the patient was not clinically suspected to have AA. 
Furthermore, a delay in any of the above numbered processes could have resulted in a potential 
delay in the diagnosis of AA, as well as the timely referral for management.  
The alarming finding that 12% of patients did not reach the clinical haematology unit at IALCH, 
despite the diagnosis being made at the IALCH laboratory, may have been due to several 
variables. The BMATs were reported well within the expected TAT. As these patients had SAA 
it is likely that the patients could have been discharged and requested to return for review of 
results and LTFU. They may have become ill and subsequently demised at home or at the base 
hospital, prior to their referral to IALCH. This highlights the importance of timeous diagnosis 





4.2 Patient characteristics 
The number of patients in the study period may not be a true estimate of the prevalence of AA in 
KZN, because some patients present to the clinical team after being diagnosed with AA at 
private sector laboratories. Greys hospital, for example, were referring BMATs to private 
laboratories prior to the year 2012. These patients (that were diagnosed at private laboratories) 
were not included in the study. 
An almost equal male:female (M:F) ratio (0.8-1) was evident in this study. This is similar to the 
demographic pattern reported in the literature. The 13-25-year age group, which is reported to be 
a peak age group, constituted 53% of patients in this cohort. Only 5.4% of patients were older 
than 60 years. There was no clear second peak in incidence in older patients.  
The majority of patients (80%) were of Black ethnicity. The KZN census 2011 revealed that 
86.9% of the population are of Black African ethnicity. Hence, this figure may be representative 
of the KZN population. However, there were too few patients from other ethnic groups to allow 
comparisons between the groups. The population described in this study represents public sector 
patients, and the patient characteristics in the private sector may differ. 
Younger patients were noted to have significantly more severe disease (p value=0.005). The 
mean ages for patients with VSAA and SAA were 25 and 27 years, compared to the mean age of 
37 years for NSAA. 
4.3 Failed Bone Marrow Aspirate and Trephine Biopsies 
The majority of failed BMATs were performed in non-haematology departments at the 
peripheral hospitals (Table 3.1). The alarmingly high number of failed BMATs is an indicator of 
a lack of skill in performing the procedure in the peripheral hospitals and at tertiary hospitals. 
This is due to the fact that there are no haematology departments/staff and consequently a lack of 
proficiency in performing the technique. This is also borne out of the observation that none of 
the BMATs performed by haematology staff at IALCH had failed, when these patients had 
subsequent BMATs at IALCH. Although there is a haematology department at KEH, initial 
BMATs for pancytopenia are performed by the department of medicine. Perhaps, this is a 
reflection of medical registrars not rotating through clinical haematology during their training. 





4.4 Clinical features 
Besides the patients with IBMFS, there was no clear clinical evidence pointing to a secondary 
cause of AA in any of the patients. Most of the patients were classified as idiopathic AA. There 
was a good correlation between the absence of clinical findings and idiopathic AA.  
Consistent with findings in the literature, symptoms of thrombocytopenia were reported in the 
majority of patients, followed by symptoms of anaemia. Symptoms of neutropenia (infections) 
were least frequent. 
Symptoms correlated with the severity of the depression in blood counts (anaemia, 
thrombocytopenia and neutropenia).  
All patients with an Hb < 6g/dl were symptomatic. Of note, is that all the patients with an Hb 
level >10g/dl had symptomatic anaemia. This finding is most likely as a result of blood 
transfusion of these patients at the time of presentation to the base hospital. These 5 patients 
were possibly markedly symptomatic and required transfusion prior to BMAT.  
4.5 Patient comorbidities 
Comorbidities in this study that have been reported in the literature to have an association with 
AA include HIV infection, CMV infection, Hepatitis virus infection, FA and DKC (refer Figure 
4.1 below).  
The patient with TB did not have any evidence of mycobacterial infiltration of the bone marrow. 
Drugs used in the treatment of TB have been implicated in AA (66). The patient on anti TB 
therapy had been on therapy for 4 months prior to the diagnosis of AA. 
The patient with DKC developed pancytopenia, and was diagnosed with AA at the age of 22 
years. It is reported in the literature that bone marrow failure usually presents by 20 years of age 
in patients with DKC. Approximately 80-90 percent of patients with classic DKC experience 
BMF by the age of 30 (177-179). This patient subsequently developed a CMV retinitis. He demised 
shortly thereafter from the opportunistic infection, and not from the AA. 
The commonest comorbidity, documented in 16.3% of the patient cohort and accounting for 37% 
of comorbidities, was HIV infection (refer Figure 4.1 below). HIV is discussed further in section 
4.9.3(a).  
Three patients had a history of jaundice, liver pathology or a hepatitis picture at presentation. It is 
unusual that these patients should have viral hepatitis simultaneous with the diagnosis of AA. 
The literature states that HAAA usually presents 2-3 months after acute viral hepatitis (104, 107). It 
is not clear if the LFT derangements could have been attributed to a viral hepatitis. The viral 
screens in these patients were negative, and there were no other clear reasons for the hepatitis, 
such as offending drugs and toxins. 
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Figure 4.1: Summary of patient comorbidities 
 
 
HIV- human immunodeficiency virus. CMV- cytomegalovirus. DKC- dyskeratosis congenita. FA- fanconi anaemia. 
TB- tuberculosis. CVA- cerebrovascular accident 
 
 
4.6 Patient medications 
All of the medications tabulated in Table 3.3 (in chapter 3), aside from the angina drugs, have 
been reported to be causally associated with AA. It was not clear in most patients when the drugs 
had been initiated, however the bone marrow request forms did not suggest that the medications 
had been initiated at the time of presentation of AA. Table 4.2 below illustrates the drugs 
consumed by patients that have a causal relationship with AA. 
One patient initially presented with non-granulomatous pan uveitis of the left eye which 
subsequently spread to the other eye. AA was diagnosed four months after starting treatment 
with Azathioprine (AZA). The AZA was subsequently discontinued and CSA initiated 
simultaneously as the patient required IST for the uveitis. Serial FBC monitoring revealed that 
the patient’s blood counts had recovered completely within 3 months of the diagnosis of AA. 
The patient is currently well on CSA therapy, as the uveitis flares up with any attempt at weaning 




























induced AA) as the simultaneous administration of CSA may have resulted in recovery of the 
AA. 
With regard to drug induced AA, a 45-year-old Caucasian female on treatment with multiple 
psychotropic drugs (including rivotril, effexor XR, zopiclone, as well as clozapine which was 
added not more than 2 months prior to the diagnosis of AA) also demised from 
thrombocytopenic complications of AA. The literature does indicate that although rare, 
psychotropic drugs may cause potentially life threatening adverse haematologic effects, and that 
middle-aged Caucasian women are at greatest risk for these with a mortality rate from 8%-17% 
(259). 
Of the 3 epileptic patients, one was HIV positive. This patient’s counts improved with a change 
in anti-epileptic therapy (from sodium valproate to lamotrigine), and with a change in the anti-
retroviral drug (from zidovudine (AZT) to Alluvia). The other 2 patients’ counts improved with 
changing the AED from phenytoin and carbamazapine to lamotrigine. These drugs (sodium 
valproate, phenytoin and carbamazepine) have been causally associated with AA, and so could 
the AZT in the first patient (259). 
Seven patients had regular exposure to anti-hypertensive agents, and these medications have 
been implicated in the aetiology of AA but these patients had been on anti-hypertensive 
treatment long before the onset of AA (260). 
The above-mentioned cases highlight the importance of correlating the onset of drug therapy 















Figure 4.2: Patient medications causally associated with AA 
 
 
ARV- antiretrovirals. TB- tuberculosis.  
 
4.7 Patient occupations and exposures 
High risk exposures that have been reported, and which are included in this patient cohort, 
include painters, factory workers (shoe factory), coal miners and pesticide exposure in a nurse 
who was an avid gardener (Figure 4.3). Aside from the nurse who admitted to using pesticides 
for almost 5 years, the duration of exposure was not clear in the painter, factory worker and one 



























4.8 Pregnant patients 
Each of the five pregnant patients with AA presented at variable gestational stages. This is in 
keeping with the general reported findings (159, 161, 163, 164). In some of the patients, the aetiological 
associations may be multifactorial. One patient had PTB and had been on anti-TB treatment at 
the time of diagnosis of AA. Another patient was on aldomet (methyldopa) for pregnancy 
induced hypertension. Although uncommon, anti-hypertensive drug therapy has been causally 
associated with AA (260). One patient had coexisting HIV. A 22-year-old patient had a history of 
herbal ingestion prior to diagnosis of AA. The contribution of these factors, combined with 
pregnancy, to the development of AA, is uncertain. 
Interestingly, four of these patients had AA diagnosed in their first pregnancies. One patient was 
diagnosed with AA during a second pregnancy. She was also HIV positive. The literature reports 
that AA can be diagnosed in any pregnancy and not necessarily a first one, however studies still 














The outcomes of the pregnant patients were varied, and are summarized in the table below 
                                 Table 4.1: Summary of outcome of pregnant patients 
 
Patient  Gestation at 
diagnosis of AA 
Pregnancy Outcome Patient outcome 
1. 6 weeks Spontaneous 
Miscarriage at 6 weeks 
BMT x 2, currently well 
2. 6 weeks Elective Termination of 
pregnancy (TOP) at 8 
weeks 
Good response to ATG/CSA. 
Currently not on any meds and 
transfusion independent 
3. 18 weeks NVD at term, 
Macerated still birth 
(MSB) of 1.0kg 
CSA initiated post-delivery, 
however patient LTFU 
4.  20 weeks Intrauterine death 
(IUD) at 22 weeks 
gestation. 
Patient demised of neutropenic 
sepsis in the Intensive Care Unit 
(ICU) at 22 weeks gestation 
5.  31 weeks Normal vaginal 
delivery (NVD) at term, 
with healthy baby 
Patient was still aplastic 8 
months’ post-delivery. Had a 
good response to CSA. Currently 
well, only on cART 
BMT- bone marrow transplant. TOP- termination of pregnancy. ATG- antithymocyte globulin. CSA- cyclosporin. 
NVD- normal vaginal delivery. MSB- Macerated still birth. LTFU- lost to follow up. IUD- intrauterine death. ICU- 
intensive care unit. cART- combination antiretroviral therapy 
As alluded to in the table above, pregnancy related AA is a complicated condition. In addition to 
complications relating to pregnancy itself, patients with AA are also more likely to experience 
complications of AA. These complications may affect the mother and/or the fetus.  
Patient 1 (Table 4.4) experienced a complication of AA (bleeding), and the spontaneous 
miscarriage was her reason for seeking medical assistance, and her incidental pancytopenia being 
discovered. She was diagnosed with AA and prompt management with transplant instituted. 
Early elective TOP in patient 2 had a favorable outcome for the patient who had a good response 
to treatment with complete remission.  Hence, early medical intervention can result in more 
promising and favorable patient outcomes. 
Patients 3 and 4, were diagnosed in the second trimester of pregnancy. Fetal outcomes were poor 
in both patients, possibly resulting from fetal hypoxia and intra-uterine growth restriction. Patient 
4 also experienced fatal complications of AA, in that she had neutropenic sepsis. It is evident that 
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the complications of pregnancy associated AA are very severe. A compounding factor is that the 
therapeutic options in pregnancy are limited.   
Patient 5 was diagnosed in the third trimester of pregnancy. She was also HIV positive. It is 
possible that both pregnancy and HIV could have contributed to the diagnosis of AA in this 
patient. The CD4 count at the diagnosis of AA was 151. The viral load was not available. The 
fetal outcome was favorable, and the patient survived. Her BMAT findings were in keeping with 
the diagnosis of AA 8 months’ post-delivery. The patient had a favorable response to CSA and 
HAART and is currently in remission. 
Although all the pregnant patients in this study were managed supportively, CSA has been used 
in the treatment of AA in pregnancy (56, 171).  
 
4.9 Laboratory Parameters 
4.9.1 Haematology 
a) Full Blood Count (FBC) including Mean Cell Volume 
The FBC at the time of the BMAT procedure was documented. The majority of patients (93%) 
demonstrated a pancytopenia. Many patients had been transfused at the time of BMAT due to the 
severity of their initial presentation (bleeding/severe anaemia). Some patients had received 
multiple red cell concentrate (RCC) or platelet transfusions. This explains the occasional finding 
of an Hb >10 g/dl or platelet count >100 x 109/l.  This may underestimate and not be truly 
representative of the severity of the AA in some patients.  
The original presentation FBC from the base hospital could not be traced because of a change in 
the laboratory information system (LIS). This accounts for the significant number of patients 
with high Hb levels (5.4%), as the higher Hb levels were found in patients who had a history of 
RCC transfusion prior to BMAT. 
Multiple attempts were made to obtain outstanding results; however, all efforts were futile. The 
NHLS-Information Technology Corporate Data Warehouse (CDW), was also contacted 
telephonically, and by email, on several occasions. Functional analysts were unable to retrieve 
the data.  
The one patient with a normal WCC (6.6 x 109/l), actually had a marked lymphocytosis with a 
severe neutropenia. Reversal of the neutrophil:lymphocyte ratio is a common finding in AA and 
this was documented in 92% of patients. This emphasizes the importance of a differential count 
being a clue to the diagnosis of AA. Patients with a lower ANC (<0.2 x 109/l) demonstrated a 
higher degree of infections ranging from mild to severe in nature. 
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It is well documented that AA is a cause of normocytic-normochromic anaemia with occasional 
macrocytosis (MCV 95-110 fl) (186, 260). The MCV ranged from 74.60-116.20 fl in this study 
cohort. Macrocytosis ranging from 102.1-116.2 was evident in only 7% of patients. Vitamin B12 
and folate levels were normal in these patients. There were no cases of megaloblastic anaemia. 
52% of cases had normocytic red cell indices.  
Predominantly microcytic indices were demonstrated in 40% of patients, albeit a mild 
microcytosis. The cohort of 37 patients with microcytic indices comprised 32 Black, 1 Caucasian 
and 4 Indian patients. 21 were female and 16 were male. The finding that females have a higher 
percentage of microcytosis may possibly be due to the confounding action of blood loss during 
menstruation. Black females were found to have a higher rate of microcytosis. Although not 
statistically significant in this study (p value of 0.2), this finding has been reported in the 
literature (262). This may be due to the increased incidence of co-existing iron deficiency. 
Iron studies were only available for 15 patients, in which the iron was either normal or increased. 
Serum iron levels ranged from 16-45.2. Ferritin levels or bone marrow iron stores were available 
in 19 patients.  Ferritin levels were normal in 10 patients and increased in 9 patients (range 332-
6961). Possible reasons for the increased ferritin include liver dysfunction, iron overload, and 
infection etc. as ferritin is an acute phase reactant (APR).  
Bone marrow iron stores were available for 10 patients only. Other marrows were inadequate for 
the accurate assessment of iron status.  BM iron stores were normal/increased in 8 patients. 2 
patients were clearly iron deficient as evidenced by the absence of bone marrow iron stores. 
Coexisting iron deficiency anaemia (IDA) was evident in patients with symptoms of bleeding.  
In summary: the increased percentage of microcytosis was an interesting observation. Only 2 
patients had iron deficiency anaemia. Despite the lack of results (iron studies/bone marrow iron 
stores) in the rest of the patient cohort, it is likely that the remainder of the patients had an 
anaemia of chronic disease. Other causes of a microcytic anaemia, such as thalassaemia, lead 
poisoning and sideroblastic anaemia etc. were unlikely in these patients. 
b) RPI: 
This was uniformly depressed in all 92 patients. None of the patients with PNH clones presented 
with hemolysis and an increased RPI at diagnosis of AA. 
c) BMAT 
An interesting observation made, was the 30 aparticulate bone marrow aspirates. This is an 
uncommon finding in the BMATs of patients with AA. Perhaps, the aspirates were markedly 
hypocellular, and as a result of the paucity of cellular elements, was misconstrued to be 
aparticulate. Also because AA is a rare condition and BMATs with AA are not commonly seen 
in the laboratory, the markedly hypocellular particles may possibly have been missed. Even with 
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the bone marrow aspirates that failed, the trephine biopsies were all markedly hypocellular for 
age. There was a good correlation between the bone marrow aspirate and trephine biopsies in all 
the patients whose aspirates were successful, where the aspirate cellularity was in keeping with 
the cellularity observed on the trephine biopsy. In patients with PNH clones, erythroid 
hyperplasia was prominent in the background of a hypocellular/acellular BM. Hence, erythroid 
hyperplasia in a patient with AA is a good indicator that a PNH clone may also be present, and 
should be investigated for. Myelodysplasia was not evident in any of the BMATs. There were no 
bone marrow granulomas detected in the patients on TB treatment and no evidence to suggest 
other aetiologies/infiltrates. Bone marrow findings correlated well with the PB counts. Of note, 
none of the patients presenting with severe pancytopenia in the context of these marrows 
demonstrated a reduction in only a single or two cell lineages on BM biopsy. 
 
d) Cytogenetics (Chromosomal analysis) 
Conventional cytogenetic analysis with GTG banding was performed. Karyotyping was 
performed according to the International System for Human Cytogenetics Nomenclature.  
Cytogenetic analysis was not requested by the clinician in 64% (59 of 92) of the cohort. All of 
the BMATs with which cytogenetic testing was not requested, were referred from peripheral 
hospitals. Most likely, AA may not have been suspected at the time of the BMAT. All the 
BMAT samples from IALCH had chromosomal analysis requested with them. This is possibly 
because patients were referred to IALCH with a provisional diagnosis of AA, or because 
BMATs were being performed after an initial failed BMAT, at the peripheral hospital. 
If AA was clinically suspected at the base hospital, it is likely that a lack of knowledge regarding 
the complete work-up of AA patients, by clinicians at the peripheral hospitals may explain the 
cytogenetics not being requested. Furthermore, the chromosomal analysis tubes require 
refrigeration and these tubes are not readily available in the peripheral hospital laboratories. This 
may have contributed to the large number of tests not requested.   
Although a few patients had karyotyping performed in 2005, and this number has slowly but 
steadily increased through the years, it was previously thought that AA was without 
chromosomal aberrations (194). These BMATs with abnormal cytogenetics were hypothesized to 
represent other disorders such as Myelodysplastic syndrome, hence perhaps cytogenetic testing 
was not routinely performed in AA in the earlier years.  
Cytogenetic testing was unsuccessful in 48.4% (16 of 33) of the patients for whom it had been 
requested. This is an expected observation due to the insufficient number of metaphases achieved 
on bone marrow aspiration (196, 197). It is likely that the scarcity of cells with mitotic potential 
obtained on bone marrow aspiration, result in the unsuccessful yield (263). Sample degeneration 
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because of a delay in transport to the laboratory, as well as a lack of skilled laboratory staff 
(technologists with expertise in cytogenetics have left the department), could also have been 
contributory to the unsuccessful karyotyping.  
The majority of the patients in whom cytogenetic testing was successfully performed (45.4%) 
had a normal karyotype. 2 patients (6.2%) had an abnormal karyotype (-7(deletion) and 
monosomy 8) that was detected on the presentation BMAT. Follow up cytogenetic testing was 
not performed in the 2 patients with an abnormal presentation karyotype. The repeat cytogenetics 
test result (performed in 2008) for the patient with a monosomy 8 stated that the test was 
cancelled as it was “requested in error”. The BMAT findings, however, were still consistent with 
a diagnosis of AA.  
Furthermore, many of the patients with normal karyotypes at presentation, did not have 
cytogenetic testing requested on subsequent BMATs. 13 patients had repeat BMATs performed 
to reassess disease status. Cytogenetic testing was only performed for 8 patients, of whom 5 had 
a normal karyotype. 1 patient had a cytogenetic aberration (monosomy7). The test was 
unsuccessful in 1 patient. 1 patient’s result stated that cytogenetics was “requested in error”, and 
5 patients did not have the test requested. 
The patient with -7(del) received CSA alone and the patient with a monosomy 8 received CSA 
with ATG. Both patients recovered their counts completely, but were subsequently LTFU. 
Molecular studies for FISH were not performed in any of the patients.  
An interesting finding, is that a patient with an initially normal male karyotype (NMK), and a 
small PNH clone (6-8%) at diagnosis of AA in 2014, was found to have a monosomy 7 on 
follow-up cytogenetic testing performed in April 2017. This patient had received ATG in 2014. 
He was also given CSA, which was discontinued due to persistent gum hypertrophy. Treatment 
was subsequently switched to tacrolimus, however transfusion requirements persistently 
increased. A BMAT was performed in April 2017, which demonstrated disease evolution to 
MDS with Excess Blasts 1 (10%). The follow up PNH FCM reported a PNH clone of <1%. This 
is an important case, highlighting disease evolution with the acquisition of a new cytogenetic 
abnormality, as well as a change in the size of the PNH clone. It is also possible that this patient 
could have had a hypoplastic MDS at presentation, as this condition may be difficult to 
distinguish from AA with a markedly hypocellular biopsy. 
The appropriate and timeous collection of cytogenetic samples (which must be requested at 
diagnosis as well as with follow up BMATs) to assess for possible clonal evolution, is 
paramount. This cannot be over-emphasized. The utility of looking for clonal evolution is 
important in individualizing patient management, and selecting the most appropriate therapeutic 
modality for a specific patient. If a patient is transplantable, and a cytogenetic aberration is 
detected, this allows time to work the patient up for possible allogeneic BMT, and in young 
patients, to look for a matched unrelated donor. Further studies on larger sample populations are 
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mandatory to detect and confirm cytogenetic aberrations in patients with AAA at diagnosis and 
follow up.  
e) Fanconi anaemia: DNA testing (PCR) 
Data was not available for 72 patients (78% of the study population). The FA DNA PCR test is 
performed in Braamfontein. It was instituted in the year 2005, after an article regarding the 
presence of the c.637_643delTACCGCC mutation in different tribal groups from South Africa,   
was published (264). 
 
Testing for FA was not routinely requested or performed at IALCH, especially in older patients. 
It is known (and has been reported) that FA can present in adulthood and not only in children. 
Furthermore, as one-third of patients are reported to be phenotypically normal, the FA screening 
test should not be omitted in patients who are not clinically suspected to have FA. FA testing is 
imperative for appropriate patient management. Therapeutic modalities such as androgen therapy 
(danazol) are important in the management of FA patients with AA. It is also important to know 
if the patient has this underlying IBMFS if ATG or BM Transplantation is being considered for 
treatment of the AA because complications, such as secondary tumours, can arise from the use of 
certain chemotherapy protocols in FA patients, and FA patients are particularly sensitive to 
chemotherapeutic agents. 
It is unclear as to why routine PCR testing for FA was not performed. 
FA DNA PCR testing was positive in 2 patients, both of whom were homozygous for the 
FANCG c. 637_643del mutation. These patients had somatic abnormalities (skeletal 
abnormalities and a horse-shoe kidney), in keeping with FA. One patient had 3 siblings, all of 
whom were diagnosed with Fanconi Anaemia. Both patients received steroid and androgen 
therapy. One patient eventually succumbed to the complications of bone marrow failure and 
demised from gram negative septicaemia. The other FA patient was lost to follow-up (LTFU), 
however it is likely that this patient may have also demised, as both patients demonstrated a poor 
therapeutic response to androgen therapy.  
f) Fanconi anaemia: Chromosomal breakage tests (CBT) 
The CBT was not performed in those patients who tested positive for the FA DNA PCR test. 
CBT failed in 7 patients as a result of insufficient specimen yield and sample deterioration. Both 
the FA DNA PCR test and CBT are not performed locally but are “send away” tests that are 
referred to specialized centres to be performed. Hence, there are several pre-analytical variables 
that may have resulted in test failure. Furthermore, challenges in obtaining missing data, were 
encountered. Some of these challenges include changes in the LIS, results not being scanned into 
patient charts as well as poor record-keeping. The chromosomal breakage test was previously 
performed in Braamfontein. It is now being performed in Bloemfontein, for the last 6 months 
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approximately. Both centres were contacted for data, which has now been archived, and not 
readily accessible. 
g) PNH  
Various methods were used to detect PNH clones. Amongst them were the HAM’s test, followed 
by the immunophenotyping of granulocytes for CD55 and CD59. The most recent method 
implemented for the diagnosis of PNH at the IALCH NHLS haematology laboratory, is that 
using fluorescent labelled aerolysin (FLAER).  
All of the positive PNH cases were diagnosed in the years 2014 and 2015. This is important 
because the laboratory method for detecting PNH had changed in our laboratory in June 2013. 
The first PNH panel using FLAER was performed on the July 1, 2013. 
The HAM’s test is a complement based assay. It is suitable for hemolytic PNH, however it 
cannot detect small populations of affected red cells. The detection limit for a PNH clone, of this 
test ranges from 4.2%-5%. Furthermore, the HAM’s test is not specific for the diagnosis of PNH 
and, as it was not frequently requested (as the obvious advantages of the newer tests became 
apparent), this test was discontinued at the haematology laboratory at IALCH in November 
2015. There were 152 Ham’s tests performed at our laboratory since 2003, with no documented 
positive result for any of these patients (265, 266). 
Aside from being a rapid and easily performed test, peripheral blood FCM testing is both a 
reproducible and an extremely sensitive diagnostic tool to detect PNH clones in different cell 
populations. Although first described in 1985, it is now the gold standard for diagnosis of PNH. 
Type I, Type II and Type III PNH cell subtypes can be accurately identified and quantified on 
the GPI-AP deficient cells (266, 267). 
The quantification of the estimated clone size and types of cell lineages involved is extremely 
important as it correlates with the varying clinical manifestations of the disease (265). For 
example, it was found that in the first ten years after initial diagnosis, patients with >20% type III 
deficiency on red cells presented mostly with clinically significant hemolysis. Almost half of the 
patients with a greater than 50% GPI deficiency on granulocytes suffered from venous 
thrombosis (268). Hence, it is clear that clone size of the GPI-AP-deficient population on 
granulocytes is an established prognostic factor for vascular sequelae, affecting prognosis as well 
as life expectancy.  
The clone size as well as the cell lineages involved can change with time, deeming follow-up 
investigations mandatory to initiate appropriate therapy. Besides with the initial diagnosis of 
PNH, serial monitoring with FCM during the course of the disease can assist with monitoring of 
the clone size (9, 269, 274). 
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Flow cytometric analysis using a “stain-lyse-no wash” method was performed at NHLS 
(IALCH) until 2013. CD55 and CD59 were detected on neutrophils and monocytes. This method 
gave a better estimate of the clone size, however fresh blood samples (<8 hours from collection) 
were required rendering the test less sensitive. This issue is particularly important as many of the 
samples had come from peripheral hospitals and could likely have been old and degenerate at the 
time of processing, possibly resulting in false negative results. Sixty-one tests had been 
performed between 2009 to June 2013. No cases of PNH were detected whilst this method was 
in use.  
 In 2013, FLAER was added to the immunophenotyping method, using a new analyzer. 
Combining FLAER with multiparametric FCM further improves the sensitivity and specificity of 
this testing method. This highly sensitive method is more robust, and has a distinct advantage in 
that it can be performed on samples stored for up to 48 hours. This makes samples from 
peripheral hospitals suitable for assessment (270). It can therefore be inferred that the high 
negative detection rate prior to the use of FLAER, was attributable to the insensitive technique 
where the older analyzers were only detecting CD55 and CD59. 
All four patients with a PNH clone presented with features suggestive of AA. The PNH clones 
were incidentally discovered in the 4 patients once the FLAER method had been instituted. The 
PNH tests that had been performed and found to be negative prior to using FLAER, were not 
subsequently repeated after FLAER had been in use, except in the 2 patients discussed below. It 
is uncertain whether the testing done pre-FLAER could possibly be falsely negative as small 
PNH clones may have been missed.  
Interestingly, 2 patients who had negative baseline PNH FCM results in 2011, when the older 
method that did not incorporate FLAER was used, where found to be positive for PNH in 2015. 
The newly detected clones were large in size, ranging from 75-80%. These patients presented 
with the hemolytic form of PNH. It is uncertain whether these patients may have had initial false 
negative results at baseline, or if the PNH clones were a new development as a consequence of 
disease evolution within the spectrum of AA-PNH. 
An important observation was made in that an increased number of FCM tests requesting the 
PNH panel, was performed after the standardized use of the FLAER method had been instituted 
at our laboratory. Sixty-six PNH panels had been requested between July 2013 and April 2015. 
Hence, the PNH detection rate may have increased for 2 reasons. Firstly, as more patients were 
being tested, the detection rate increased. This may have been attributable to a change in the 
departmental protocol, which incorporated PNH testing in the work-up of AA. Secondly, the 
increased sensitivity of the new testing method resulted in the diagnosis of more cases of PNH. 
There is no reported association between pregnancy or TB and PNH, and the PNH clone was 




h) ANF  
The patient who tested ANF positive did not fulfil criteria for Systemic Lupus Erythematosus 
(SLE). As subsequent testing was negative, the low titer was therefore likely to be insignificant.  
 
4.9.2 Biochemistry: 
a) Urea and Electrolytes (U&E) 
In keeping with AA, the majority of patients (96%) had normal renal function. The derangements 
in renal function were most likely attributable to co-existing sepsis. 
b) Liver Function Tests (LFT) 
Liver Function Test derangements were demonstrated in a significant number of patients (16%). 
The reasons for deranged LFTs are most likely multifactorial, and include underlying infections, 
which were identified in 62% of the cohort with deranged LFTs. Antibiotics and antivirals, 
amongst other drugs, also derange the LFT, and could be contributory factors. The LFTs in the 
patients with Hepatitis B-Sag positivity were not deranged. 
It is important to perform a baseline LFT at presentation to assist with accurate assessment of the 
aetiology, and also prior to starting treatment with therapeutic agents such as CSA.  
 
4.9.3 Viral screen 
a) HIV 
The overall prevalence of HIV differs substantially with age, sex and race. Females display a 
higher HIV prevalence compared to men, which was also demonstrated in this study. This is in 
keeping with the heterosexual mode of acquisition of HIV. While all race groups are affected by 
HIV, the key populations in SA are Black African females aged 20-34 years, and Black African 
males aged 25-49 (270). However, slight differences in the median age at presentation were noted 
in the study population. The range in females was 22-46 years with a median of 33 years. Male 
patients ranged from 23-27 years with a median age of 26 years. Hence, females in this study 
were older, and males younger than expected from the literature. The reason for this is 
unexplained. 
A variable range of CD4 counts was evident at presentation. Thus, an association with CD4 
count and AA could not be inferred. Furthermore, CD4 counts may not be an accurate indication 
of HIV burden at presentation of AA, as many patients had a leucopenia, including a 
lymphopenia. This is further compounded by the unavailable VL data at presentation for many 
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patients. Although rare, cases of AA associated with HIV have been reported (127, 128, 272, 273). 
More studies need to be conducted in this regard. 
Of the patients with an interval between the diagnosis of HIV and AA, five of these patients, 
known with HIV infection, were not on combination antiretroviral therapy (cART) at the time of 
diagnosis of AA.  
Of the 5 patients not on cART, 2 patients with CD4 counts of 381 cells/mm3 and 388 cells/mm3, 
respectively, would not have been eligible for cART at the time of presentation as the previous 
criteria for initiation of ART, which has subsequently been revised twice since then, was a CD4 
count of <200 cells/mm3.   
One of the 5 patients not on cART, had defaulted his therapy prior to being diagnosed with AA. 
It is not known why the remaining 2 patients with CD4 counts <200 cells/mm3 (CD4 count of 
117 cells/mm3and 147 cells/mm3) were not on cART at the time of diagnosis of AA, despite 
being eligible for ARV therapy, and having had the prior diagnosis of HIV. 
Unfortunately, the viral loads (at the time of diagnosis of HIV and AA) were not 
performed/available for the majority of patients. This information would have been of great 
value in assessing the actual status of HIV infection at the time of presentation with AA.  
Only 3 of the patients with an interval between the diagnosis of HIV and AA were on cART at 
the time of diagnosis of AA. 
Of the total cohort of HIV positive patients (simultaneous diagnosis and an interval between the 
diagnosis) 10 patients were not on cART and this may be a possible indicator of active HIV 
infection being associated with new onset of AA.  
For some of the patients, follow up CD4 counts and viral loads were performed six months later 
and at various other intervals. Patients who were lost to follow up at IALCH were still 
continuing their visits to their respective ARV clinics. These results were accessible on the 
TrakCare LIS. CD4 counts showed significant improvement and viral loads were undetectable, 
in keeping with a good response to cART. An improvement was also noted in the FBCs of three 
of the patients. Two of the patients recovered their counts on cART. One patient had an FBC that 
normalized, however the patient was still on CSA for severe relapsing uveitis. 
South Africa has the largest and highest profile HIV epidemic worldwide. There was an 
estimated 7 million people living with HIV in 2015 (274). The 2008 national estimate for HIV 
prevalence amongst South Africans was 10.6%. In 2012, this figure increased to 12.2%. In 2015, 
the HIV prevalence increased to 19.2% in the general South African population. The prevalence 
does however vary significantly within the provinces. KZN has a prevalence of almost 40% in 
some areas compared to the Northern and Western Cape, which demonstrate a prevalence of 
18% (275).  
This study did not demonstrate an increased prevalence of AA in HIV. The prevalence of 16.3% 
HIV positive patients in the study population is similar to the background prevalence, or perhaps 
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even lower when compared to the expected prevalence of 19% and up to 40% in some areas of 
KZN.  
Possible reasons for this figure being an underestimate include: 
1) A higher threshold for performing BMATs in HIV positive patients with cytopenias. Patients 
with pancytopenia are often empirically started on therapy for opportunistic infections, 
instead of having a BMAT performed initially to accurately establish the cause of 
pancytopenia. AA may be under-diagnosed in this population group. 
2) BMATs are only performed at tertiary level hospitals in KZN. There may be delays in the 
referral system, which could result in patients demising prior to obtaining a BMAT.  
However, a retrospective review of a case series of 257 HIV positive adults at Chris Hani 
Baragwanath Academic Hospital, who underwent a BMAT examination, in order to assess the 
diagnostic usefulness of bone marrow examination and evaluate possible predictors of a 
diagnostic examination, did not implicate AA as a diagnostic BM finding in any of the patients 
(276). Another study, conducted to assess the diagnostic utility of bone marrow biopsies 
performed for the investigation of fever and/or cytopenias in HIV-infected adults at Groote 
Schuur hospital between 2004 and 2007, found that SAA comprised only 1 out of a total of 70 
cases. It was a unique diagnosis in only 1 out of 49 patients (0.6%) (277). The earlier study 
(published in 2001), was conducted in the pre-cART era, further elucidating that perhaps, AA is 
not increased with active HIV infection.  
An important observation was that none of the HIV negative patients being followed up until 
now, have contracted HIV during/after supportive therapy with blood and blood products. This is 
important because the risk of HIV transmission, albeit minimal, has been reported during blood 
transfusion. One patient had a false positive result, which was subsequently negative on 
confirmatory testing. Included in the management protocol for AA patients at the IALCH 
Clinical Haematology Unit, are routine 6-monthly viral screens. This allows monitoring for 




Table 4.2: Follow-up characteristics of simultaneously diagnosed HIV and AA pts 
 
Patient Month and 
Year of 
Diagnosis of 















1. May 2008 238 cells/mm3 <20 copies/ml Feb 2017: CD4 679 
cells/mm3 
















response  to 
CSA x2 









5 Feb 2014 323 cells/mm3 <40 copies/ml March 2016:  
CD4 not available 
VL suppressed 
LTFU on 





HIV- human immunodeficiency virus. AA- aplastic anaemia. CD4- cluster differentiation 4.     ml-millilitre. VL- 
viral load. LTFU- lost to follow up. cART- combined antiretroviral therapy. FBC- full blood count. Nov- November. 
Oct- October. LDL- lower than detectable limit. CSA- ciclosporin. Sep- September. TF- transfusion. Feb- February  
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Table 4.3: Follow-up characteristics of patients with an interval between the diagnosis of 
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LTFU on CSA 
5. October 
2011 
Feb 2012 117 
cells/mm3 
















7. April 2014 May 2015 388 
cells/mm3 






Well and TF 
independent, 
on CSA and 
ARV 
8. June 2015 July 2015 381 
cells/mm3 




HIV- human immunodeficiency virus. AA- aplastic anaemia. CD4- cluster differentiation 4. ml-millilitre. VL- viral 
load. LTFU- lost to follow up. cART- combination antiretroviral therapy. FDC- fixed dose combination. Nov- 
November. Oct- October. LDL- lower than detectable limit. CSA- ciclosporin. Sep- September. TF- transfusion. 




b) Hepatitis B  
The HepBSAg was positive in three patients. One patient had chronic hepatitis with a positive 
HepBSAg result over 3 consecutive years. The hepatitis B core IgM and the hepatitis E antigen 
were consistently negative in this patient. LFTs were normal in this patient. A coincidental 
finding was the equivocal CMV IgM result which was obtained twice, a year apart. 
In the other 2 patients, the positive HepBSAg result could indicate either acute infection or a 
persistent carrier state. The hepatitis B core IgM and the hepatitis E antigen were not available in 
these patients, limiting accurate identification of the disease state. One of the patients was HIV 
positive on HAART, with a CD4 count of 381 at diagnosis of AA. LFTs were normal in this 
patient. Deranged LFTs with a cholestatic picture, were evident in the HIV negative patient.  
A 33-year-old HIV positive female with a CD4 of 151 at the time of diagnosis of AA, had an 
equivocal HepBSAg result. She was 31 weeks pregnant, and on antihypertensive therapy at the 
time of testing. Her LFTs were not deranged.  
In a number of patients there were other factors that could be contributory to the liver function 
test derangements. There was no clear association with prior hepatitis virus infection and the 
subsequent onset of AA. 
c) Other viruses 
There was no documented co-infection of patients with EBV or Parvovirus. 
Of the patients whose parvovirus IgM was positive, PCR was not performed in one patient. 
Parvovirus PCR was negative for the other four patients. 
Majority of the patients tested negative for acute CMV infection. 1 patient had an equivocal 
CMV IgM result. 4 patients had evidence of recent CMV exposure, indicated by the positive 
CMV IgM serology. CMV IgG was positive in 3 of the patients. However, PCR was only 
performed in 1 of the 4 patients, and this was negative. LFTs were normal in this patient cohort. 
An equivocal HIV result was documented in 1 patient with DKC and deranged LFTs. The patient 
with DKC was diagnosed with AA prior to the CMV infection (retinitis). 
A positive CMV PCR result was obtained in a 21-year-old HIV negative female, for whom the 
CMV IgM and IgG were not available. In addition to symptomatic anaemia, the patient presented 
with jaundice, diarrhea and abdominal pain. LFTs were grossly deranged in keeping with a 
diagnosis of viral hepatitis. This was an unusual case of acute hepatitis with simultaneous onset 
of AA. As mentioned earlier, AA usually occurs 2-3 months after the hepatitis. This patient was 




4.10 Patient management and outcomes 
Important observations were made relating to: 
1. The thirteen patients diagnosed with AA, but not being referred to the clinical 
haematology unit at IALCH timeously. 
2. The six patients that had only one hospital visit and were LTFU. 
3. The eleven patients that were LTFU after being referred back to their base hospitals for 
either transfusion, HAART or management of their opportunistic infections etc. 
4. The five patients that were LTFU on CSA, or whilst awaiting ATG treatment. 
5. The 2 patients that were successfully treated with BMT 
6. The 3 patients who spontaneously recovered their counts 
7. The one patient who recovered counts once HAART had been initiated, not requiring 
specific immunosuppressive treatment for the AA. 
8. The one patient who recovered his counts with a change in the ARV agent as well as the 
AED. 
Points 1-4 above highlight the issues of the scarcity of resources, which is an important limiting 
factor in the KZN public health sector. It also highlights the importance of treating AA 
timeously, as delaying treatment increases mortality. 
Referral: A significant number of patients (14%) did not reach the clinical team at IALCH. 
Although the exact reason is unknown, it is likely that there may have been deficits in the referral 
of these patients or that these patients may have been very ill at diagnosis, and subsequently 
demised. In the peripheral areas of KZN, patients often travel long distances to see clinicians and 
have to wait for transportation to be booked, before they can be referred to a tertiary level 
hospital for work-up.  
Drugs: The process of obtaining ATG therapy for patients requires motivation and approval. 
Patients had to wait for ATG to be approved, for beds to become available for administration of 
ATG, and 5 patients eventually demised while awaiting ATG therapy. There have also been 
instances when ATG was not available from the supplier. Addressing this pressing issue is 
critical for optimal patient care. 
Bed constraints: The limited amount of beds in the haematology ward has always been a 
restrictive factor in adequate patient management.  Beds are often prioritized for patients with 
acute leukaemia, and patients with AA wait long periods for beds to become available 
(especially for ATG therapy which requires in-patient management). Perhaps if this resource was 
more easily available, patients could have been treated at IALCH from the outset. Supportive 
measures such as blood transfusions could have been provided and infections treated at IALCH, 
and these patients would not have been LTFU. This may perhaps, have also resulted in a lower 
mortality rate and a greater number of patients with a favorable outcome. 
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Bone marrow transplantation: Although bone marrow transplant (BMT) has proved curative 
for 50% of the transplanted AA patients in this study, the first BMT for AA was performed at 
IALCH in 2011. Hence, not many patients had the option of transplantation for AA, earlier on. 
To date there have been 9 BMT for AA in the BMT unit at IALCH. 4 of the 9 patients have been 
included in this study because their diagnosis was made at the NHLS haematology laboratory 
during the study period. The other patients have either had the diagnosis made elsewhere (private 
laboratories) or they have been diagnosed with AA outside the study period (after October 2015). 
Although it is anticipated that the number of transplants for AA will increase in the years to 
come, this would to some extent depend on the availability of a fully HLA-matched sibling 
donor for the patient.   
HIV infection: The institution of ARV therapy may modify the number of HIV positive patients 
presenting with AA. As has been reported in the literature, BM transplantation has been used as a 
therapeutic modality for HIV positive patients with SAA. Due to the limited resources and lack 
of expertise in transplanting HIV positive patients, this may not be feasible in our setting.  
Mortality: It is likely that the mortality rate has been underestimated, as 24% only accounts for 
22 patients in the study population. This figure does not take into account those patients who did 
not reach the clinical haematology unit at IALCH, as well as those patients that have been LTFU, 
and subsequently demised. This indicates that AA is fatal if untreated.  
The steepest mortality was found to be in the first year and the sharpest decline, as illustrated on 
the Kaplan-Meier survival estimate graph (on the following page), is between 0- 600 days. 
Seventy three percent of deaths were sepsis related. Most of the deaths occurred close to 
presentation. Two patients demised from intracranial bleeds. One patient demised from an acute 
pulmonary embolus and one other patient died from acute graft versus host disease. The cause of 
death was not known in two patients. . None of the patients who demised had received treatment 
with ciclosporin or ATG. 
The 2 year survival rate was 66.7% for the patient cohort, and the 5 year the survival rate was 
61.5%. However, this number may not be truly representative of the entire patient cohort due to 












































4.11. Study limitations 
Having conducted a retrospective study, some limitations were encountered. 
1. As data was retrieved from BMAT request forms and available patient records, an element of 
missing information was present for a number of the variables. Fortunately, the large number of 
patients in the cohort was sufficient to make reasonable inferences from the data. 
2. The NHLS Laboratory Information System (LIS) has changed over the years, the most recent 
change to the TrakCare system being implemented in 2010/2011. Obtaining results prior to this 
time was a lengthy arduous process, with some results not being accessible. Furthermore, 
specialized testing is performed at specialist referral laboratories, e.g. FA DNA PCR testing is 
performed in Braamfontein. FA chromosomal breakage tests are performed in Bloemfontein. 
These results are subsequently obtained by email, often at a much later time (as the testing takes 
some time). Results need to be manually scanned into patient files. This process was omitted for 
a few patients and some patients had blank scanned documents. A better system of record 
keeping is required for these send away tests.   
3. Prior to the year 2012/2013, PNH as well as testing for Fanconi anaemia and cytogenetics 
were not routinely performed. This is an important limitation in terms of assessing co-existing 
conditions and the accurate incidence of IBMFS. 
4. The large number of patients LTFU has impacted on the accurate assessment of patient 
response to therapy, the toxicities and adverse effects of therapy, the complications of the 
disease, as well as overall patient survival/outcome. 
5. This study was a review of BMATs referred to the NHLS haematology laboratory at IALCH 
only. Many patients with AA that were referred to clinical haematology unit at IALCH had 
BMATs that were referred to, and analyzed at private sector laboratories such as Heinsworth and 
partners, Ampath or Lancet laboratories. Hence, this study does not take into consideration 
patients whose diagnosis of AA was made at other laboratories, and may not be totally 




CHAPTER 5: CONCLUSION 
This study of adult patients with a bone marrow diagnosis of AA had several aims. Amongst 
them was a review of the epidemiological and clinic-pathological features of acquired AA in this 
patient cohort, as well as an assessment of laboratory investigations performed at diagnosis. The 
clinical outcome and management was also reviewed. The objective was to collate this data and 
compare these findings with that documented elsewhere in the literature. 
This study has demonstrated that the presentation of AAA in adults at IALCH, NHLS, exhibits 
shared characteristics with that of other developed and developing countries. The patients were 
mostly in the younger age group. No bimodal age distribution was evident in this cohort of 
patients. 
The majority of the cases were idiopathic AAA. Offending drugs and toxins were suspected to be 
causal in a few patients, some of whom in which the AA resolved upon drug 
withdrawal/substitution. 3 patients demonstrated IBMFS with a poor outcome. This highlights 
the challenges encountered in treating patients with DKC and FA.  
This study did not show an increased incidence of HIV associated AA. The prevalence of HIV 
positive patients with AA was similar to the background prevalence of HIV in KZN. Easy access 
to cART and the new ARV roll-out programme could modify future findings, as some patients 
showed recovery from the AA with the institution of ART. This may affect the number of HIV 
positive patients who present with AA, and the prevalence may decrease further. However, more 
studies with a larger number of HIV positive patients with AA will be required to elaborate on 
this. 
It is apparent that pregnancy outcomes are variable, and early elective TOP perhaps appears to 
have the safest outcome. Long term follow-up of these patients is mandatory to assess if 
spontaneous resolution of AA occurs. 
With regard to patient outcomes, it is clear that patients with AA that are diagnosed early and 
managed with IST have a fairly good outcome. This elaborates on the need for an early accurate 
diagnosis, prompt referral and patient management, as reflected by the significant number of 
patients who did not reach the clinical haematology department, despite the diagnosis of AA 
being made. 
This study has also highlighted deficiencies in the clinical and laboratory diagnostic sytems in 
the province of KZN: 
There is an apparent lack of clinical acumen by non-haematologists in the work-up of AA 
patients, which is possibly a contributory factor to increased patient mortality. There is also a 
distinct deficit in the expertise demonstrated in performing BMATs at base hospitals, which in 
most cases are tertiary level institutions. This results in a delayed diagnosis of AA. Improving 
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undergraduate/postgraduate training programmes, with rotation of medical registrars through 
clinical haematology requires serious consideration for the future.  
The comprehensive work-up as well as the appropriate and timely management of AA requires 
very close collaboration between the haematopathologist and the clinical haematologist. 
Specialized testing requires skilled and competent laboratory staff, and as many of the tests are 
send away tests, results are often not readily available culminating in delayed or even a lack of 
diagnosis of important conditions like FA.  Our laboratory has experienced staffing difficulties in 
specialized field of cytogenetics testing for several years, as senior and experienced cytogenetics 
staff have resigned, and these posts have not yet been filled. 
It is important for the clinical haematology unit to have a standardized protocol in place for the 
holistic work-up and diagnosis of patients suspected to have AA, as well as for the existing AA 
patients. This is clear from the paucity of data such as cytogenetics and FA/PNH screens in the 
earlier years of this study. These tests have important implications in the management and follow 
up of patients with AA. 
The need to motivate for ATG, and more significantly, limited hospital beds is a critical issue in 
the management of AA patients in KZN. This contributed to the large number of patients who 
are LTFU, and also to the mortality rates as specific therapy is often delayed. Of the patients who 
were treated, many had a good response to IST. Bone marrow transplantation is also a promising 
therapeutic modality in the management of AA patients in our setting.
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Aim 
The aim of this study is to collect data regarding the demographics, aetiology/associations, 
clinical presentation, laboratory parameters and outcomes of adult patients with a bone marrow 
diagnosis of Aplastic Anaemia (AA) at the National Health Laboratory Service (NHLS), Inkosi 
Albert Luthuli Central Hospital, Durban, KwaZulu-Natal.  
Specific Objectives 
1) To illustrate the demographics, clinical presentation, management and outcomes in adult 
patients with a confirmed bone marrow diagnosis of AA. 
2) To correlate the full blood count (FBC), bone marrow aspirate and trephine findings 
3) To document the disease severity (using the above in 2) 
4) To document aetiological associations, in particular viruses such as Human Immunodeficiency 
Virus (HIV), and connective tissue disorders such as systemic lupus erythematosus (SLE) 
4) To establish if there is a relationship with the CD4 count/viral load and disease presentation in 
HIV infected patients 
5) To determine the presence, or subsequent emergence, of a Paroxysmal Nocturnal 
Haemoglobinuria (PNH) clone in these patients 
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Background 
Aplastic anaemia (AA) is a rare disease that is classified as a bone marrow failure syndrome. 
Aplastic anaemia is a haemopoietic stem cell (HSC) disorder characterized by a markedly 
reduced bone marrow cellularity. Bone marrow failure may result in a peripheral pancytopenia (a 
decrease in all cell lines). Cytopenias involving a single myeloid lineage may dominate; 
lymphopoeisis is usually relatively well preserved. 
 
Epidemiology and Pathogenesis: 
Aplastic anaemia is rare in Western Europe and the United States (2 cases per million population 
per year), but the incidence in China, Southeast Asia and Mexico is estimated to be three to four 
times higher. It is primarily a disease of children and younger adults, with another peak in 
incidence in patients 60 years and older. 
Aplastic anaemia may be inherited or acquired.  
Irrespective of the aetiology, haemopoiesis is markedly reduced in all patients with aplastic 
anaemia, as reflected by bone marrow histology. Obligatory involvement of multiple lineages 
points toward HSC or very early haemopoietic progenitor cells as main targets of the 
pathophysiologic mechanism in aplastic anaemia. Clinical response to immunosuppressive 
therapy targeting T-cells (e.g. anti-thymocyte globulin) supports an immune-mediated 
pathogenesis for aplastic anaemia. 
Aplastic anaemia is usually associated with normal cytogenetics. An abnormal karyotype in a 
patient with a hypocellular marrow is more consistent with a diagnosis of Myelodysplastic 
Syndrome, although some investigators believe that certain chromosomal abnormalities such as 
trisomy 8 or deletion 13q can still be consistent with a diagnosis of Aplastic anaemia.  
 
Associations with PNH: 
Paroxysmal Nocturnal Haemoglobinuria (PNH) is an acquired, chronic haemolytic anaemia in 
which haemolysis is largely intravascular. In addition to haemolytic anaemia, the patient may 
have thrombosis and pancytopenia. This triad when present is highly characteristic of PNH. 
PNH is a rare disorder (estimated prevalence of less than 1 in 100 000) that can occur anywhere 
in the world. There is no evidence of family clustering and PNH has been observed at all ages 
from 1 to 72 years; however, it is most common in young adults. 
The natural history of PNH is a very chronic disorder. It may afflict the patient for decades. The 
median survival is estimated to be about 10 years. Spontaneous recovery may occur in some 
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cases. Not infrequently, at some stage in the disease, the anaemia may be associated with other 
cytopenias. When a PNH patient becomes less hemolytic and more pancytopenic, he or she 
becomes very similar to a patient with AA. Conversely a patient with aplastic anaemia may 




Examples of inherited forms of aplastic anaemia include Fanconi’s Anaemia and Dyskeratosis 
Congenita. 
Acquired aplastic anaemia (AAA) may be idiopathic or secondary to an underlying cause. 
Aplastic anaemia can arise during pregnancy, with drug exposure (e.g. non-steroidal anti-
inflammatories, anti-thyroid drugs, gold etc.) or in association with viral infections and 
autoimmune diseases. Hepatitis-associated aplastic anaemia is a variant of aplastic anaemia in 
which aplastic anaemia follows an acute attack of viral hepatitis. The aplastic anaemia is often 
fatal if untreated. Hepatitis-associated aplastic anaemia accounts for 2-5% of cases of aplastic 
anaemia in Europe and 4-10% of cases in East Asia. Aplastic anaemia has been reported to occur 
in 28-33% of patients requiring orthotopic liver transplantation for fulminant non-A, non-B, and 
non-C hepatitis. This seronegative hepatitis in patients with post hepatitis aplastic anaemia does 
not appear to be caused by any of the known hepatitis viruses and often is referred to as 
Hepatitis/Aplastic Anaemia syndrome. Aplastic anaemia evolves with a typical delay of several 
weeks to months after the episode of hepatitis, usually after improvement of liver enzymes. 
 
Clinical presentation of Aplastic Anaemia 
Idiopathic aplastic anaemia usually arises in a previously healthy patient who has no history of 
malignancy or collagen vascular disorder, and no exposure to cytotoxic drugs or radiation. 
Symptoms and signs of aplastic anaemia are a consequence of bone marrow failure. Patients may 
present with pallor and fatigue due to anaemia, mucocutaneous bleeding due to 
thrombocytopenia, or infection due to neutropenia. More severe haemorrhage into the central 
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Classification 
Classification and prognosis in AA are related to the severity in the depression of peripheral 
blood counts.  
Severe aplastic anaemia (SAA) is defined by: 
-Bone marrow cellularity <25%, or 25-50% with <30% residual hematopoietic cells         
 -AND any 2 out of 3 of the following: 
 Peripheral blood neutrophil count < 0.5 x 109/l 
 Peripheral blood platelet count < 20 x 109/l 
 Peripheral blood reticulocyte count <20 x 109/l  
 
Very severe aplastic anaemia (VSAA):  
As above, but absolute peripheral blood neutrophil count of <0.2 x10^9/l 
Non-severe aplastic anaemia (NSAA):  
-Patients not fulfilling the criteria for severe or very severe Aplastic Anaemia  
-With a hypocellular bone marrow, with 2 out of the 3 of the following: 
 Neutrophils <1.5 x 109/l  
 Platelets <100 x 109/l 
 Haemoglobin <10 g/l 
 
 
Management of AA 
Rarely, patients with aplastic anaemia can spontaneously recover normal haematopoiesis. 
Spontaneous remission is most often seen with drug induced aplastic anaemia and usually occurs 
within 1-2 months of discontinuing the offending drug. 
The standard of care for moderate aplastic anaemia is not well established. Except for cases in 
which there is transfusion dependence, specific treatment is optional, because survival rates are 
not positively influenced by treatment.  
Without treatment, almost all patients with severe or very severe aplastic anaemia will eventually 
succumb to infection or to haemorrhagic complications. Therefore, such patients require 
immediate supportive and eventually, specific therapy once a diagnosis is confirmed. 
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Besides supportive therapy with leuco-depleted red cell and single donor platelet transfusions, 
specific therapeutic options for patients with severe aplastic anaemia consists of allogeneic 
haemopoietic stem cell transplantation (HSCT) or immunosuppressive therapy with ATG and 
ciclosporin.  At the time of diagnosis, all potential transplantation candidates should be HLA 
typed to identify a sibling donor or a matched, unrelated donor. 
 
AA in developing countries such as Africa 
There is a paucity of information regarding AA in Southern Africa, and an extensive literature 
search has shown no publications.  
I have selected this topic, not only because of my own personal interest in this disease condition, 
but also because studies regarding aplastic anaemia are lacking in developing countries such as 
South Africa, and the rest of Africa. The above objectives and the data collected and analyzed 
will assist in providing useful epidemiological and clinical information in our local setting, as 
such a study has not been conducted previously.  
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Study Design 
A retrospective review of bone marrow aspirate and trephines, laboratory investigations and 
clinical data of adult patients with a confirmed diagnosis of aplastic anaemia at the NHLS 




The study population will consist of all adult patients (over the age of 12 years) with a bone 
marrow diagnosis of aplastic anaemia at the Haematology Laboratory (NHLS), Inkosi Albert 
Luthuli Central Hospital, Durban, KwaZulu-Natal, South Africa, between the period            1 
January 2005 - 30 October 2015. 
 
Sampling Strategy 
Bone marrow aspirate and trephine biopsies confirming the diagnosis of aplastic anaemia, that 
were assessed at the NHLS Haematology Laboratory from 1 January 2005 - 30 October 2015 
will be included. Additional laboratory investigations and clinical data for these patients will 
then also be reviewed. 
 
Sample size 
Approximately 45 bone marrow aspirate and trephine biopsies and the corresponding patient 
investigations/clinical data will be studied. 
 
Inclusion Criteria 
All adult patients (>12yrs of age), with a bone marrow diagnosis of aplastic anaemia at the 
Haematology Laboratory (NHLS), Inkosi Albert Luthuli Central Hospital, Durban, Kwa-Zulu 
Natal, South Africa will be included. 
 
Exclusion Criteria  
Paediatric bone marrow aspirate and trephine biopsies with the diagnosis of aplastic anaemia will 
be excluded from the study.  
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Data Collection Methods and Tools 
Data collection will include a review of the following: 
A) Demographic data and history submitted with the bone marrow samples by requesting 
doctors. 
B) Relevant laboratory investigations obtained from the Trak Care Laboratory Information 
System: 
1. Full blood count including differential and peripheral blood smear  
2. Reticulocyte count 
3. Bone marrow aspirate and trephine biopsies 
4. Bone marrow cytogenetic studies (if available) 
5. Flow cytometry for detection of a paroxysmal nocturnal haemoglobinuria clone 
6. CD4 counts in HIV positive patients 
7. Virological investigations including: 
   Human Immunodeficiency Virus Enzyme linked immunosorbent assays and viral load 
   Hepatitis A, B and C antibody tests 
   Hepatitis B Surface Antigen tests 
   Parvovirus Enzyme linked immunosorbent assays and Polymerase Chain Reaction tests 
   Cytomegalovirus Enzyme linked immunosorbent assays 
   Epstein Barr Virus Enzyme linked immunosorbent assays 
 
C) Clinical data regarding the presenting symptoms, clinical course, selected management 
strategies and patient outcomes (such as treatment responses and overall survival). 
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Data Analysis 




Haematology Laboratory (National Health Laboratory Service) and the department of Clinical 
Haematology, Inkosi Albert Luthuli Central Hospital, Durban, KwaZulu-Natal, South Africa. 
 
Study period 
The study period will include patients presenting from 1 January 2005 to 30 October 2015. 
 
Limitations 
This retrospective review will be based on data extracted from bone marrow aspirates and 
trephine biopsies, as well as available clinical notes of patients with AA, diagnosed at the 
Haematology Laboratory (NHLS). Bone marrow report and sample availability and integrity, as 
well as the completeness and detail of clinical notes will impact on the study. 
Morphological shortfalls may also affect the study.  
The sample population is exclusively from the public (state) sector, and may therefore not be an 
accurate representation of aplastic anaemia in the province, as it will not include patients seen in 
the private sector, who may have different. 
 
Ethical considerations 
No direct patient contact will be made during this study. 
All data will be extracted from laboratory investigations and available clinical information.  
No informed consent will be required. 
All patient information is strictly confidential. 
There is no financial benefit for anyone involved in the study. 
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This study will be conducted according to the ethical principles for medical research on human 
subjects as defined by the World Medical Association Declaration of Helsinki. 
The protocol will be submitted to the Ethics Committee for approval, and permission will be 
obtained from Inkosi Albert Luthuli Central Hospital to access the relevant clinical data. 
 
Funding 
No funding is required 
 
Reporting and Implementation 
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Appendix 2: Aplastic Anaemia: Data Collection Sheet 
 
1) Patients study number:_____________________________ 
2)  
3) Date of Diagnosis  
Episode number of bone marrow/s: 
 
__________________________________________________ 
4) Age/ Date of Birth:    _____________________________ 
 
5) Gender:  M                               F   
 
6) Ethnic Group:  a) Black 
                                b) Asian 
                                c) Coloured 
                                d) White 
 
7) Occupation:  _______________________________________ 
Previous (Major occupations):__________________________________________________ 
 
Current:  ___________________________________________ 
 





9) Relevant Medication/Exposures prior to Diagnosis 
(e.g. cytotoxic agents, radiation, pesticides, toxins): 
 
          a) Yes                           No 
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b) If Yes, give details: 
______________________________________________________________________________
______________________________________________________________ 








d) Infections: _____________________________________________ 
e) Pyrexia: _____________________________________________ 
f) Dysmorphic features 
 




















Yes:                                                 No: 
     If Yes, result: 





14) Flow cytometry for Paroxysmal Nocturnal  Haemoglobinuria (PNH): 
 
 
a) Peripheral blood _______________________________ 
b) Bone marrow _______________________________ 
c) PNH clone detected:      Yes                          No 
d) If Yes, Size of the PNH clone: 
______________________________________________________________________________
_________________________________________________________     
 
FBC:   WCC=  ____    Hb=  ____     MCV= ____     PLT=____ 
 
15) Differential:  
 
N=____     L= ____     M= ____           E= ____         B=____ 
 
16) Reticulocyte count:   Corrected: ____________________ 
                                                           Absolute: _____________________ 
 










20) Anti-Nuclear Factor (ANF):  ________________________ 
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21) Pregnant:    Yes                             No        




17) HIV Serology: 
 a) Reactive=                                               Non-reactive= 
 b) If reactive: 
       -Date of diagnosis: ____________________________________ 
       -CD4 count at diagnosis: _______________________________ 
       -Viral Load at diagnosis: _______________________________ 
          c) Is the patient receiving ARV’s?        Yes               No 
          d) If yes: 
       -Date treatment started: ________________________________ 
       -Treatment regimen: ___________________________________ 
-Treatment complications: ______________________________ 
 
 
e) Follow-up viral loads/CD4 counts: 
DATE VIRAL LOAD CD4 COUNT 
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   18) Hepatitis A Serology:            Negative 
                                                            IgG  + 
                                                            IgM + 
  19) Hepatitis B Serology:             
                                                         Hepatitis B Surface Antigen + 
                                                         Hepatitis B Surface Antibody +                                 
                                                         Titre:  _________ 
 
   20) Hepatitis C Serology:               Negative 
                                                            IgG +                  
                                                            IgM + 
 
 
  21) Parvovirus:              Negative: 
                                           IgG +                  
                                           IgM+ 
                           PCR:     POS                            NEG 
 
 
  22) Cytomegalovirus:   Negative:                 
                                           IgG +                  
                                           IgM +                   
                            PCR:    POS                             NEG      
 
23) Epstein Barr Virus Serology:            Negative:           
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                                                                      IgG + 
                                                                      IgM + 
 
24) Disease Severity:   ________________________________ 
 
25) Managemement of Patient: 
Observation:          ⎕  
Supportive care: (RBC and platelet transfusions)    ⎕ 
Ciclosporin only:        ⎕ 
ATG (Equine)/ Ciclosporin/Methylprednisolone (Triple Therapy):   ⎕ 
Bone marrow transplant from matched sibling donor   ⎕ 
 
26) Patient outcomes 
Alive at end of study:       ⎕ 
Demised during study:       ⎕ 









- 135 - 
 
Appendix 3: Ethical approvals 
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Appendix 4: Summarized diagnosis and further investigations for AA 
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Appendix 6: Normal Reference Ranges (for NHLS IALCH) 
FBC: 
Test Sex Age Low High 
White Cell Count (x 109/L)   12.0-12.9 3.9 10.2 
White Cell Count F 13.0-999 3.9 12.6 
White Cell Count M 13.0-999 3.92 10.4 
     
Red Cell Count (x 1012/L) F 12.0-12.9 4.05 4.98 
Red Cell Count M 12.0-12.9 4.43 5.53 
Red Cell Count F 13.0-999 3.8 4.8 
Red Cell Count M 13.0-999 4.5 5.5 
     
Haemoglobin (g/dl) F 12.0-12.9 11.7 14.9 
Haemoglobin M 12.0-12.9 12.5 16.5 
Haemoglobin F 13.0-999 12 15 
Haemoglobin M 13.0-999 13 17 
     
Haematocrit (L/L) F 12.0-12.9 .351 .436 
Haematocrit M 12.0-12.9 .368 .473 
Haematocrit F 13.0-999 .36 .46 
Haematocrit M 13.0-999 .4 .5 
     
Mean Cell Volume (fL)   12.0-12.9 77.1 91.5 
Mean Cell Volume F 13.0-999 78.9 98.5 
Mean Cell Volume M 13.0-999 83.1 101.6 
     
- 145 - 
 
Test Sex Age Low High 
Mean Cell Haemoglobin (pg)   12.0-12.9 25.8 31.7 
Mean Cell Haemoglobin F 13.0-999 26.1 33.5 
Mean Cell Haemoglobin M 13.0-999 27.8 34.8 
     
Mean Cell Haemoglobin 
Concentration (g/dL) 
  12.0-12.9 33 35.1 
Mean Cell Haemoglobin 
Concentration 
F 13.0-999 32.7 34.9 
Mean Cell Haemoglobin 
Concentration 
M 13.0-999 33 35 
     
Red Cell Distribution Width (%)   12.0-12.9 11.6 14.8 
Red Cell Distribution Width F 13.0-999 12.4 17.3 
Red Cell Distribution Width M 13.0-999 12.1 16.3 
     
Platelet Count (x109/L)   12.0-12.9 180 440 
Platelet Count F 13.0-999 186 454 
Platelet Count M 13.0-999 171 388 
     
Mean Platelet Volume (fL)   12.0-12.9 7 11.4 
Mean Platelet Volume F 13.0-999 7.3 11.3 
Mean Platelet Volume M 13.0-999 7.1 11 
     
Neutrophils %   12.0-12.9 33 59 
Neutrophils % F 13.0-999 34 72 
Neutrophils % M 13.0-999 32 76 
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Test Sex Age Low High 
     
Lymphocytes %   12.0-12.9 33 50 
Lymphocytes % F 13.0-999 21 56 
Lymphocytes % M 13.0-999 18 56 
     
Monocytes %   12.0-12.9 0 6 
Monocytes % F 13.0-999 3 10 
Monocytes % M 13.0-999 4 12 
     
Eosinophils %   12.0-12.9 0 3 
Eosinophils % F 13.0-999 0 6 
Eosinophils % M 13.0-999 0 8 
     
Basophils %   12.0-12.9 0 1 
Basophils % F 13.0-999 0 1 
Basophils % M 13.0-999 0 2 
     
Neutrophils (x 109/L)   12.0-12.9 1.5 7.4 
Neutrophils F 13.0-999 1.6 8.3 
Neutrophils M 13.0-999 1.6 6.98 
     
Lymphocytes (x 109/L)   12.0-12.9 1 3.6 
Lymphocytes F 13.0-999 1.4 4.5 
Lymphocytes M 13.0-999 1.4 4.2 
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Test Sex Age Low High 
Monocytes (x 109/L)   12.0-12.9 .1 .7 
Monocytes F 13.0-999 .2 .8 
Monocytes M 13.0-999 .3 .8 
     
Eosinophils (x 109/L)   12.0-12.9 0 .7 
Eosinophils F 13.0-999 0 .4 
Eosinophils M 13.0-999 0 .95 
     
Basophils (x 109/L)   12.0-12.9 0 .1 
Basophils F 13.0-999 0 .1 
Basophils M 13.0-999 0 .1 
     
 
  
- 148 - 
 
Reticulocyte count  
Test 
 
Age Low High 
     
Reticulocyte Count Absolute 
(Manual) (x 1012/L) 
  12.0-999 3.8          5.5 
     
Reticulocyte Count (Miller)    
(x 1012/L) 
  .008-999 3.8 5.5 
     
 
Reticulocyte Production Index reference range: 
1 - 2  Adequate response 
< 1    Inadequate bone marrow response 
> 2    Indicative of haemolysis, recent bleeding or nutritional support 
 
Liver function tests 
Test Sex Age Low High 
Total protein (g/L)   12.0-17.9 57 80 
Total protein   18.0-999 60 78 
     
Albumin (g/L) F 12.0-17.9 29 42 
Albumin   18.0-999 35 52 
     
Total bilirubin (umol/l)   12.0-999 5 21 
     
Conjugated bilirubin (DBil)   12.0-12.9 0 5 
Conjugated bilirubin (DBil)   13.0-999 0 3 
     
Alanine transaminase (ALT) (U/L) M 12.0-17.9 5 30 
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Test Sex Age Low High 
Alanine transaminase (ALT) M 18.0-999 10 40 
Alanine transaminase (ALT) F 12.0-17.9 5 20 
Alanine transaminase (ALT) F 18.0-999 7 35 
     
Aspartate transaminase (AST) 
(U/L) 
M 12.0-12.9 0 38 
Aspartate transaminase (AST) M 13.0-15.9 0 39 
Aspartate transaminase (AST) M 16.0-17.9 0 39 
Aspartate transaminase (AST) M 18.0-999 15 40 
Aspartate transaminase (AST) F 12.0-12.9 0 37 
Aspartate transaminase (AST) F 13.0-15.9 0 32 
Aspartate transaminase (AST) F 16.0-17.9 0 30 
Aspartate transaminase (AST) F 18.0-999 13 35 
     
Alkaline phosphatase (ALP) (U/L) M 12.0-12.9 42 362 
Alkaline phosphatase (ALP) M 13.0-15.9 74 390 
Alkaline phosphatase (ALP) M 16.0-17.9 52 171 
Alkaline phosphatase (ALP) M 18.0-999 53 128 
Alkaline phosphatase (ALP) F 12.0-12.9 51 332 
Alkaline phosphatase (ALP) F 13.0-15.9 50 162 
Alkaline phosphatase (ALP) F 16.0-17.9 47 119 
Alkaline phosphatase (ALP) F 18.0-999 42 98 
     
Gamma-glutamyl transferase 
(GGT) (U/L) 
M 12.0-12.9 3 22 
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Test Sex Age Low High 
Gamma-glutamyl transferase 
(GGT) 
M 13.0-17.9 2 42 
Gamma-glutamyl transferase 
(GGT) 
M 18.0-999 0 67 
Gamma-glutamyl transferase 
(GGT) 
F 12.0-12.9 4 22 
Gamma-glutamyl transferase 
(GGT) 
F 13.0-17.9 4 24 
Gamma-glutamyl transferase 
(GGT) 
F 18.0-999 0 39 
 
Urea and electrolytes 
Test Sex Age Low High 
Creatinine (umol/L)   12.0-12.9 37 63 
Creatinine   13.0-14.9 40 72 
Creatinine F 15.0-17.9 39 85 
Creatinine F 18.0-999 49 90 
Creatinine M 15.0-17.9 36 96 
Creatinine M 18.0-999 64 104 
     
Sodium (mmol/L)     136 145 
     
Potassium(mmol/L)   12.0-999 3.5 5.1 
     
Chloride(mmol/L)   12.0-999 98 107 
     
Bicarbonate(mmol/L)     23 29 
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Test Sex Age Low High 
Anion gap(mmol/L)     9 16 
     
Urea(mmol/L) F 12.0-12.9 1.8 5.7 
Urea F 13.0-15.9 1.4 5.4 
Urea F 16.0-17.9 1.4 5.4 
Urea M 12.0-12.9 1.8 6.4 
Urea M 13.0-15.9 2.5 6.4 
Urea M 16.0-17.9 1.8 7.1 
Urea   18.0-999 2.1 7.1 
 
Vitamin B12, Folate, Ferritin and Iron studies 
Test Sex Age Low High 
Serum folate 
(nmol/L) 
    >12.2   
     
Vitamin B12 
(pmol/L) 
    156 672 
     
Ferritin (ug/L) M 19.0-999 22 322 
Ferritin F 19.0-999 10 291 
     
Iron (umol/L) M 12.0-999 11.6 31.3 
Iron F 12.0-999 9 30.4 
     
Transferrin (g/L) M 12.0-12.9 1.73 3.8 
Transferrin M 13.0-15.9 1.71 3.74 
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Test Sex Age Low High 
Transferrin M 16.0-17.9 1.94 3.48 
Transferrin M 18.0-59.9 2.15 3.65 
Transferrin F 12.0-12.9 1.85 3.77 
Transferrin F 13.0-15.9 1.93 3.91 
Transferrin F 16.0-17.9 1.81 4.16 
Transferrin F 18.0-59.9 2.5 3.8 
Transferrin   60.0-89.9 1.9 3.75 
Transferrin   90.0-999 1.86 3.47 
     
% Saturation (%) M   20 50 
% Saturation F   15 50 
 
CD4 
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